Document:

EX-10.34

 Exhibit 10.34 

EXECUTION VERSION 

COMBINATION AGREEMENT 

by and between 
 REMEDY
PARTNERS, INC. 
 and 

CHLOE OX HOLDINGS, LLC 

Dated: November 14, 2019 
 NO AGREEMENT,
ORAL OR WRITTEN, REGARDING OR RELATING TO ANY OF THE MATTERS COVERED BY THIS DOCUMENT HAS BEEN ENTERED INTO BETWEEN THE PARTIES. THIS DOCUMENT IS INTENDED SOLELY TO FACILITATE DISCUSSIONS AMONG THE PARTIES IDENTIFIED HEREIN. IT IS NOT INTENDED TO
CREATE, AND WILL NOT BE DEEMED TO CREATE, A LEGALLY BINDING OR ENFORCEABLE OFFER OR AGREEMENT OF ANY TYPE OR NATURE PRIOR TO THE ACTUAL EXECUTION OF THIS DOCUMENT BY EACH SUCH PARTY AND THE DELIVERY OF AN EXECUTED COPY HEREOF BY EACH SUCH PARTY TO
THE OTHER PARTY. 

 Table of Contents 

 

							
	 	 	 	  	Page	 
	 ARTICLE 1 DEFINITIONS; CONSTRUCTION
	  	 	3	 
	 Section 1.1
	 	Definitions	  	 	3	 
	 Section 1.2
	 	Construction	  	 	12	 
	 ARTICLE 2 THE COMBINATION; CLOSING; TAX TREATMENT OF THE COMBINATION
	  	 	13	 
	 Section 2.1
	 	The Combination	  	 	13	 
	 Section 2.2
	 	The Closing	  	 	13	 
	 Section 2.3
	 	Tax Treatment of the Combination	  	 	14	 
	 ARTICLE 3 REPRESENTATIONS AND WARRANTIES OF REMEDY OPCO
	  	 	14	 
	 Section 3.1
	 	Organization and Power	  	 	14	 
	 Section 3.2
	 	Authorization	  	 	14	 
	 Section 3.3
	 	Capitalization; Subsidiaries	  	 	15	 
	 Section 3.4
	 	Consents and Approvals; No Violations	  	 	15	 
	 Section 3.5
	 	Financial Statements	  	 	16	 
	 Section 3.6
	 	Permits; Compliance with Laws	  	 	16	 
	 Section 3.7
	 	Absence of Certain Events	  	 	16	 
	 Section 3.8
	 	Brokers	  	 	17	 
	 Section 3.9
	 	Litigation	  	 	17	 
	 Section 3.10
	 	Transactions with Affiliates	  	 	17	 
	 Section 3.11
	 	No Undisclosed Liabilities	  	 	17	 
	 Section 3.12
	 	Material Customers	  	 	18	 
	 Section 3.13
	 	Certain Contracts; No Defaults	  	 	18	 
	 Section 3.14
	 	Benefit Plans	  	 	18	 
	 Section 3.15
	 	Labor Relations	  	 	20	 
	 Section 3.16
	 	Taxes	  	 	20	 
	 Section 3.17
	 	Healthcare and Data Protection Representations	  	 	21	 
	 Section 3.18
	 	Assets and Properties	  	 	22	 
	 Section 3.19
	 	No Other Representations or Warranties	  	 	22	 
	 ARTICLE 4 REPRESENTATIONS AND WARRANTIES OF PARENT
	  	 	23	 
	 Section 4.1
	 	Organization and Power	  	 	23	 
	 Section 4.2
	 	Authorization	  	 	23	 
	 Section 4.3
	 	Capitalization; Subsidiaries	  	 	23	 
	 Section 4.4
	 	Consents and Approvals; No Violations	  	 	24	 
	 Section 4.5
	 	Financial Statements	  	 	24	 
	 Section 4.6
	 	Permits; Compliance with Laws	  	 	25	 
	 Section 4.7
	 	Absence of Certain Events	  	 	25	 
	 Section 4.8
	 	Brokers	  	 	26	 
	 Section 4.9
	 	Litigation	  	 	26	 
	 Section 4.10
	 	Transactions with Affiliates	  	 	26	 
	 Section 4.11
	 	No Undisclosed Liabilities	  	 	26	 
	 Section 4.12
	 	Material Customers	  	 	26	 
	 Section 4.13
	 	Certain Contracts; No Defaults	  	 	26	 
	 Section 4.14
	 	Benefit Plans	  	 	27	 

  
 - i - 

							
	 Section 4.15
	 	Labor Relations	  	 	28	 
	 Section 4.16
	 	Taxes	  	 	29	 
	 Section 4.17
	 	Healthcare and Data Protection Representations	  	 	29	 
	 Section 4.18
	 	Assets and Properties	  	 	31	 
	 Section 4.19
	 	No Other Representations or Warranties	  	 	31	 
	 ARTICLE 5 COVENANTS
	  	 	31	 
	 Section 5.1
	 	Reasonable Best Efforts	  	 	31	 
	 Section 5.2
	 	Covenants of Remedy Opco	  	 	32	 
	 Section 5.3
	 	Covenants of Parent	  	 	32	 
	 Section 5.4
	 	Control of Other Party’s Business	  	 	33	 
	 Section 5.5
	 	Advice of Changes	  	 	33	 
	 Section 5.6
	 	Remedy Opco Options	  	 	33	 
	 Section 5.7
	 	Public Announcements	  	 	34	 
	 Section 5.8
	 	Confidentiality	  	 	34	 
	 Section 5.9
	 	Additional Agreements	  	 	34	 
	 Section 5.10
	 	Parent Book-Up	  	 	35	 
	 Section 5.11
	 	Pre-Closing Taxes of New Remedy Corp	  	 	35	 
	 ARTICLE 6 CLOSING DELIVERABLES
	  	 	35	 
	 Section 6.1
	 	Deliveries by Parent	  	 	35	 
	 Section 6.2
	 	Deliveries by Remedy	  	 	36	 
	 ARTICLE 7 CONDITIONS PRECEDENT
	  	 	37	 
	 Section 7.1
	 	Conditions to Obligations of Parent	  	 	37	 
	 Section 7.2
	 	Conditions to Obligations of Remedy Opco	  	 	38	 
	 Section 7.3
	 	Frustration of Conditions Precedent	  	 	39	 
	 ARTICLE 8 TERMINATION
	  	 	39	 
	 Section 8.1
	 	Termination	  	 	39	 
	 Section 8.2
	 	Effect of Termination	  	 	40	 
	 ARTICLE 9 MISCELLANEOUS
	  	 	40	 
	 Section 9.1
	 	Survival; Liability	  	 	40	 
	 Section 9.2
	 	Expenses	  	 	40	 
	 Section 9.3
	 	Amendment; Benefit; Assignability	  	 	41	 
	 Section 9.4
	 	Notices	  	 	41	 
	 Section 9.5
	 	Waiver	  	 	42	 
	 Section 9.6
	 	Entire Agreement	  	 	43	 
	 Section 9.7
	 	Counterparts	  	 	43	 
	 Section 9.8
	 	Headings	  	 	43	 
	 Section 9.9
	 	Severability	  	 	43	 
	 Section 9.10
	 	Governing Law; Jurisdiction	  	 	43	 
	 Section 9.11
	 	Counsel	  	 	44	 
	 Section 9.12
	 	Waiver of Trial by Jury	  	 	44	 
	 Section 9.13
	 	Specific Performance and Remedies	  	 	44	 
	 Section 9.14
	 	New Remedy Corp; Certain Effects of Joint Investment Agreement	  	 	44	 
	 Section 9.15
	 	Non-Recourse	  	 	45	 

  
 - ii - 

 EXHIBITS 
  

					
	 Exhibit A
	  	-   	  	Form of A&R Parent LLCA
			
	 Exhibit B
	  	-   	  	Form of Joint Investment Agreement
			
	 Exhibit C
	  	-   	  	Form of New Remedy Corp Charter
			
	 Exhibit D
	  	-   	  	Form of Registration Rights Agreement

  

  
 - iii - 

 COMBINATION AGREEMENT 

THIS COMBINATION AGREEMENT (this “Agreement”) is entered into as of November 14, 2019, by and between Remedy Partners,
Inc., a Delaware corporation (“Remedy Opco”) and Chloe Ox Holdings, LLC, a Delaware limited liability company doing business as Signify Health (“Parent”). Certain capitalized terms used herein are defined in
Section 1.1. 
 RECITALS 

WHEREAS, following the execution of this Agreement and prior to the Closing, it is anticipated that each of the following entities will
change their names, in accordance with, and pursuant to, the terms and provisions of their respective organizational documents, as follows: (i) Parent shall be renamed “Cure TopCo, LLC”, (ii) Chloe Ox Aggregator, LLC, a Delaware
limited liability company, which is an equityholder of Parent, shall be renamed “Cure Aggregator, LLC” (“Cure Aggregator”) (iii) Chloe Ox Intermediate 1, LLC, a Delaware limited liability company and a direct wholly-owned
Subsidiary of Parent shall be renamed “Cure Intermediate 1, LLC”, (iv) Chloe Ox Intermediate 2, LLC, a Delaware limited liability company and an indirect wholly-owned Subsidiary of Parent shall be renamed “Cure Intermediate 2,
LLC”, (v) Chloe Ox Intermediate 3, LLC, a Delaware limited liability company and an indirect wholly-owned Subsidiary of Parent shall be renamed “Cure Intermediate 3, LLC” and (vi) Signify Health, LLC, a Delaware limited liability
company and an indirect wholly-owned Subsidiary of Parent (“Cure Borrower”) shall be renamed “Cure Borrower, LLC”; 

WHEREAS, on or prior to the Business Day prior to the Closing (each as defined below), Remedy Opco and its Subsidiaries shall take the
following actions to effect a restructuring and reorganization: (a) each of Liberty Health, Inc., Remedy Holdings, Inc. and Remedy Systems, Inc. (each of which are Subsidiaries of Remedy Opco and are currently treated as corporations for U.S.
federal income tax purposes) shall be converted to limited liability companies that are treated as entities disregarded as separate from Remedy Opco for United States federal income Tax purposes; (b) the following entities shall be formed:
(i) a Delaware corporation as a direct, wholly-owned Subsidiary of Remedy Opco (“New Remedy Corp”) and (ii) a Delaware corporation as a direct, wholly-owned Subsidiary of New Remedy Corp and indirect Subsidiary of Remedy
Opco (“Remedy Merger Sub”); (c) following the entity formations described in clause (b), Remedy Merger Sub shall merge with and into Remedy Opco, with Remedy Opco continuing as the surviving entity in such merger and becoming
a wholly-owned Subsidiary of New Remedy Corp (the “Remedy Opco Merger”); (d) in connection with the Remedy Opco Merger, (i) each share of capital stock of Remedy Merger Sub shall be cancelled and converted into a share of
capital stock of Remedy Opco, (ii) each share of capital stock Remedy Opco held by Remedy Acquisition L.P. shall be cancelled and converted into the right to receive equity securities of New Remedy Corp and (iii) each share of capital
stock of Remedy Opco held by all other equityholders shall be cancelled and converted into the right to receive equity securities of New Remedy Corp; (e) in connection with the Remedy Opco Merger, Remedy Opco will assign to New Remedy Corp, and
New Remedy Corp shall assume, the Remedy Stockholders’ Agreement (as defined below); (f) the Remedy Option Conversion and Remedy Equity Plan Assignment and Assumption (each as defined below) shall be consummated; and (g) no earlier than
one Business Day following the consummation of the Remedy Opco Merger, Remedy Opco (which is currently treated as a corporation for U.S. federal income tax purposes) shall be converted into a limited liability company that is treated as an entity
disregarded as separate from New Remedy Corp for United States federal income Tax purposes under the name Remedy Partners, LLC (all such actions, collectively, the “Pre-Closing
Restructuring”); 

 WHEREAS, Remedy Opco and Parent wish to effect a business combination (referred to
herein, and defined below, as the Combination) by means of a contribution by New Remedy Corp of all of the issued and outstanding Equity Interests of Remedy Opco to Parent in exchange for newly issued Parent Series A Preferred Units, on the terms
and subject to the conditions set forth in this Agreement and in accordance with the applicable Laws of the State of Delaware; 

WHEREAS, a special committee (the “Special Committee”) of the Board of Directors (the “Remedy Board”)
of Remedy Opco, which was formed for the purpose of evaluating the Combination and consists of members of such Remedy Board that were not appointed by or on behalf of NM Fund V (as defined below), has recommended that the full Remedy Board approve
this Agreement, the other Transaction Documents, the Combination and the other transactions contemplated by this Agreement and the other Transaction Documents (including the Remedy Opco Merger and the
Pre-Closing Restructuring), and determined that this Agreement and the other Transaction Documents, the Combination and the other transactions contemplated by this Agreement and the other Transaction Documents
are advisable and in the best interests of the stockholders of Remedy Opco; 
 WHEREAS, the full Remedy Board has approved this
Agreement, the other Transaction Documents, the Combination and the other transactions contemplated by this Agreement and the other Transaction Documents (including the Remedy Opco Merger and the Pre-Closing
Restructuring), and determined that this Agreement and the other Transaction Documents, the Combination and the other transactions contemplated by this Agreement and the other Transaction Documents are advisable and in the best interests of the
stockholders of Remedy Opco; 
 WHEREAS, the Board of Directors of Parent (the “Parent Board”) has approved this
Agreement and the other Transaction Documents, the Combination and the other transactions contemplated by this Agreement and determined that this Agreement, the Combination and the other transactions contemplated by this Agreement and the other
Transaction Documents are advisable and in the best interests of Parent and its members; 
 WHEREAS, each of NM Fund V and Remedy
Acquisition, L.P. has approved this Agreement, the other Transaction Documents, the Combination and the other transactions contemplated by this Agreement and the other Transaction Documents (including the Remedy Opco Merger and the Pre-Closing Restructuring) in accordance with the applicable requirements of the Remedy Stockholders’ Agreement and the Existing Parent LLCA (as defined below). 

WHEREAS, in connection with the Remedy Opco Merger, Remedy Acquisition, L.P. will exercise its drag-along rights pursuant to
Section 4.2 of the Remedy Stockholders Agreement, with the consent of the Majority Other Investors (as defined below); 

  
 - 2 - 

 WHEREAS, the Majority Other Investors have approved this Agreement, the other
Transaction Documents, the Combination and the other transactions contemplated by this Agreement and the other Transaction Documents (including the Remedy Opco Merger and the Pre-Closing Restructuring) in
accordance with the applicable requirements of the Remedy Stockholders’ Agreement and have consented to Remedy Acquisition, L.P. exercise of its drag-along rights pursuant to Section 4.2 of the Remedy Stockholders Agreement; and 

NOW THEREFORE, in consideration of the above premises, the various respective agreements and covenants herein contained, and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows: 

ARTICLE 1 
 DEFINITIONS;
CONSTRUCTION 
 Section 1.1 Definitions. As used in this Agreement, the following terms will have the respective meanings set
forth below: 
 “$” shall have the meaning set forth in Section 1.2(d). 

“A&R Parent LLCA” shall mean that certain Second Amended and Restated Limited Liability Company Agreement of Parent, to
be entered into at the Closing by and among Parent and the other parties thereto, in substantially the form attached as Exhibit A, with such changes, modifications or revisions, if any, as are agreed to prior to Closing by Parent and Remedy
Opco (acting following recommendation of such changes, modifications or revisions by the Special Committee). 
 “Action”
shall mean any claim, charge, grievance, complaint, action, suit, arbitration, mediation, assessment, audit, investigation, litigation or proceeding commenced, brought or conducted by or before any Governmental Entity. 

“Affiliate” shall mean, with respect to any Person, any Person that, directly or indirectly, Controls, is Controlled by, or
is under common Control with or of, such Person. The term “Control” (including, with correlative meanings, the terms “Controlled by” and “under common Control with”), as used with respect to any entity, shall mean the
possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such entity, whether through the ownership of voting securities, by Contract or otherwise. 

“Agreement” shall have the meaning set forth in the Preamble. 

“Business Day” shall mean any calendar day other than a Saturday, Sunday or other calendar day on which banking institutions
in New York, New York are required to be closed for the day. 
 “Closing” shall have the meaning set forth in
Section 2.2. 
 “Closing Date” shall have the meaning set forth in
Section 2.2. 

  
 - 3 - 

 “CMMI” shall have the meaning specified in
Section 7.1(f). 
 “CMS” shall have the meaning specified in
Section 7.1(f). 
 “CMS Approval” shall have the meaning specified in
Section 7.1(f). 
 “CMS Expiration” shall have the meaning specified in
Section 7.1(f). 
 “Code” shall mean the United States Internal Revenue Code of 1986, as amended
from time to time. 
 “Combination” shall have the meaning set forth in Section 2.1. 

“Contract” shall mean any written or oral contracts, subcontracts, agreements, bonds, notes, indentures, mortgages, debt
instruments, licenses, sublicenses, franchises, leases, subleases, commitments, undertakings, purchase orders or other legally binding arrangements. 

“Cure Aggregator” shall have the meaning set forth in the Recitals. 

“Cure Borrower” shall have the meaning set forth in the Recitals. 

“Covered Refund” means any tax refund actually received after Closing in cash by New Remedy Corp (and any tax credit received
by New Remedy Corp in lieu thereof that relates to a taxable period or portion thereof of New Remedy Corp that ends on or before the Closing Date, other than any such tax refund (or credit) that is attributable to the carryback of a Tax attribute
from a taxable period ending after the Closing Date, and net of (i) any costs related to obtaining such refund and (ii) Taxes payable or expected to be payable in respect of or as a result of such refund. Notwithstanding the foregoing,
Covered Refund will not include any credits, deductions, or other tax attributes that do not result in an actual receipt of cash by New Remedy Corp. 

“Data Handling” shall mean the collection, storage, processing, use, transmission, disclosure, deletion, and securing of
data, including Sensitive Data. 
 “Data Protection Obligations” shall mean, with respect to any Person, all privacy
policies, terms of use, Laws, industry requirements and contractual obligations applicable to such Person that relate to Data Handling, privacy, security, the obligation to provide data breach notifications and the protection and/or processing of
personal data, including but not limited to the Health Insurance Portability and Accountability Act of 1996 as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and their implementing regulations; Title V of
the Gramm-Leach-Bliley Act, 15 U.S.C. 6801 et seq.; the Fair Credit Reporting Act, 15 U.S.C. § 1681; and all other similar Laws in force directly applicable to such Person in any jurisdiction in which such Person operates. 

“Debt” shall mean for any Person, without duplication, all (a) indebtedness of such Person (i) for borrowed money,
together with all accrued but unpaid interest thereon and other payment obligations thereon (including any prepayment premiums, breakage costs and other related fees or any Liability payable as a result of the prepayment thereof upon the
consummation of the Transactions), (ii) evidenced by bonds, debentures, notes or other similar 

  
 - 4 - 

 
instruments or debt securities, or (iii) under letters of credit, banker’s acceptances or similar facilities issued for the account of such Person, but only to the extent drawn upon;
and (b) any indebtedness of any other Person of a type that is referred to in clause (a) above and which is guaranteed by such Person; provided, that “Debt” shall not include (x) accounts payable, or (y) Debt
owing from the Person to any of its Subsidiaries or from a Subsidiary of such Person to such Person or any other Subsidiary of such Person. 

“Effect” shall mean any event, circumstance, change, occurrence, state of facts, condition, development or effect. 

“Equity Interest” means, with respect to any Person, (a) any capital stock, partnership or membership interest, units of
participation or other similar interest (however designated) in such Person and (b) any option, warrant, purchase right, conversion right, exchange right or other Contract which would entitle any other Person to acquire any such interest in
such Person or otherwise entitle any other Person to share in the equity, profits, earnings, losses or gains of such Person (including any interest, the value of which is in any way based on, linked to or derived from any interest described in (a),
including stock appreciation, phantom stock, profit participation or other similar rights). 
 “ERISA” shall have the
meaning set forth in Section 3.14(a). 
 “Exchanged Units” shall have the meaning set forth in
Section 2.1. 
 “Exhibit” shall mean the exhibits to this Agreement. 

“Existing Parent LLCA” shall mean that certain Amended and Restated Limited Liability Company Agreement of Parent, dated as
of December 21, 2017, by and among Parent and the members of Parent party thereto. 
 “Fraud” shall mean actual and
knowing (and not imputed or constructive) fraud, as determined in accordance with the Laws of the State of Delaware, in the making of the representations and warranties contained in this Agreement.    In the case of a Party, such
fraud shall only be deemed to exist if both: (a) any of the specific individuals included in the definition of “Knowledge” for such Party had actual knowledge (as opposed to imputed or constructive knowledge) that any such
representation or warranty of such Party contained in this Agreement, as qualified by the Schedules, was actually and materially false when made; and (b) the other Party (to whom the representation or warranty was made) relied upon such
representation or warranty in entering into this Agreement with lack of actual knowledge (as opposed to imputed or constructive knowledge) of the falsity of such representation or warranty. 

“Fundamental Representations” shall mean the representations and warranties contained in Sections 3.1, 3.2,
3.3, 3.4, 3.8, 4.1, 4.2, 4.3, 4.4 and 4.8. 
 “GAAP” shall mean
generally accepted accounting principles as in effect in the United States of America. 
 “General Enforceability
Exceptions” shall have the meaning set forth in Section 3.2(a). 

  
 - 5 - 

 “Government Program” shall mean “federal health care program” as
defined in 42 U.S.C. §1320a-7b(f), including Medicare, state Medicaid programs, state CHIP programs, TRICARE, and any other similar or successor federal, state or local healthcare payment programs with or
sponsored, in whole or in part, by any Governmental Entity. 
 “Governmental Entity” shall mean any federal, state,
provincial, local, municipal, foreign or other governmental, administrative, judicial or regulatory or self-regulatory agency, commission, board, bureau or body, or any court, tribunal, administrative hearing body, arbitration or mediation panel,
commission, or other similar dispute-resolving panel, or taxing authority under or for the account of any of the foregoing, including any subdivisions of any of the foregoing. 

“Healthcare Laws” shall mean all federal and applicable state Laws relating to the regulation, provision or administration
of, or payment for, healthcare products or services, including, but not limited to: (i) Title XVIII of the Social Security Act, 42 U.S.C. §§ 1395-1395kkk-1 (the Medicare statute) and the
regulations promulgated thereunder; (ii) Title XIX of the Social Security Act, 42 U.S.C. §§ 1396-1396v (the Medicaid statute) and the regulations promulgated thereunder; (iii) TRICARE, 10 U.S.C. § 1071-1110b and the
regulations promulgated thereunder; (iv) Patient Protection and Affordable Care Act, Public Law 111-148 and the regulations promulgated thereunder; (v) Health Care and Education Reconciliation Act of
2010, Public Law 111-152 and the regulations promulgated thereunder; (vi) the Health Care Fraud Statute, 18 U.S.C. § 1347 and the regulations promulgated thereunder; (vii) the Civil Monetary
Penalties Law (42 U.S.C. § 1320a-7a), (viii) the federal anti-kickback statutes (42 U.S.C. § 1320a-7b), (ix) the federal self-referral law (42 U.S.C.
§1395nn), (x) criminal false claims statutes (e.g. 18 U.S.C. §§ 287 and 1001), (xi) the Program Fraud Civil Remedies Act of 1986 (31 U.S.C. §3801, et seq.), (xii) the Beneficiary Inducement Statute (42 U.S.C. §1320a-7a(a)(5)), (xiii) quality and safety Laws relating to the regulation, provision or administration of, or payment for, healthcare products or services; (xiv) licensure Laws relating to the
regulation, provision or administration of, or payment for, healthcare products or services; and (xv) any similar or analogous state and local Laws, and as each of (i) through (xiv) as may be amended from time to time. 

“Injunction” shall have the meaning set forth in Section 7.1(c). 

“Intended Tax Treatment” shall have the meaning set forth in Section 2.3. 

“IRS” shall mean the United States Internal Revenue Service. 

“Joint Investment Agreement” shall mean that certain Joint Investment Agreement, to be entered into at the Closing, in
substantially the form attached as Exhibit B, with such changes, modifications or revisions, if any, as are agreed to prior to Closing by Parent and Remedy Opco (acting following recommendation of such changes, modifications or revisions by
the Special Committee). 
 “Knowledge” shall mean (a) in the case of Remedy Opco, the actual knowledge of Steve
Wiggins, Chris Garcia, Steve Senneff, Robert Meier and Vincent Fitts, and (b) in the case of Parent, the actual knowledge of Bradford Kyle Armbrester, Nathan Goldstein and David Pierre. 

  
 - 6 - 

 “Labor Union” shall have the meaning set forth in
Section 3.15. 
 “Law” shall mean any federal, state, local or foreign law (including common
law), code, statute, ordinance, rule, regulation, judgment, order, injunction, decree, arbitration award, legally binding agency requirement, license or permit promulgated, declared or issued by any Governmental Entity. 

“Liability” shall mean, with respect to any Person, any liability, debt, deficiency, penalty, assessment, fine, claim or
other loss, fee, cost, expense or obligation of such Person whether known or unknown, whether asserted or unasserted, whether determined, determinable or otherwise, whether absolute or contingent, whether accrued or unaccrued, whether liquidated or
unliquidated, whether directly incurred or consequential, whether due or to become due and whether or not required under GAAP to be accrued on the financial statements of such Person. 

“Liens” shall mean all claims, charges, mortgages, security interests, liens, deeds of trust, encumbrances, easements, rights
of first refusal or first offer, options, buy/sell agreements, pledges and equitable interests of any kind or nature whatsoever, whether voluntarily incurred or imposed by or arising under Contract or Law, other than, with respect to securities,
transfer restrictions arising under federal and state securities Laws. 
 “Look-Back-Date” shall have the meaning set forth
in Section 3.17(a). 
 “Majority Other Investors” shall have the meaning ascribed to such term in
the Remedy Stockholders’ Agreement. 
 “Material Remedy Customer” shall mean each of the five (5) largest
customers of the Remedy Companies as a whole (measured by consolidated revenue for the periods (x) beginning on January 1, 2017 and ending on December 31, 2017 and (y) beginning on January 1, 2018 and ending on
December 31, 2018). 
 “Material Signify Customer” shall mean each of the five (5) largest customers of the
Signify Companies as a whole (measured by consolidated revenue for the periods (x) beginning on January 1, 2017 and ending on December 31, 2017 and (y) beginning on January 1, 2018 and ending on December 31, 2018). 

“New Remedy Corp” shall have the meaning set forth in the Recitals. 

“New Remedy Corp Charter” shall mean the Amended and Restated Certificate of Incorporation of New Remedy Corp, to be in
effect at the Closing, in substantially the form attached as Exhibit C, with such changes, modifications or revisions, if any, as are agreed to prior to Closing by Parent and Remedy Opco (acting following recommendation of such changes,
modifications or revisions by the Special Committee). 
 “New Remedy Option” shall have the meaning set forth in
Section 5.6(a). 
 “NM Fund V” shall mean New Mountain Partners V, L.P., a Delaware limited
partnership. 

  
 - 7 - 

 “NM Persons” shall mean NM Fund V, Remedy Acquisition, L.P. and their
respective Affiliates, and their respective directors, managers and officers; and “NM Person” shall mean any of the foregoing. 

“NM SPA” shall have the meaning set forth in Section 5.10. 

“Notices” shall have the meaning set forth in Section 9.4. 

“Organizational Documents” shall mean: (a) the certificate of incorporation, articles of incorporation or articles of
association, by-laws, stockholders agreements, voting agreements, investors rights agreements, registration rights agreements or any other similar agreement or side letter of any corporation; (b) the
partnership agreement and any statement of partnership of a general partnership; (c) the limited partnership agreement and the certificate of limited partnership of a limited partnership; (d) the certificate of formation and operating
agreement of any limited liability company; (e) any charter or similar document adopted or filed in connection with the creation, formation, or organization of a Person; and (f) any amendment to any of the foregoing. 

“Outside Date” shall have the meaning set forth in Section 8.1(c). 

“Parent” shall have the meaning set forth in the Preamble. 

“Parent Board” shall have the meaning set forth in the Recitals. 

“Parent Class A Common Units” shall mean Class A Common Units of Parent as described in the Existing
Parent LLCA. 
 “Parent Class B Common Units” shall mean Class B Common Units of Parent as
described in the Existing Parent LLCA. 
 “Parent ERISA Affiliate” shall have the meaning set forth in
Section 4.14(a). 
 “Parent Series A Preferred Units” shall mean Series A Preferred Units of
Parent as described in the A&R Parent LLCA. 
 “Parent Series B Preferred Units” shall mean Series B Preferred Units of
Parent as described in the A&R Parent LLCA. 
 “Parties” shall mean the parties to this Agreement.  

“Person” shall mean any individual, partnership, joint venture, corporation, trust, unincorporated organization, limited
liability company, unlimited liability company, group, Governmental Entity, and any other person or entity. 
 “Pre-Closing Remedy Tax Liabilities” shall mean any and all Liabilities for or resulting from Taxes of New Remedy Corp, including Liabilities for or resulting from (i) Taxes of Remedy Opco or any
Subsidiary of Remedy Opco for which New Remedy Corp is or may be liable (as a successor or otherwise), and (ii) Taxes resulting from or attributable to the Pre-Closing Restructuring or the Combination, in each case for all periods, or portions
of periods, ending on or before the Closing Date (determined, in the case of any period which includes, but does not end on, the Closing Date, on a closing of the books basis as if such period had ended at the close of the Closing Date). 

  
 - 8 - 

 “Pre-Closing Restructuring” shall
have the meaning set forth in the Recitals. 
 “Recitals” shall mean the recitals to this Agreement. 

“Registration Rights Agreement” shall mean that certain Registration Rights Agreement, to be entered into at the Closing, in
substantially the form attached as Exhibit D, with such changes, modifications or revisions, if any, as are agreed to prior to Closing by Parent and Remedy Opco (acting following recommendation of such changes, modifications or revisions by
the Special Committee). 
 “Remedy Balance Sheet Date” shall have the meaning set forth in
Section 3.5. 
 “Remedy Benefits Plan” shall have the meaning set forth in
Section 3.14(a). 
 “Remedy Board” shall have the meaning set forth in the Recitals. 

“Remedy Companies” shall mean Remedy Opco and its Subsidiaries; and “Remedy Company” means Remedy Opco or
any of its Subsidiaries. 
 “Remedy ERISA Affiliate” shall have the meaning set forth in
Section 3.14(a). 
 “Remedy Exchange” shall have the meaning set forth in
Section 2.1. 
 “Remedy Financial Statements” shall have the meaning set forth in
Section 3.5. 
 “Remedy Interim Financial Statements” shall have the meaning set forth in
Section 3.5. 
 “Remedy Material Adverse Effect” shall mean any Effect that, individually or in
the aggregate, has, or would reasonably be expected to have, a material adverse effect on (a) the ability of Remedy Opco to consummate the transactions contemplated by this Agreement or (b) the assets, liabilities, business, financial
condition, or results of operations of Remedy Opco and its Subsidiaries, taken as a whole; provided, however, that, with respect to clause (b) only, no Effect arising out of or in connection with or resulting from any of the
following shall be deemed by itself or by themselves, either alone or in combination, to constitute or contribute to a Remedy Material Adverse Effect: (i) adverse changes affecting any or all of the industries in which Remedy Opco or its
Subsidiaries operate; (ii) general political, economic or business conditions or changes therein (including the commencement, continuation or escalation of a war, armed hostilities or other international or national calamity or acts of
terrorism); (iii) adverse changes in general financial or capital market conditions, including interest rates or currency exchange rates; (iv) any earthquake, hurricane or other natural disaster, weather-related event or act of god;
(v) any changes in, or change in interpretation or application of, any Law or GAAP after the date of this Agreement; (vi) the public announcement of this Agreement or the transactions contemplated by this Agreement; (vii) any action
or omission expressly contemplated by the 

  
 - 9 - 

 
terms of this Agreement, or taken or omitted with the written consent of Parent; and (viii) any failure of Remedy Opco and its Subsidiaries to meet financial projections or any estimates of
revenues or earnings (provided that the exception set forth in this clause (viii) shall not prevent or otherwise affect any determination that the underlying reasons for any such failure constitutes or contributed to a Remedy Material
Adverse Effect). Notwithstanding the foregoing, in the case of clauses (i) through (v) above, such Effects shall be considered in determining whether a Remedy Material Adverse Effect has occurred to the extent (and solely to the extent) such
Effects, individually or in the aggregate, have or would reasonably be expected to have an adverse impact on Remedy Opco and its Subsidiaries, taken as a whole, that is disproportionate to the adverse impact on other Persons operating in the same
industry as Remedy Opco and its Subsidiaries. 
 “Remedy Merger Sub” shall have the meaning set forth in the Recitals. 

“Remedy Opco” shall have the meaning set forth in the Preamble. 

“Remedy Opco Equity Plan” shall have the meaning set forth in Section 5.6(a). 

“Remedy Opco Option” shall have the meaning set forth in Section 5.6(a). 

“Remedy Option Conversion” shall have the meaning set forth in Section 5.6(a). 

“Remedy Stockholders’ Agreement” shall mean that certain Stockholders’ Agreement of Remedy Opco, dated as of
January 15, 2019, by and among Remedy Opco and the stockholders of Remedy Opco party thereto. 
 “Representatives”
shall mean, with respect to any Person, such Person’s Affiliates, directors, officers, partners, members, managers, trustees, employees, agents and advisors. 

“Sensitive Data” shall mean (a) Protected Health Information, as defined by 45 C.F.R. § 160.103, (b) information
required by any applicable Law, industry standard, contract obligation or other requirement to be encrypted, masked or otherwise protected from disclosure or requires any Person to be notified if such information is lost, misused, wrongly accessed,
wrongly acquired or compromised, (c) government identifiers, such as Social Security or other tax identification numbers, driver’s license numbers and other government-issued identification numbers, (d) account, credit or debit card
numbers, with or without any required security code, access code, personal identification number or password that would permit access to an individual’s financial account, and account information, including balances and transaction data,
(e) user names, email addresses, passwords, or other credentials for accessing accounts, (f) personal data, revealing racial or ethnic origin, political opinions, religious or philosophical beliefs, or trade-union membership; or data
concerning health or sex life and sexual orientation, and (g) any other sensitive personally-identifiable data and information regarding individuals or their employment, family, health or financial status, such as salary, benefits, and marital
status. 
 “Signify Balance Sheet Date” shall have the meaning set forth in Section 4.5. 

“Signify Benefit Plan” shall have the meaning set forth in Section 4.14(a). 

  
 - 10 - 

 “Signify Blocker” shall mean New Mountain Partners V Special (AIV-C), LLC. 
 “Signify Companies” shall mean Parent and its Subsidiaries; and
“Signify Company” means Parent or any of its Subsidiaries. 
 “Signify Financial Statements” shall have
the meaning set forth in Section 4.5. 
 “Signify Interim Financial Statements” shall have the
meaning set forth in Section 4.5. 
 “Signify Material Adverse Effect” shall mean any Effect
that, individually or in the aggregate, has, or would reasonably be expected to have, a material adverse effect on (a) the ability of Parent to consummate the transactions contemplated by this Agreement or (b) the assets, liabilities,
business, financial condition, or results of operations of Parent and its Subsidiaries, taken as a whole; provided, however, that, with respect to clause (b) only, no Effect arising out of or in connection with or resulting from
any of the following shall be deemed by itself or by themselves, either alone or in combination, to constitute or contribute to a Signify Material Adverse Effect: (i) adverse changes affecting any or all of the industries in which Parent or its
Subsidiaries operate; (ii) general political, economic or business conditions or changes therein (including the commencement, continuation or escalation of a war, armed hostilities or other international or national calamity or acts of
terrorism); (iii) adverse changes in general financial or capital market conditions, including interest rates or currency exchange rates; (iv) any earthquake, hurricane or other natural disaster, weather-related event or act of god;
(v) any changes in, or change in interpretation or application of, any Law or GAAP after the date of this Agreement; (vi) the public announcement of this Agreement or the transactions contemplated by this Agreement; (vii) any action
or omission expressly contemplated by the terms of this Agreement, or taken or omitted with the written consent of Remedy Opco; and (viii) any failure of Parent and its Subsidiaries to meet financial projections or any estimates of revenues or
earnings (provided that the exception set forth in this clause (viii) shall not prevent or otherwise affect any determination that the underlying reasons for any such failure constitutes or contributed to a Signify Material Adverse
Effect). Notwithstanding the foregoing, in the case of clauses (i) through (v) above, such Effects shall be considered in determining whether a Signify Material Adverse Effect has occurred to the extent (and solely to the extent) such Effects,
individually or in the aggregate, have or would reasonably be expected to have an adverse impact on Parent and its Subsidiaries, taken as a whole, that is disproportionate to the adverse impact on other Persons operating in the same industry as
Parent and its Subsidiaries. 
 “Special Committee” shall have the meaning set forth in the Recitals. 

“Subsidiary” shall mean, with respect to any Person, any corporation, association, partnership, limited liability company,
trust or other entity of which fifty percent (50%) or more of the total voting power, whether by way of Contract or otherwise, of shares of capital stock or other equity interests (including limited liability company or partnership interests)
entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly (e.g., through another Subsidiary), by (a) such Person
(b) such Person and one or more of its Subsidiaries, or (c) one or more Subsidiaries of such Person. For the avoidance of doubt, a Subsidiary of a Person includes direct and indirect Subsidiaries (e.g., a Subsidiary of a Subsidiary). 

  
 - 11 - 

 “Tax” (including with correlative meaning the term
“Taxes”) includes all taxes (or similar charges) imposed, collected or administered by any taxing authority (or similar authority), together with all interest, penalties, fines, and additions to tax imposed in respect thereof,
including those levied on, or measured by, or referred to as income, earnings, profits, gross receipts, estimated, sales, use, ad valorem, value added, intangible, unitary, transfer, franchise, license, payroll, employment, estimated, excise, stamp,
occupation, premium, property, prohibited transactions, windfall or excess profits, customs, duties, import and export, capital, corporate, goods and services, withholding, business, real or personal property, wage, severance, utility, social
security or other similar taxes, in each case, whether disputed or not. 
 “Transaction Documents” shall mean this
Agreement, the Joint Investment Agreement, the A&R Parent LLCA, the Registration Rights Agreement and the other documents and instruments expressly required by the terms of this Agreement to be executed in connection herewith. 

“Transactions” shall mean the transactions contemplated by the Transaction Documents. 

“Treasury Regulations” shall mean the Treasury Regulations (including temporary regulations) promulgated by the United States
Department of Treasury with respect to the Code or other federal Tax statutes. 
 Section 1.2 Construction. 

(a) For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine
gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include the masculine and feminine genders. 

(b) As used in this Agreement, the words “include” and “including,” and variations thereof, shall not be deemed to be
terms of limitation, but rather shall be deemed to be followed by the words “without limitation.” 
 (c) Except as otherwise
indicated, all references in this Agreement to Sections, Schedules and Exhibits are intended to refer to Sections of this Agreement and Schedules and Exhibits to this Agreement. 

(d) Any capitalized term used in any Exhibit, but not otherwise defined therein, shall have the meaning ascribed to such term this Agreement.
Any reference to $ in this Agreement shall mean United States dollars. 
 (e) When calculating the period of time before which, within which
or following which any act is to be done or step taken pursuant to this Agreement, if the last day of such period is not a Business Day, the period shall end on the next succeeding Business Day. 

  
 - 12 - 

 ARTICLE 2 

THE COMBINATION; CLOSING; TAX TREATMENT OF THE COMBINATION 

Section 2.1 The Combination(a) .  

(a) On or prior to the Business Day prior to Closing, Remedy Opco shall consummate the Pre-Closing
Restructuring as described herein, and otherwise pursuant to documentation reasonably acceptable to Remedy Opco and Parent. Prior to Closing, Remedy Opco and New Remedy Corp will not, and will cause their Subsidiaries to not, take any action
inconsistent with the Pre-Closing Restructuring or that would cause any of New Remedy Corp’s Subsidiaries to be treated, as of the Closing, for U.S. federal income tax purposes as other than entities
disregarded from New Remedy Corp. 
 (b) Upon the terms and subject to the conditions set forth in this Agreement, at the Closing,
(i) all of the outstanding Parent Class A Common Units shall be exchanged for and converted into Parent Series B Preferred Units on a one-for-one basis (for
the avoidance of doubt, all Parent Class B Common Units shall remain outstanding) and (ii) New Remedy Corp shall contribute, convey and otherwise assign to Parent, and Parent shall accept, all of the issued and outstanding Equity Interests
of Remedy Opco, in exchange for 3,384,542.7 newly-issued Parent Series A Preferred Units (the “Exchanged Units”), which such Exchanged Units shall be issued by Parent to New Remedy Corp at the Closing (the transactions described in
this clause (ii) are referred to herein as the “Remedy Exchange”). 
 (c) Immediately following
the consummation of the transactions described in Section 2.1(b), Parent will contribute the Equity Interests of Remedy Opco in successive steps to Cure Borrower; provided, that such contribution to Cure Borrower
shall involve several intermediate contributions to direct and indirect Subsidiaries of Parent that are direct and indirect parent entities of Cure Borrower. Immediately following such contribution to Cure Borrower, Remedy Opco shall be a
wholly-owned indirect Subsidiary of Parent and direct wholly-owned Subsidiary of Cure Borrower. 
 (d) The transactions described in
Section 2.1(a), (b) and (c) are collectively referred to herein as the “Combination”. 

Section 2.2 The Closing. The closing of the Remedy Exchange (the “Closing”) shall occur by the electronic
exchange of executed documents in portable document format (i.e., PDF), at 9:00 A.M. Eastern Time (i) on the date that is one (1) Business Day following the satisfaction or waiver of the conditions precedent set forth in
Article 7 (except for those conditions that by their nature are to be satisfied by the delivery of documents or taking of actions or otherwise at the Closing, but subject to the satisfaction of such conditions at the Closing or, if
permissible, written waiver by the party hereto entitled to the benefit of such conditions at the Closing) or (ii) on such other date and as may be agreed in writing by each of the Parties; provided, however, that unless
consented to in writing by each of the Parties, in no event shall the Closing take place prior to the first (1st) Business Day following the consummation of the
Pre-Closing Restructuring. The date on which the Closing occurs in accordance with the preceding sentence is referred to in this Agreement as the “Closing Date.” 

  
 - 13 - 

 Section 2.3 Tax Treatment of the Combination. For United States federal income
tax purposes, the Parties intend that (1) the transactions described in clauses (b), (c) and (g) of the second Recital constitute a reorganization described in Section 368(a)(1)(F) and
Section 368(a)(1)(E) of the Code; (2) the transactions described in clause (a) of the second Recital constitute tax-free liquidations pursuant to Section 332 of the Code and a tax-free change in
classification of Liberty Health Partners, LLC whereby Liberty Health Partners, LLC will become an entity disregarded from its owner for U.S. federal income tax purposes; (3) the Remedy Exchange constitutes a transaction governed by
Section 721(a) of the Code; (4) the transactions described in Section 2.1(c) are disregarded transactions; and (5) the occurrence of any Forfeiture Event (as defined in the A&R Parent LLCA) is
treated as a Tax-free adjustment to the Remedy Exchange (collectively, the “Intended Tax Treatment”). The Parties agree to file all Tax returns in a manner consistent with the Intended Tax Treatment, except upon a contrary final
determination by an applicable taxing authority. 
 ARTICLE 3 

REPRESENTATIONS AND WARRANTIES OF REMEDY OPCO 

Remedy Opco hereby represents and warrants to Parent as follows: 

Section 3.1 Organization and Power. As of the date hereof, Remedy Opco is a corporation duly organized, validly existing and in
good standing under the Laws of the State of Delaware. As of the Closing Date, following the consummation of the Pre-Closing Restructuring, Remedy Opco will be a limited liability company duly organized,
validly existing and in good standing under the Laws of the State of Delaware. Remedy Opco has all requisite organizational power and authority to execute and deliver this Agreement and the other Transaction Documents to which it is or will be a
party and to perform its obligations hereunder and thereunder. 
 Section 3.2 Authorization. 

(a) The execution, delivery and performance by Remedy Opco of this Agreement and the other Transaction Documents to which it is or will be a
party and the consummation of the Combination and each of the other transactions contemplated hereby and thereby have been duly and validly authorized by all requisite action of Remedy Opco, and no other corporate (or equivalent) act or proceeding
on the part of Remedy Opco, the Remedy Board or the equityholders of Remedy Opco is necessary to authorize the execution, delivery or performance of this Agreement or any other Transaction Document to which Remedy Opco is or will be a party or the
consummation of any of the transactions contemplated hereby or thereby’ provided, that the Pre-Closing Restructuring transaction and related documents will require the approval of the boards of
directors and stockholders of New Remedy Corp and Remedy Merger Sub (and the conversion of Remedy Opco Subsidiaries to limited liability companies will require approval of their respective boards of directors and stockholders). This Agreement has
been duly executed and delivered by Remedy Opco and, assuming the due execution and delivery of this Agreement and such other Transaction Documents by the other parties hereto and thereto, this Agreement constitutes, and the other Transaction
Documents to which Remedy Opco is or will be a party, upon execution and delivery by Remedy Opco, will each constitute, a legal, valid 

  
 - 14 - 

 
and binding obligation of Remedy Opco, enforceable in accordance with their terms, except as the enforceability hereof or thereof may be limited by any applicable bankruptcy, insolvency,
reorganization, moratorium or other similar Laws affecting the enforcement of creditor’s rights generally and as limited by the availability of specific performance and other equitable remedies or applicable equitable principles (whether
considered in a proceeding at law or in equity) (collectively, the “General Enforceability Exceptions”). 
 (b) The Remedy
Board (including the Special Committee) has determined that this Agreement, the other Transaction Documents to which Remedy Opco is or will be a party and the Combination are fair to and in the best interests of Remedy Opco and its stockholders.

 Section 3.3 Capitalization; Subsidiaries. As of the date hereof, there are 135,993,425 shares of Senior Convertible Preferred
Stock, par value $0.001, of Remedy Opco, 118,074,187 shares of Common Stock, par value $0.001, of Remedy Opco, and 24,548,672 Remedy Opco Options issued and outstanding, which such shares of Senior Convertible Preferred Stock, shares of Common Stock
and Remedy Opco Options collectively constitute all of the issued and outstanding Equity Interests of Remedy Opco. All of the issued and outstanding Equity Interests of Remedy Opco have been duly authorized, are validly issued, fully paid and, to
the extent applicable, nonassessable, and will be, as of immediately prior to the Closing, owned free and clear of any Liens (other than Liens arising under the Remedy Stockholders’ Agreement that will cease to apply to Remedy Opco following
the consummation of the Combination). Other than as set forth in this Agreement, except for the Remedy Opco Options and for rights arising under the Remedy Stockholders’ Agreement that will cease to apply to Remedy Opco following the
consummation of the Combination, there are no outstanding or authorized options, warrants, restricted stock units, rights (including any preemptive rights), pledges, calls, puts, rights to subscribe, conversion or exchange rights or other Contracts
or commitments, in each case to which Remedy Opco is a party or which are binding upon Remedy Opco, providing for the issuance, disposition or acquisition of any of its Equity Interests or any rights or interests exercisable therefor, and there are
no outstanding or authorized equity appreciation, phantom stock, profit participation or similar rights with respect to the Equity Interests of Remedy Opco. All of the issued and outstanding Equity Interests of Remedy Opco’s Subsidiaries are
directly or indirectly owned by Remedy Opco, free and clear of all Liens (other than immaterial Liens and any Liens arising under the Remedy Stockholders’ Agreement that will cease to apply to such Subsidiaries following the consummation of the
Combination). 
 Section 3.4 Consents and Approvals; No Violations. Except for a filing related to the CMS Approval, no filing
with or notice to, and no permit, authorization, registration, consent or approval of, any Governmental Entity or any other Person is required on the part of Remedy Opco for the execution, delivery and performance by Remedy Opco of this Agreement or
the consummation by Remedy Opco of the transactions contemplated by this Agreement and the other Transaction Documents, except for any such filings, notices, permits, authorizations, registrations, consents or approvals of which the failure to make
or obtain would not, individually or in the aggregate, reasonably be expected to have a Remedy Material Adverse Effect. Neither the execution, delivery and performance by Remedy Opco of this Agreement or the other Transaction Documents to which it
is or will be a party nor the consummation by Remedy Opco of the transactions contemplated hereby or thereby will (i) conflict with or result 

  
 - 15 - 

 
in any breach, violation or infringement of any provision of the Organizational Documents of Remedy Opco, (ii) result in a material breach, material violation or infringement of, constitute
(with or without due notice or lapse of time or both) a material default (or give rise to the creation of any material Lien or any material right of termination, amendment, cancellation or acceleration) under, require delivery of notice to or the
consent of any Person under, or result in the payment of any additional fee, penalty, consent fee or other amount, or to loss of a material benefit under, any of the terms, conditions or provisions of any Contract or (iii) violate or infringe
any Law applicable to Remedy Opco, its Subsidiaries or any of their respective properties or assets, except in the case of clauses (i) through (iii), as would not reasonably be expected to have a Remedy Material Adverse Effect.

 Section 3.5 Financial Statements. Remedy Opco has made available to Parent true, correct and complete copies of the following
financial statements (collectively, with any notes thereto, the “Remedy Financial Statements”): (i) the audited consolidated balance sheet of Remedy Opco and its Subsidiaries, as of and for the fiscal year ended December 31, 2018 and the
related statements of income, stockholders’ equity and cash flows for the year then ended and (ii) the unaudited consolidated balance sheet of Remedy Opco and its Subsidiaries, as of September 30, 2019 (such date, the “Remedy Balance Sheet
Date”), and the related unaudited consolidated statement of income for the nine (9)-month period then ended (the “Remedy Interim Financial Statements”). Except as disclosed on Schedule 3.5, the Remedy Financial Statements have been
prepared in accordance with GAAP applied on a consistent basis (except as may be noted therein), and present fairly in accordance with GAAP in all material respects the financial position and the results of operations of Remedy Opco and its
Subsidiaries as of the respective dates thereof and for the respective periods covered thereby, except that the Remedy Interim Financial Statements do not contain the footnotes required by GAAP and are subject to normal year-end adjustments (each of which would not reasonably be expected to be material). 
 Section 3.6
Permits; Compliance with Laws. Remedy Opco and its Subsidiaries hold all material permits, licenses, franchises, variances, exemptions, certifications, registrations, orders and other authorizations, consents and approvals of all Governmental
Entities necessary for the conduct of their respective businesses as presently conducted, except as would not be material to Remedy Opco and its Subsidiaries, taken as a whole. Remedy Opco and its Subsidiaries are in compliance with all Laws
applicable to the operation of their respective businesses and the ownership of their properties and assets, except as would not be material to Remedy Opco and its Subsidiaries, taken as a whole. 

Section 3.7 Absence of Certain Events. From the Remedy Balance Sheet Date through the date of this Agreement: 

(a) except as expressly contemplated by this Agreement (including, for the avoidance of doubt, as part of or in connection with the Pre-Closing Restructuring) or as disclosed on Schedule 3.7, Remedy Opco and its Subsidiaries have conducted their respective businesses in the ordinary course and neither Remedy Opco, nor any of its
Subsidiaries, have: 
 (i) amended or otherwise modified its Organizational Documents; 

  
 - 16 - 

 (ii) (A) except for repurchases of Equity Interests held by current or
former employees of Remedy Opco or its Subsidiaries in the ordinary course, reclassified, repurchased, combined, split, subdivided or redeemed, or purchased or otherwise acquired, directly or indirectly, any of its Equity Interests or amended the
terms of any of its Equity Interests, or (B) declared, set aside, made or paid any distribution of assets or properties in respect of any Equity Interests in Remedy Opco or its Subsidiaries, except intercompany dividends; 

(iii) adopted a plan of complete or partial liquidation, dissolution, consolidation, restructuring, recapitalization or other
reorganization of Remedy Opco or any of its Subsidiaries; 
 (iv) incurred any material Debt; or 

(v) authorized, agreed, resolved, consented or entered into any Contract to do any of the foregoing; and 

(b) there has been no Remedy Material Adverse Effect. 

Section 3.8 Brokers. No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission
in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Remedy Opco or any of its Subsidiaries, for which Parent, Remedy Opco or any of their respective Subsidiaries or equityholders could
be liable. 
 Section 3.9 Litigation. As of the date hereof, there is no Action pending or, to the Knowledge of Remedy Opco,
threatened in writing against or affecting Remedy Opco or any of its Subsidiaries or, to the Knowledge of Remedy Opco, any present officer or director of Remedy Opco or any of its Subsidiaries in his or her capacity as such, in each case that if
adversely determined would reasonably be expected to have a Remedy Material Adverse Effect. 
 Section 3.10 Transactions with
Affiliates. There are no transactions, arrangements or Contracts by or among any NM Person (excluding Remedy Opco, its parent entities and its Subsidiaries), on the one hand, and Remedy Opco, any of its parent entities or any of its and their
Subsidiaries, on the other hand, other than transactions arrangements and Contracts listed or described on Schedule 3.10. 

Section 3.11 No Undisclosed Liabilities. Except as set forth on Schedule 3.11, to the Knowledge of Remedy Opco the Remedy
Companies have no material Liabilities except for Liabilities, (a) reflected or reserved for on the face of the Remedy Interim Financial Statements, (b) fully satisfied as of the date hereof, (c) that have arisen since the date of the
Remedy Balance Sheet Date in the ordinary course, or (d) incurred directly pursuant to the Transactions or as otherwise contemplated by this Agreement. 

  
 - 17 - 

 Section 3.12 Material Customers. Except as disclosed on Schedule 3.12, to
the Knowledge of Remedy Opco no Material Remedy Customer has cancelled, terminated or otherwise materially altered (including any material reduction in the rate or amount of sales or purchases or material increase in the prices charged or paid, as
the case may be) or notified a Remedy Company in writing of any intention to do any of the foregoing or otherwise threatened in writing to cancel, terminate or materially alter (including any material reduction in the rate or amount of sales or
purchases or material increase in the prices charged or paid as the case may be) its relationship with a Remedy Company. To the Knowledge of Remedy Opco, there are no facts or circumstances that would be reasonably likely to result in a material
change in the relationships of the Remedy Companies with any Material Remedy Customer as a result of the consummation of the Transactions. 

Section 3.13 Certain Contracts; No Defaults. Schedule 3.13 contains a listing of each: (a) Contract between any Remedy
Company and any Material Remedy Customer (other than purchase orders entered into in the ordinary course); (b) note, other evidence of indebtedness, guarantee, loan, credit or financing agreement or instrument or other Contract in respect of Debt,
in each case, having an outstanding principal amount in excess of $250,000; (c) Contract for the acquisition or disposition of any Person, business division thereof or any material assets thereof, in each case, involving payments in excess of
$250,000, other than Contracts in which the applicable acquisition or disposition has been consummated and there are no obligations ongoing; (d) joint venture Contract, partnership agreement or limited liability company agreement with a third
party (in each case, other than solely between or among the Remedy Companies); and (e) Contract containing covenants expressly limiting in any material respect the freedom of the Remedy Companies (i) to compete with any Person in a product
line or line of business or to operate in any geographic area, (ii) to sell or purchase any other Person, or (iii) to solicit or employ any Person. True, complete, accurate copies of each such Contract, in each case, as amended or
otherwise modified and in effect, have been delivered to Parent. Except as set forth on Schedule 3.13, as of the date of this Agreement, all of the Contracts set forth on Schedule 3.13 are in full force and effect, subject to the
General Enforceability Exceptions, and represent the valid and binding obligations of a Remedy Company party thereto and, to the Knowledge of Remedy Opco, represent the valid and binding obligations of the other parties thereto. Except as set forth
on Schedule 3.13, no Remedy Company or, to the Knowledge of Remedy Opco, any other party thereto is in breach or violation of or default under, or has repudiated any material provision of any such Contract, in each case except as would not be
material to Remedy Opco and its Subsidiaries, taken as a whole. 
 Section 3.14 Benefit Plans.  

(a) As used herein, (i) a “Remedy Benefit Plan” shall mean each “employee benefit plan” (as defined in
Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), whether or not subject to ERISA), and each employment, consulting, individual independent contractor, bonus, deferred compensation,
incentive compensation, stock purchase, stock option or other equity or equity-based, retention, change in control, severance or termination pay, medical, life or other welfare benefit insurance, supplemental unemployment benefits, profit-sharing,
pension or retirement plan, program policy, agreement or arrangement, and each other fringe or other employee benefit plan, program policy, agreement or arrangement providing compensation or other benefits to any current or former employee,
director, officer, consultant or individual independent contractor, in each case, whether written or unwritten, and which is currently maintained, sponsored or contributed to or 

  
 - 18 - 

 
required to be contributed to or by any Remedy Company or a Remedy ERISA Affiliate, or under which any Remedy Company or a Remedy ERISA Affiliate has or would reasonably be expected to have any
Liability, and (ii) “Remedy ERISA Affiliate” shall mean all employers (whether or not incorporated) that would be treated together with Remedy Opco or any of its Affiliates as a “single employer” within the meaning of
Section 414 of the Code. 
 (b) (i) Each Remedy Benefit Plan was established and is maintained and administered in all material
respects in accordance with its terms and in compliance with all applicable Laws, including ERISA and the Code, (ii) all contributions required to be made with respect to any Remedy Benefit Plan on or before the date hereof have been timely and
completely made, and (iii) each Remedy Benefit Plan which is intended to be qualified within the meaning of Section 401(a) of the Code (A) has received a favorable determination as to its qualification upon which it can rely, or
(B) has been established under a standardized master and prototype or volume submitter plan for which a current favorable Internal Revenue Service advisory letter or opinion letter has been obtained by the plan sponsor and is valid as to the
adopting employer, and, in each case, nothing has occurred that would reasonably be expected to affect such qualification, except in the case of clauses (i) through (iii), as would not reasonably be expected to have a Remedy
Material Adverse Effect. 
 (c) No Remedy Company nor any of its Remedy ERISA Affiliates sponsors or contributes to, or has sponsored or
contributed to, or had any obligations with respect to, any Remedy Benefit Plan that is (i) a multiemployer pension plan (as defined in Section 3(37) of ERISA), (ii) a pension plan subject to Section 302 of ERISA, Title IV of ERISA or
section 412 of the Code, (iii) a “multiple employer plan” governed by Section 413(c) of the Code, or (iv) a “multiple employer welfare arrangement” as defined in Section 3(40) of ERISA. 

(d) No material amount that could be received (whether in cash or property or the vesting of property) by any “disqualified
individual” of any Remedy Company or any Remedy ERISA Affiliate under any Remedy Benefit Plan or otherwise as a result of the consummation of the Transactions (whether alone or in combination with any other event) would constitute an
“excess parachute payment” within the meaning of Section 280G of the Code. To the Knowledge of Remedy Opco, (i) each plan or arrangement that provides for nonqualified deferred compensation subject to Section 409A of the
Code has been and is, operated, maintained and administered in all material respects, in compliance with Section 409A of the Code, and (ii) neither any Remedy Company nor any Remedy ERISA Affiliate is required to gross-up any Person in respect of any Tax under Section 4999 or 409A of the Code, in each case except as would not be material to Remedy Opco and its Subsidiaries, taken as a whole. 

(e) The consummation of the Transactions will not, whether alone or in connection with any other event, (i) entitle any current or former
employee, officer, director, consultant or individual independent contractor of any Remedy Company or any Remedy ERISA Affiliate to severance pay, unemployment compensation or any other payment, benefit, or award under any Remedy Benefit Plan or
otherwise or (ii) accelerate or modify the time of payment or vesting, or increase the amount of any benefit, award or compensation due any such current or former employee, officer, director, consultant or individual independent contractor
under any Remedy Benefit Plan or otherwise, in each case except as would not be material to Remedy Opco and its Subsidiaries, taken as a whole. 

  
 - 19 - 

 Section 3.15 Labor Relations.  

(a) Except as set forth on Schedule 3.15(a), (i) no Remedy Company is a party, or otherwise subject, to any collective bargaining
agreement or other Contract with any labor union, works council or other employee representative body (each, a “Labor Union”), and no such Contract is being negotiated by any Remedy Company; (ii) no employee of a Remedy Company
is represented by a Labor Union; (iii) no notice, consent or consultation obligations with respect to any employees of any Remedy Company, or any Labor Union, will be a condition precedent to, or triggered by, the execution of this Agreement or
the consummation of the Transactions; and (iv) in the last two years there has not been any labor strike, slowdown, work stoppage, lockout, picketing, labor organization effort or drive, petition seeking recognition of a bargaining
representative filed with any labor relations board or other Governmental Entity, unfair labor practice complaint or grievance, or other similar labor activity or dispute affecting any Remedy Company, except in the case of clause (iv), as
would not reasonably be expected to have a Remedy Material Adverse Effect. 
 (b) To the Knowledge of Remedy Opco, no current executive,
officer, director, key employee or group of employees has given notice of termination of employment or otherwise disclosed plans to terminate employment with any of the Remedy Companies within the twelve (12) month period following the date
hereof. No executive, officer, director or key employee of any of the Remedy Companies is employed under a non-immigrant work visa or other work authorization that is limited in duration. 

(c) Except as set forth on Schedule 3.15(c), the Remedy Companies are, and in the last four years have been, in material compliance with
all applicable Laws respecting employment and employment practices, terms and conditions of employment, including but not limited to wages and hours and the classification and compensation of employees and independent contractors. Except as set
forth on Schedule 3.15(c), no Remedy Company has incurred, and to the Knowledge of Remedy Opco no circumstances exist under which any of the Remedy Companies would reasonably be expected to incur, any material Liability arising from the
failure to pay wages (including overtime wages), the misclassification of employees as independent contractors, and/or the misclassification of employees as exempt from the requirements of the Fair Labor Standards Act or applicable state Law. 

Section 3.16 Taxes. Except as set forth on Schedule 3.16:  

(a) (i) all material Tax Returns required to be filed by or with respect to any Remedy Company have been properly prepared and timely
filed, and all such Tax Returns are true and complete in all material respects, (ii) the Remedy Companies have timely paid all Taxes which are due and payable by the Remedy Companies, and (iii) all Taxes required to be withheld by the
Remedy Companies have been withheld and timely paid over to the appropriate Governmental Entity, in each case except as would not be material to Remedy Opco and its Subsidiaries, taken as a whole. 

  
 - 20 - 

 (b) No material deficiency for any Taxes has been asserted or assessed by any Governmental
Entity in writing against a Remedy Company except for deficiencies which have been fully satisfied by payment, settled or withdrawn. No audit or other proceeding by any Governmental Entity is pending or threatened in writing against a Remedy Company
with respect to any Taxes due from a Remedy Company. To the Knowledge of Remedy Opco, no Remedy Company has ever received a written claim from any Governmental Entity in a jurisdiction in which the Remedy Company does not file a Tax Return that the
Remedy Company is or may be subject to taxation by that jurisdiction. There are no outstanding waivers or agreements regarding the application of the statute of limitations with respect to any material amounts of Taxes or material Tax Returns of a
Remedy Company (other than pursuant to an extension of time to file). 
 (c) None of the Remedy Companies is party to any Tax
indemnification, Tax allocation or Tax sharing agreements, other than (x) customary agreements or arrangements with customers, vendors, lessors, lenders and the like or other agreements that do not relate primarily to Taxes or
(y) agreements the only parties to which are Remedy Companies. 
 Section 3.17 Healthcare and Data Protection
Representations. 
 (a) Except as set forth on Schedule 3.17(a), (i) the Remedy Companies are, and at all times since
January 1, 2016 (the “Look-Back Date”) have been, in compliance in all material respects with all Healthcare Laws, and (ii) to the Knowledge of Remedy Opco, since the Look-Back Date, no Remedy Company has, for itself, or
on behalf of its customers or otherwise, billed for or received any payment or reimbursement materially in excess of amounts permitted by Law or the applicable billing guidelines for any Government Program or any commercial payor for which any
Remedy Company has not submitted or requested an adjustment to such payment or amounts within the time frames required by such third party payor and/or Law, in each case except as would not be material to Remedy Opco and its Subsidiaries, taken as a
whole. There is no Action pending or, to the Knowledge of Remedy Opco, threatened, involving any Government Program or any commercial payor program, including the Remedy Companies’ participation in and the reimbursement received from the
Government Programs or any such program, and no Remedy Company has any reason to believe that any such Action is pending, imminent or threatened. To the Knowledge of Remedy Opco, the Remedy Companies have not caused any customer to submit any false
claim or statement to any third party, except as would not be material to Remedy Opco and its Subsidiaries, taken as a whole. 
 (b) To the
Knowledge of Remedy Opco, no Remedy Company nor any of their respective Representatives have since the Look-Back Date directly or indirectly: (i) offered to pay or solicited any remuneration, in cash or in kind, to, or made any financial
arrangements with, any past or present customers, past or present suppliers, contractors, third parties, or third party payors of the business in order to obtain business or payments from such persons or entities, other than in the ordinary course
and in compliance with Law in all material respects, including all Healthcare Laws; (ii) given or received, or agreed to give or receive any gift or gratuitous payment of any kind, nature or description (whether in money, property or services)
to any customer or potential customer, supplier or potential supplier, contractors, third party payor or any other person other than in the ordinary course and in material compliance with Law, including all Healthcare Laws; (iii) made or agreed
to make any contributions, payment or gift of funds or property to, or for the private use of, any governmental official, employee or agent where either the contribution, payment or gift or the purpose of such contribution, payment or gift is or was
in violation in any material respect of any Healthcare Law or other applicable Law; 

  
 - 21 - 

 
(iv) established or maintained any unrecorded fund or asset for any purpose or made any materially false or artificial entries on any of its books or records for any reason; or (v) made or
agreed to make any payment to any person with the intention or understanding that any part of such payment would be used for the purpose other than that described in the documents supporting such payment, in each case except as would not be material
to Remedy Opco and its Subsidiaries, taken as a whole. None of the Remedy Companies or, to the Knowledge of Remedy Opco, any of their respective Representatives have been excluded, debarred or suspended from participating in any Government Program.

 (c) Since the Look-Back Date, to the Knowledge of Remedy Opco: (i) each Remedy Company is and has been in compliance with all
applicable Data Protection Obligations in all material respects; (ii) no Remedy Company has been party to any claims or received any written complaints or requests from any Person in respect of any material breach of any Data Protection
Obligations or otherwise regarding any Remedy Company’s uses or disclosures of, or security practices or incidents regarding, Sensitive Data; (iii) no Remedy Company has received any written complaints, allegations or notices of potential
or actual material non-compliance with any Data Protection Obligations, or any notices of inspection or audit or requests for information from any Governmental Entity or any other relevant authority or
regulator with respect to any Data Protection Obligations; (iv) no Sensitive Data in the custody, control or possession of any Remedy Company has been the subject of unauthorized or unlawful processing, or accidental loss, destruction or
damage, or other breach in any material respect and each Remedy Company has complied in all material respects with all of its obligations under all applicable Data Protection Obligations regarding the security of Sensitive Data (including regarding
the appointment of any data processor); and (v) each Remedy Company has, when acting as a data processor or a data controller under a written agreement, complied in all material respects with all Data Protection Obligations contained within the
relevant written agreement, in each case as would not reasonably be expected to have a Remedy Material Adverse Effect. 
 Section 3.18
Assets and Properties. The Remedy Companies own and have good title to or hold a valid and exclusive leasehold interest in all material assets, properties and rights used in the operation of their business, which comprise all of the tangible
assets, properties and rights of every type and description, whether real or personal, that are used in or necessary for the conduct of the business as conducted on the date hereof and are adequate to conduct the business in substantially the same
manner immediately following the Closing as conducted on the date hereof, in each case as would not reasonably be expected to have a Remedy Material Adverse Effect. 

Section 3.19 No Other Representations or Warranties. REMEDY OPCO DOES NOT MAKE ANY REPRESENTATIONS OR WARRANTIES TO PARENT EXCEPT
AS EXPRESSLY SET FORTH IN THIS ARTICLE 3. ANY AND ALL STATEMENTS MADE OR INFORMATION COMMUNICATED BY REMEDY OPCO, ITS EQUITYHOLDERS OR ANY OF ITS OR THEIR RESPECTIVE REPRESENTATIVES OUTSIDE OF THIS AGREEMENT, WHETHER VERBALLY OR IN WRITING,
ARE DEEMED TO HAVE BEEN SUPERSEDED BY THIS AGREEMENT, IT BEING INTENDED THAT NO SUCH PRIOR OR CONTEMPORANEOUS STATEMENTS OR COMMUNICATIONS OUTSIDE OF THIS AGREEMENT SHALL SURVIVE THE EXECUTION AND DELIVERY OF THIS AGREEMENT. 

  
 - 22 - 

 ARTICLE 4 

REPRESENTATIONS AND WARRANTIES OF PARENT 

Parent represents and warrants to Remedy Opco as follows: 

Section 4.1 Organization and Power. Parent is a limited liability company duly organized, validly existing and in good standing
under the Laws of the State of Delaware. Parent has all requisite organizational power and authority to execute and deliver this Agreement and the other Transaction Documents to which it is or will be a party and to perform its obligations hereunder
and thereunder. 
 Section 4.2 Authorization.  

(a) The execution, delivery and performance by Parent of this Agreement and the other Transaction Documents to which it is or will be a party
and the consummation of the Combination and each of the other transactions contemplated hereby and thereby have been duly and validly authorized by all requisite action of Parent, and no other corporate (or equivalent) act or proceeding on the part
of Parent, the Parent Board or the equityholders of Parent is necessary to authorize the execution, delivery or performance of this Agreement or any other Transaction Document to which Parent is or will be a party or the consummation of any of the
transactions contemplated hereby or thereby. This Agreement has been duly executed and delivered by Parent and, assuming the due execution and delivery of this Agreement and such other Transaction Documents by the other parties hereto and thereto,
this Agreement constitutes, and the other Transaction Documents to which Parent is or will be a party, upon execution and delivery by Parent, will each constitute, a legal, valid and binding obligation of Parent, enforceable in accordance with their
terms, subject to the General Enforceability Exceptions. 
 (b) The Parent Board has determined that this Agreement, the other Transaction
Documents and the Combination are fair to and in the best interests of Parent and its equityholders. 
 Section 4.3 Capitalization;
Subsidiaries.  
 (a) As of the date hereof, there are 3,533,133.2 Parent Class A Common Units of Parent and 453,106 Parent
Class B Common Units issued and outstanding, which collectively constitute all of the issued and outstanding Equity Interests of Parent. All of the issued and outstanding Equity Interests of Parent have been duly authorized and are validly
issued, and have not been issued in violation of, and, except as set forth in the Existing Parent LLCA, are not subject to, any preemption, subscription or similar rights. Other than as set forth in this Agreement or as set forth in the Existing
Parent LLCA and except for the Parent Class B Common Units, there are no outstanding or authorized options, profits interests, warrants, restricted units, rights (including any preemptive rights), pledges, calls, puts, rights to subscribe,
conversion or exchange rights or other Contracts or commitments, in each case to which Parent 

  
 - 23 - 

 
is a party or which are binding upon Parent, providing for the issuance, disposition or acquisition of any of its Equity Interests or any rights or interests exercisable therefor, and there are
no outstanding or authorized equity appreciation, phantom stock, profit participation or similar rights with respect to the Equity Interests of Parent. All of the issued and outstanding Equity Interests of Parent’s Subsidiaries are directly or
indirectly owned by Parent, free and clear of all Liens (other than immaterial Liens and Liens arising under the Existing Parent LLCA, the Organizational Documents of such Subsidiaries or any applicable credit agreements or other debt financing
documents). 
 (b) The Exchanged Units, when issued to New Remedy Corp at the Closing, will be free and clear of all Liens, other than any
Liens arising under the A&R Parent LLCA. 
 Section 4.4 Consents and Approvals; No Violations. No filing with or notice to,
and no permit, authorization, registration, consent or approval of, any Governmental Entity or any other Person is required on the part of Parent for the execution, delivery and performance by Parent of this Agreement or the consummation by Parent
of the transactions contemplated by this Agreement and the other Transaction Documents, except for any such filings, notices, permits, authorizations, registrations, consents or approvals of which the failure to make or obtain would not,
individually or in the aggregate, reasonably be expected to have a Signify Material Adverse Effect. Neither the execution, delivery and performance by Parent of this Agreement or the other Transaction Documents to which it is or will be a party nor
the consummation by Parent of the transactions contemplated hereby or thereby will (i) conflict with or result in any breach, violation or infringement of any provision of the Organizational Documents of Parent, (ii) result in a material
breach, material violation or infringement of, constitute (with or without due notice or lapse of time or both) a material default (or give rise to the creation of any material Lien or any material right of termination, amendment, cancellation or
acceleration) under, require delivery of notice to or the consent of any Person under, or result in the payment of any additional fee, penalty, consent fee or other amount, or to loss of a material benefit under, any of the terms, conditions or
provisions of any Contract or (iii) violate or infringe any Law applicable to Parent, its Subsidiaries or any of their respective properties or assets, except in the case of clauses (i) through (iii), as would not reasonably be
expected to have a Signify Material Adverse Effect. 
 Section 4.5 Financial Statements. Parent has made available to Remedy
Opco true, correct and complete copies of the following financial statements (collectively, with any notes thereto, the “Signify Financial Statements”): (i) the audited consolidated balance sheet of Signify Health, LLC and its
Subsidiaries, as of and for the year ended December 31, 2018 and the related consolidated statements of income, changes in member’s equity and cash flows for the year then ended and (ii) the unaudited consolidated balance sheet of
Signify Health, LLC and its Subsidiaries, as of September 30, 2019 (such date, the “Signify Balance Sheet Date”), and the related unaudited consolidated statement of income for the nine (9)-month period then ended (the
“Signify Interim Financial Statements”). Except as disclosed on Schedule 4.5, the Signify Financial Statements have been prepared in accordance with GAAP applied on a consistent basis (except as may be noted therein), and
present fairly in accordance with GAAP in all material respects the financial position and the results of operations of Parent and its Subsidiaries as of the respective dates thereof and for the respective periods covered thereby, except that the
Signify Interim Financial Statements do not contain the footnotes required by GAAP and are subject to normal year-end adjustments (each of which would not reasonably be expected to be material). 

  
 - 24 - 

 Section 4.6 Permits; Compliance with Laws. Parent and its Subsidiaries hold all
material permits, licenses, franchises, variances, exemptions, certifications, registrations, orders and other authorizations, consents and approvals of all Governmental Entities necessary for the conduct of their respective businesses as presently
conducted, except as would not be material to Remedy Opco and its Subsidiaries, taken as a whole. Parent and its Subsidiaries are in compliance with all Laws applicable to the operation of their respective businesses and the ownership of their
properties and assets, except as would not be material to Remedy Opco and its Subsidiaries, taken as a whole. 
 Section 4.7 Absence
of Certain Events. From the Signify Balance Sheet Date through the date of this Agreement: 
 (a) except as expressly contemplated by
this Agreement or as disclosed on Schedule 4.7, Parent and its Subsidiaries have conducted their respective businesses in the ordinary course and neither Parent, nor any of its Subsidiaries, have: 

(i) amended or otherwise modified its Organizational Documents; 

(ii) (A) except for repurchases of Equity Interests held by current or former employees of Parent or its Subsidiaries in
the ordinary course, reclassified, repurchased, combined, split, subdivided or redeemed, or purchased or otherwise acquired, directly or indirectly, any of its Equity Interests or amended the terms of any of its Equity Interests, or
(B) declared, set aside, made or paid any distribution of assets or properties in respect of any Equity Interests in Parent or its Subsidiaries, except intercompany dividends; 

(iii) adopted a plan of complete or partial liquidation, dissolution, consolidation, restructuring, recapitalization or other
reorganization of Parent or any of its Subsidiaries; 
 (iv) incurred any material Debt; 

(v) (A) made any payment or distribution to or for the benefit of any NM Person, (B) gave or provided anything of
value to or for the benefit of any NM Person, (C) assumed or acquired any Liability of any NM Person, or (D) made any commitment to do any of the foregoing (in each case excluding Parent and its Subsidiaries from the definition of NM
Person); or 
 (vi) authorized, agreed, resolved, consented or entered into any Contract to do any of the foregoing; and 

(b) there has been no Signify Material Adverse Effect. 

  
 - 25 - 

 Section 4.8 Brokers. No broker, finder or investment banker is entitled to any
brokerage, finder’s or other fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Parent or any of its Subsidiaries, for which Remedy Opco, Parent or any of their
respective Subsidiaries or equityholders could be liable. 
 Section 4.9 Litigation. As of the date hereof, there is no Action
pending or, to the Knowledge of Parent, threatened in writing against or affecting Parent or any of its Subsidiaries or, to the Knowledge of Parent, any present officer or director of Parent or any of its Subsidiaries in his or her capacity as such,
in each case that if adversely determined would reasonably be expected to have a Signify Material Adverse Effect. 
 Section 4.10
Transactions with Affiliates. There are no transactions, arrangements or Contracts by or among any NM Person (excluding Parent and its Subsidiaries), on the one hand, and Parent or any of its Subsidiaries, on the other hand, other than
transactions arrangements and Contracts listed or described on Schedule 4.10. 
 Section 4.11 No Undisclosed Liabilities.
Except as set forth on Schedule 4.11, to the Knowledge of Parent the Signify Companies have no material Liabilities except for Liabilities, (a) reflected or reserved for on the face of the Signify Interim Financial Statements,
(b) fully satisfied as of the date hereof, (c) that have arisen since the date of the Signify Balance Sheet Date in the ordinary course, or (d) incurred directly pursuant to the Transactions or as otherwise contemplated by this
Agreement. 
 Section 4.12 Material Customers. Except as disclosed on Schedule 4.12, to the Knowledge of Parent no
Material Signify Customer has cancelled, terminated or otherwise materially altered (including any material reduction in the rate or amount of sales or purchases or material increase in the prices charged or paid, as the case may be) or notified a
Signify Company in writing of any intention to do any of the foregoing or otherwise threatened in writing to cancel, terminate or materially alter (including any material reduction in the rate or amount of sales or purchases or material increase in
the prices charged or paid as the case may be) its relationship with a Signify Company. To the Knowledge of Parent, there are no facts or circumstances that would be reasonably likely to result in a material change in the relationships of the
Signify Companies with any Material Signify Customer as a result of the consummation of the Transactions. 
 Section 4.13 Certain
Contracts; No Defaults. Schedule 4.13 contains a listing of each: (a) Contract between any Signify Company and any Material Signify Customer (other than purchase orders entered into in the ordinary course); (b) note, other
evidence of indebtedness, guarantee, loan, credit or financing agreement or instrument or other Contract in respect of Debt, in each case, having an outstanding principal amount in excess of $250,000; (c) Contract for the acquisition or disposition
of any Person, business division thereof or any material assets thereof, in each case, involving payments in excess of $250,000, other than Contracts in which the applicable acquisition or disposition has been consummated and there are no
obligations ongoing; (d) joint venture Contract, partnership agreement or limited liability company agreement with a third party (in each case, other than solely between or among the Signify Companies); and (e) Contract containing
covenants expressly limiting in any material respect the freedom of the Signify Companies (i) to compete with any Person in a product line or line of business or to operate in any geographic area, (ii) to sell or purchase any other
Person, or (iii) to 

  
 - 26 - 

 
solicit or employ any Person. True, complete, accurate copies of each such Contract, in each case, as amended or otherwise modified and in effect, have been delivered to Remedy Opco. Except as
set forth on Schedule 4.13, as of the date of this Agreement, all of the Contracts set forth on Schedule 4.13 are in full force and effect, subject to the General Enforceability Exceptions, and represent the valid and binding
obligations of a Signify Company party thereto and, to the Knowledge of Parent, represent the valid and binding obligations of the other parties thereto. Except as set forth on Schedule 4.13, no Signify Company or, to the Knowledge of Parent,
any other party thereto is in breach or violation of or default under, or has repudiated any material provision of any such Contract, in each case except as would not be material to Parent and its Subsidiaries, taken as a whole. 

Section 4.14 Benefit Plans.  

(a) As used herein, (i) a “Signify Benefit Plan” shall mean each “employee benefit plan” (as defined in
Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), whether or not subject to ERISA), and each employment, consulting, individual independent contractor, bonus, deferred compensation,
incentive compensation, stock purchase, stock option or other equity or equity-based, retention, change in control, severance or termination pay, medical, life or other welfare benefit insurance, supplemental unemployment benefits, profit-sharing,
pension or retirement plan, program policy, agreement or arrangement, and each other fringe or other employee benefit plan, program policy, agreement or arrangement providing compensation or other benefits to any current or former employee,
director, officer, consultant or individual independent contractor, in each case, whether written or unwritten, and which is currently maintained, sponsored or contributed to or required to be contributed to or by any Signify Company or a Parent
ERISA Affiliate, or under which any Signify Company or a Parent ERISA Affiliate has or would reasonably be expected to have any Liability, and (ii) “Parent ERISA Affiliate” shall mean all employers (whether or not incorporated) that
would be treated together with Parent or any of its Affiliates as a “single employer” within the meaning of Section 414 of the Code. 

(b) (i) Each Signify Benefit Plan was established and is maintained and administered in all material respects in accordance with its terms
and in compliance with all applicable Laws, including ERISA and the Code, (ii) all contributions required to be made with respect to any Signify Benefit Plan on or before the date hereof have been timely and completely made, and (iii) each
Signify Benefit Plan which is intended to be qualified within the meaning of Section 401(a) of the Code (A) has received a favorable determination as to its qualification upon which it can rely, or (B) has been established under a
standardized master and prototype or volume submitter plan for which a current favorable Internal Revenue Service advisory letter or opinion letter has been obtained by the plan sponsor and is valid as to the adopting employer, and, in each case,
nothing has occurred that would reasonably be expected to affect such qualification, except in the case of clauses (i) through (iii), as would not reasonably be expected to have a Signify Material Adverse Effect. 

(c) No Signify Company nor any of its Parent ERISA Affiliates sponsors or contributes to, or has sponsored or contributed to, or had any
obligations with respect to, any Signify Benefit Plan that is (i) a multiemployer pension plan (as defined in Section 3(37) of ERISA), (ii) a pension plan subject to Section 302 of ERISA, Title IV of ERISA or section 412 of the Code,
(iii) a “multiple employer plan” governed by Section 413(c) of the Code, or (iv) a “multiple employer welfare arrangement” as defined in Section 3(40) of ERISA. 

  
 - 27 - 

 (d) No material amount that could be received (whether in cash or property or the vesting of
property) by any “disqualified individual” of any Signify Company or any Parent ERISA Affiliate under any Signify Benefit Plan or otherwise as a result of the consummation of the Transactions (whether alone or in combination with any other
event) would constitute an “excess parachute payment” within the meaning of Section 280G of the Code. To the Knowledge of Parent, (i) each plan or arrangement that provides for nonqualified deferred compensation subject to
Section 409A of the Code has been and is, operated, maintained and administered in all material respects, in compliance with Section 409A of the Code, and (ii) neither any Signify Company nor any Parent ERISA Affiliate is required to gross-up any Person in respect of any Tax under Section 4999 or 409A of the Code, in each case except as would not be material to Parent and its Subsidiaries, taken as a whole. 

(e) The consummation of the Transactions will not, whether alone or in connection with any other event, (i) entitle any current or former
employee, officer, director, consultant or individual independent contractor of any Signify Company or any Parent ERISA Affiliate to severance pay, unemployment compensation or any other payment, benefit, or award under any Signify Benefit Plan or
otherwise or (ii) accelerate or modify the time of payment or vesting, or increase the amount of any benefit, award or compensation due any such current or former employee, officer, director, consultant or individual independent contractor
under any Signify Benefit Plan or otherwise, in each case except as would not be material to Parent and its Subsidiaries, taken as a whole. 

Section 4.15 Labor Relations.  

(a) Except as set forth on Schedule 4.15(a), (i) no Signify Company is a party, or otherwise subject, to any collective bargaining
agreement or other Contract with any Labor Union, and no such Contract is being negotiated by any Signify Company; (ii) no employee of a Signify Company is represented by a Labor Union; (iii) no notice, consent or consultation obligations
with respect to any employees of any Signify Company, or any Labor Union, will be a condition precedent to, or triggered by, the execution of this Agreement or the consummation of the Transactions; and (iv) in the last two years there has not
been any labor strike, slowdown, work stoppage, lockout, picketing, labor organization effort or drive, petition seeking recognition of a bargaining representative filed with any labor relations board or other Governmental Entity, unfair labor
practice complaint or grievance, or other similar labor activity or dispute affecting any Signify Company, except in the case of clause (iv), as would not reasonably be expected to have a Signify Material Adverse Effect. 

(b) To the Knowledge of Parent, no current executive, officer, director, key employee or group of employees has given notice of termination of
employment or otherwise disclosed plans to terminate employment with any of the Signify Companies within the twelve (12) month period following the date hereof. No executive, officer, director or key employee of any of the Signify Companies is
employed under a non-immigrant work visa or other work authorization that is limited in duration. 

  
 - 28 - 

 (c) Except as set forth on Schedule 4.15(c), the Signify Companies are, and in the
last four years have been, in material compliance with all applicable Laws respecting employment and employment practices, terms and conditions of employment, including but not limited to wages and hours and the classification and compensation of
employees and independent contractors. Except as set forth on Schedule 4.15(c), no Signify Company has incurred, and to the Knowledge of Parent no circumstances exist under which any of the Signify Companies would reasonably be expected to
incur, any material Liability arising from the failure to pay wages (including overtime wages), the misclassification of employees as independent contractors, and/or the misclassification of employees as exempt from the requirements of the Fair
Labor Standards Act or applicable state Law. 
 Section 4.16 Taxes. Except as set forth on Schedule 4.16: 

(a) (i) all material Tax Returns required to be filed by or with respect to any Signify Company have been properly prepared and timely
filed, and all such Tax Returns are true and complete in all material respects, (ii) the Signify Companies have timely paid all Taxes which are due and payable by the Signify Companies, and (iii) all Taxes required to be withheld by the
Signify Companies have been withheld and timely paid over to the appropriate Governmental Entity, in each case except as would not be material to Parent and its Subsidiaries, taken as a whole. 

(b) No material deficiency for any Taxes has been asserted or assessed by any Governmental Entity in writing against a Signify Company except
for deficiencies which have been fully satisfied by payment, settled or withdrawn. No audit or other proceeding by any Governmental Entity is pending or threatened in writing against a Signify Company with respect to any Taxes due from a Signify
Company. To the Knowledge of Parent, no Signify Company has ever received a written claim from any Governmental Entity in a jurisdiction in which the Signify Company does not file a Tax Return that the Signify Company is or may be subject to
taxation by that jurisdiction. There are no outstanding waivers or agreements regarding the application of the statute of limitations with respect to any material amounts of Taxes or material Tax Returns of a Signify Company (other than pursuant to
an extension of time to file). 
 (c) None of the Signify Companies is party to any Tax indemnification, Tax allocation or Tax sharing
agreements, other than (x) customary agreements or arrangements with customers, vendors, lessors, lenders and the like or other agreements that do not relate primarily to Taxes or (y) agreements the only parties to which are Signify
Companies. 
 Section 4.17 Healthcare and Data Protection Representations.  

(a) Except as set forth on Schedule 4.17(a), (i) the Signify Companies are, and at all times since the Look-Back Date have been, in
compliance in all material respects with all Healthcare Laws, and (ii) to the Knowledge of Parent, since the Look-Back Date, no Signify Company has, for itself, or on behalf of its customers or otherwise, billed for or received any payment or
reimbursement materially in excess of amounts permitted by Law or the applicable billing guidelines for any Government Program or any commercial payor for which any Signify Company has not submitted or requested an adjustment to such payment or
amounts within the time frames required by such third party payor and/or Law, in each case except as would not be 

  
 - 29 - 

 
material to Parent and its Subsidiaries, taken as a whole. There is no Action pending or, to the Knowledge of Parent, threatened, involving any Government Program or any commercial payor program,
including the Signify Companies’ participation in and the reimbursement received from the Government Programs or any such program, and no Signify Company has any reason to believe that any such Action is pending, imminent or threatened. To the
Knowledge of Parent, the Signify Companies have not caused any customer to submit any false claim or statement to any third party, except as would not be material to Parent and its Subsidiaries, taken as a whole. 

(b) To the Knowledge of Parent, no Signify Company nor any of their respective Representatives have since the Look-Back Date directly or
indirectly: (i) offered to pay or solicited any remuneration, in cash or in kind, to, or made any financial arrangements with, any past or present customers, past or present suppliers, contractors, third parties, or third party payors of the
business in order to obtain business or payments from such persons or entities, other than in the ordinary course and in compliance with Law in all material respects, including all Healthcare Laws; (ii) given or received, or agreed to give or
receive any gift or gratuitous payment of any kind, nature or description (whether in money, property or services) to any customer or potential customer, supplier or potential supplier, contractors, third party payor or any other person other than
in the ordinary course and in material compliance with Law, including all Healthcare Laws; (iii) made or agreed to make any contributions, payment or gift of funds or property to, or for the private use of, any governmental official, employee
or agent where either the contribution, payment or gift or the purpose of such contribution, payment or gift is or was in violation in any material respect of any Healthcare Law or other applicable Law; (iv) established or maintained any
unrecorded fund or asset for any purpose or made any materially false or artificial entries on any of its books or records for any reason; or (v) made or agreed to make any payment to any person with the intention or understanding that any part
of such payment would be used for the purpose other than that described in the documents supporting such payment, in each case except as would not be material to Parent and its Subsidiaries, taken as a whole. None of the Signify Companies or, to the
Knowledge of Parent, any of their respective Representatives have been excluded, debarred or suspended from participating in any Government Program. 

(c) Since the Look-Back Date, to the Knowledge of Parent: (i) each Signify Company is and has been in compliance with all applicable Data
Protection Obligations in all material respects; (ii) no Signify Company has been party to any claims or received any written complaints or requests from any Person in respect of any material breach of any Data Protection Obligations or
otherwise regarding any Signify Company’s uses or disclosures of, or security practices or incidents regarding, Sensitive Data; (iii) no Signify Company has received any written complaints, allegations or notices of potential or actual
material non-compliance with any Data Protection Obligations, or any notices of inspection or audit or requests for information from any Governmental Entity or any other relevant authority or regulator with
respect to any Data Protection Obligations; (iv) no Sensitive Data in the custody, control or possession of any Signify Company has been the subject of unauthorized or unlawful processing, or accidental loss, destruction or damage, or other
breach in any material respect and each Signify Company has complied in all material respects with all of its obligations under all applicable Data Protection Obligations regarding the security of Sensitive Data (including regarding the appointment
of any data processor); and (v) each Signify Company has, when acting as a data processor or a data controller under a written agreement, complied in all material respects with all Data Protection Obligations contained within the relevant
written agreement, in each case as would not reasonably be expected to have a Signify Material Adverse Effect. 

  
 - 30 - 

 Section 4.18 Assets and Properties. The Signify Companies own and have good
title to or hold a valid and exclusive leasehold interest in all material assets, properties and rights used in the operation of their business, which comprise all of the tangible assets, properties and rights of every type and description, whether
real or personal, that are used in or necessary for the conduct of the business as conducted on the date hereof and are adequate to conduct the business in substantially the same manner immediately following the Closing as conducted on the date
hereof, in each case as would not reasonably be expected to have a Signify Material Adverse Effect. 
 Section 4.19 No Other
Representations or Warranties. PARENT DOES NOT MAKE ANY REPRESENTATIONS OR WARRANTIES TO REMEDY OPCO EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE 4. ANY AND ALL STATEMENTS MADE OR INFORMATION COMMUNICATED BY PARENT, ITS EQUITYHOLDERS OR ANY OF
ITS OR THEIR RESPECTIVE REPRESENTATIVES OUTSIDE OF THIS AGREEMENT, WHETHER VERBALLY OR IN WRITING, ARE DEEMED TO HAVE BEEN SUPERSEDED BY THIS AGREEMENT, IT BEING INTENDED THAT NO SUCH PRIOR OR CONTEMPORANEOUS STATEMENTS OR COMMUNICATIONS OUTSIDE OF
THIS AGREEMENT SHALL SURVIVE THE EXECUTION AND DELIVERY OF THIS AGREEMENT. 
 ARTICLE 5 

COVENANTS 
 Section 5.1
Reasonable Best Efforts. Each of Remedy Opco and Parent shall, and shall cause its’ respective Subsidiaries to, (i) use all reasonable best efforts to take, or cause to be taken, all actions necessary to comply promptly with all legal
requirements which may be imposed on such Party or its Subsidiaries with respect to the transactions contemplated hereby and, subject to Section 2.2, to consummate the transactions contemplated by this Agreement as promptly as practicable and
(ii) obtain (and to cooperate with the other party to obtain) any consent, authorization, order or approval of, or any exemption by, any Governmental Entity and/or any other public or private third party which is required to be obtained or made
by such Party or any of its Subsidiaries in connection with the transactions contemplated by this Agreement; provided, however, that a Party shall not be obligated to take any action pursuant to the foregoing if the taking of such action or such
compliance or the obtaining of such consent, authorization, order, approval or exemption would result in a material condition or restriction on such Party that is not contingent on the occurrence of the Closing. Each of Remedy Opco and Parent will
promptly cooperate with and furnish information to the other in connection with any such efforts by, or requirement imposed upon, any of them or any of their respective Subsidiaries in connection with the foregoing. 

  
 - 31 - 

 Section 5.2 Covenants of Remedy Opco. Except as expressly contemplated by this
Agreement (including, for the avoidance of doubt, with respect to any actions taken in connection with effectuating the Pre-Closing Restructuring), from the execution of this Agreement until the earlier of the
Closing and the termination of this Agreement in accordance with its terms, unless otherwise consented to in writing by Parent (which consent shall not be unreasonably withheld, delayed or conditioned): (a) Remedy Opco shall, and shall cause its
Subsidiaries to, carry on their respective businesses in the usual, regular and ordinary course and use commercially reasonable efforts to preserve intact their present business organizations, maintain their rights, franchises, licenses and other
authorizations issued by Governmental Entities and preserve their relationships with employees, customers, suppliers and other Persons with whom they have business dealings and (b) Remedy Opco shall not, nor shall it permit any of its
Subsidiaries to, (i) enter into any new material line of business, (ii) incur or commit to any capital expenditures or any obligations or liabilities in connection therewith other than capital expenditures and obligations or liabilities
incurred or committed to in the ordinary course of business, (iii) enter into or terminate any material Contract or make any change to any existing material Contract, except in the ordinary course of business, (iv) make, declare or pay any
dividend or other distribution upon or in respect of any Equity Interest of Remedy Opco (which, for the avoidance of doubt, shall not limit its Subsidiaries from making such dividends or distributions to Remedy Opco or any of its other Subsidiaries)
other than as contemplated by Section 5.11, (v) issue, create, incur, assume, guarantee, endorse or otherwise become liable or responsible with respect to (whether directly, contingently or otherwise) any
material indebtedness for borrowed money, (vi) directly or indirectly, through merger, consolidation or otherwise, acquire any capital stock or other equity interest in, or all or any substantial portion of the assets of, any Person,
(vii) merge or consolidate with any Person, or (viii) agree to, or make any commitment to, take, or authorize, any of the foregoing. 

Section 5.3 Covenants of Parent. Except as expressly contemplated by this Agreement, from the execution of this Agreement until
the earlier of the Closing and the termination of this Agreement in accordance with its terms, unless otherwise consented to in writing by Remedy Opco (which consent shall not be unreasonably withheld, delayed or conditioned): (a) Parent shall, and
shall cause its Subsidiaries to, carry on their respective businesses in the usual, regular and ordinary course and use commercially reasonable efforts to preserve intact their present business organizations, maintain their rights, franchises,
licenses and other authorizations issued by Governmental Entities and preserve their relationships with employees, customers, suppliers and other Persons with whom they have business dealings and (b) Parent shall not, nor shall it permit any of
its Subsidiaries to, (i) enter into any new material line of business, (ii) incur or commit to any capital expenditures or any obligations or liabilities in connection therewith other than capital expenditures and obligations or
liabilities incurred or committed to in the ordinary course of business, (iii) enter into or terminate any material Contract or make any change to any existing material Contract, except in the ordinary course of business, (iv) make,
declare or pay any dividend or other distribution upon or in respect of any Equity Interest of Parent (which, for the avoidance of doubt, shall not limit its Subsidiaries from making such dividends or distributions to Parent or any of its other
Subsidiaries), other than distributions made pursuant to Section 4.4 (Tax Distributions) of the Existing Parent LLCA in an amount not to exceed $10,000,000, (v) issue, create, incur, assume, guarantee, endorse or otherwise become liable or
responsible with respect to (whether directly, contingently or otherwise) any material indebtedness for borrowed money, (vi) directly or indirectly, through merger, consolidation or otherwise, acquire any capital stock or other equity interest in,
or all or 

  
 - 32 - 

 
any substantial portion of the assets of, any Person, (vii) merge or consolidate with any Person, (viii) (A) make any payment or distribution to or for the benefit of any NM Person,
(B) give or provide anything of value to or for the benefit of any NM Person, or (C) assume or acquire any Liability of any NM Person (in each case excluding Parent and its Subsidiaries from the definition of NM Person), or (ix) agree
to, or make any commitment to, take, or authorize, any of the foregoing. 
 Section 5.4 Control of Other Party’s
Business. Nothing contained in this Agreement (including, without limitation, Section 5.5) shall give Remedy Opco or New Remedy Corp, directly or indirectly, the right to control or direct the operations of Parent or
shall give Parent, directly or indirectly, the right to control or direct the operations of Remedy Opco, in each case, prior to the Closing. Prior to the Closing, each of Remedy Opco and Parent shall exercise, consistent with the terms and
conditions of this Agreement, complete control and supervision over its and its Subsidiaries’ respective operations. 

Section 5.5 Advice of Changes. Each of Remedy Opco and Parent shall confer on a regular basis with the other, and promptly advise
the other orally and in writing of any change or event having, or which would reasonably be expected to have, with respect to Remedy Opco, a Remedy Material Adverse Effect or, with respect to Parent, a Signify Material Adverse Effect, or which would
cause or constitute a material breach of any of the representations, warranties or covenants of such Party contained herein; provided, however, that any noncompliance with the foregoing shall not constitute the failure to satisfy a
condition set forth in ARTICLE 7 or give rise to any right of termination under ARTICLE 8 unless the underlying breach shall independently constitute such a failure or give rise to such a right. 

Section 5.6 Remedy Opco Options.  

(a) Upon the terms and subject to the conditions of this Agreement, as part of the Pre-Closing
Restructuring, each option to purchase Common Stock of Remedy Opco (each, a “Remedy Opco Option”) granted under the Remedy Partners, Inc. 2012 Equity Incentive Plan (the “Remedy Opco Equity Plan”), whether vested or
unvested, that is outstanding immediately prior to the Pre-Closing Restructuring, shall, upon the completion of the Pre-Closing Restructuring, cease to represent a right
to acquire shares of Common Stock of Remedy Opco and shall be converted in connection with the Pre-Closing Restructuring and without any action on the part of the holder thereof, into an option to purchase
capital stock of New Remedy Corp (each such option so converted, a “New Remedy Option”). Such conversion and replacement of Remedy Opco Options hereunder (the “Remedy Option Conversion”) is intended to comply with
Section 409A of the Code and the applicable regulations thereunder (including Treas. Reg. Section 1.409A-1(b)(5)(v)(D)) and each New Remedy Option shall continue to have, and be subject to, the same
terms and conditions (including, vesting, expiration date, exercise provisions and transfer restrictions as set forth in the Remedy Opco Equity Plan and the applicable option award agreement) as were applicable to the corresponding Remedy Opco
Option immediately prior to the completion of the Pre-Closing Restructuring. Remedy Opco shall cause New Remedy Corp to take all actions necessary to effectuate and consummate the Remedy Option Conversion,
including providing (i) any required notices and applicable documentation regarding such conversion to the holders of such options and (ii) for the assumption by New Remedy Corp of the Remedy Opco Equity Plan (with such changes or
amendments to such plan as is necessary to effectuate the foregoing) (such assumption, the “Remedy Equity Plan Assignment and Assumption”). 

  
 - 33 - 

 (b) Remedy Opco shall cause New Remedy Corp to reserve for issuance a number of shares of
capital stock of New Remedy Corp at least equal to the number of shares of capital stock of New Remedy Corp that will be subject to New Remedy Options as a result of the actions contemplated by this Section 5.6. 

Section 5.7 Public Announcements. Remedy Opco and Parent shall consult with each other before issuing any press release or, to the
extent practical, otherwise making any public statement with respect to this Agreement or the transactions contemplated hereby. The Parties intend to make a press release or public statement following the execution of this Agreement, which will be
in a form to be mutually agreed upon by the Parties; provided, that neither Party shall make (or permit its Affiliate to make) any other press release or public statement prior to the Closing without the prior written consent of the other Party,
except as required by applicable Law. 
 Section 5.8 Confidentiality. Each of the Parties shall keep the existence of this
Agreement and the terms contained herein, including any discussions among the Parties with respect thereto, confidential, and shall instruct their respective directors (or equivalent), executives, employees, equityholders, affiliates, advisors and
other representatives to do the same. Notwithstanding the foregoing or anything else contained herein to the contrary, in no event shall this Section 5.8 prohibit or restrict the issuance of any press release or making of any public statement
that complies with Section 5.7, nor shall any direct or indirect equityholder of either of the Parties that is an investment fund or investment partnership (or similar investment vehicle) be prohibited from disclosing information about the
Combination in connection with their normal fundraising, marketing, information, or reporting activities to their investors or potential investors who are subject to customary confidentiality obligations. Notwithstanding the foregoing, after
consulting with the other Party on a general communication plan, each Party (and its Subsidiaries) may make announcements from time to time to their respective employees, customers, suppliers and other business relations and otherwise as they may
reasonably determine in good faith is necessary or appropriate to facilitate their business operations. Notwithstanding anything herein to the contrary, each of the Parties (and each employee, representative, or other agent of such Party) may
disclose to any and all persons, without limitation of any kind, the tax treatment, tax structure or tax strategies of, and the tax strategies relating to the Combination and this Agreement and any transactions entered into by a Party and its
Subsidiaries and all materials of any kind (including opinions and other tax analyses) that are provided to the Party relating to such tax treatment, tax strategies and tax structure. 

Section 5.9 Additional Agreements. At any time and from time to time following the Closing, upon the request of any Party, each
other Party shall, and shall cause its Subsidiaries to, do, execute, acknowledge and deliver, and cause to be done, executed, acknowledged or delivered, all such further acts, deeds, assignments, transfers, conveyances, powers of attorney or
assurances as may be reasonably required to effectuate the transactions expressly contemplated hereby. 

  
 - 34 - 

 Section 5.10 Parent Book-Up. Immediately
prior to the Remedy Exchange, Parent will adjust the capital accounts of its then current members to reflect a revaluation of Parent’s property pursuant to Treasury Regulations Section 1.704-1(b)(2)(iv)(f). 

Section 5.11 Pre-Closing Taxes of New Remedy Corp. The Parties agree and acknowledge that
Remedy Opco may pay dividends and make distributions, and cause its Subsidiaries to pay dividends and make distributions, to New Remedy Corp prior to Closing, in amounts intended to permit New Remedy Corp to satisfy its Pre-Closing Remedy Tax Liabilities and pay administrative or operating expenses (such dividends and distributions received by New Remedy Corp, the “Pre-Closing Remedy
Tax Distributions”).    The decision as to the amount of Pre-Closing Remedy Tax Distributions to be made shall be determined in good faith by mutual agreement of (1) a
Majority of the Minority Holders (as defined in the Joint Investment Agreement), and (2) the Board of Directors of Remedy Opco; provided, that if they cannot so agree then the amount of Pre-Closing Remedy
Tax Distributions shall be equal to $1,000,000. New Remedy Corp as of the Closing will have no cash on hand other than the amount of the Pre-Closing Remedy Tax Distribution. Except as otherwise consented to by
any NM Person, within fifteen (15) days after the receipt by New Remedy Corp of any Covered Refund (it being understood that a credit that qualifies as a Covered Refund will be treated as received when utilized to pay a Tax otherwise then due),
New Remedy Corp shall contribute the amount of such Covered Refund to Parent as an adjustment to the contribution described in Section 2.1(b), New Remedy Corp shall not be entitled to any additional Equity Interests in Parent in connection with
such contribution and the Parties shall not take a contrary tax return position except upon a contrary final determination by an applicable taxing authority. To the extent permitted by law, in cases where New Remedy Corp is eligible to receive a
refund of Taxes that would constitute a Covered Refund, it will elect to receive such refund in cash in lieu of receiving a credit. 

ARTICLE 6 
 CLOSING DELIVERABLES

 At the Closing, the Parties shall deliver the documents and perform the acts which are set forth in this Article 6;
provided, however, that all such documents and acts shall be deemed to have occurred or to have been delivered simultaneously and no action or delivery shall be deemed to have been taken or delivered until all such actions have been
taken and all such deliveries delivered, unless any such action or delivery is waived in writing by the Party for whose benefit such action or delivery should have been taken or delivered. 

Section 6.1 Deliveries by Parent. At the Closing, Parent shall deliver, or cause to be delivered, to New Remedy Corp: 

(a) duly executed copies (executed by Parent and each of its Affiliates that are identified as parties thereto) of the A&R Parent LLCA, the
Joint Investment Agreement and the Registration Rights Agreement, each dated as of the Closing Date; 
 (b) evidence of the issuance of the
Exchanged Units to New Remedy Corp; 

  
 - 35 - 

 (c) evidence of the execution and effectiveness of the releases, and the contribution of
rights under the representation and warranty insurance policies to Parent or one or more of its Subsidiaries (or evidence reasonably satisfactory to New Remedy Corp that Parent or one or more of its Subsidiaries is a beneficiary of such policies),
in each case as set forth on Schedule 6.1(c); 
 (d) evidence of the termination of all management fees, advisory fees and other
compensation payable by any Signify Company to any NM Person (including any contingent compensation such as fees payable in connection with an initial public offering, debt financing or fundamental transaction); 

(e) duly executed copies (executed by Parent and each of its Affiliates that are identified as parties thereto) of the management rights
letters, in form and substance reasonably acceptable to the parties thereto, for those stockholders of New Remedy Corp set forth on Schedule 6.1(e); and 

(f) a counterpart signature page to the assignment and assumption agreement described in Section 6.2(c) duly executed
by Parent. 
 Section 6.2 Deliveries by Remedy. At the Closing, Remedy Opco shall deliver, or cause to be delivered, to Parent:

 (a) a properly completed IRS Form W-9 properly completed by New Remedy Corp; 

(b) documentation evidencing the consummation of the transactions constituting the Pre-Closing
Restructuring; 
 (c) an assignment and assumption agreement, in form and substance reasonably acceptable to each of the Parties, duly
executed by New Remedy Corp and providing for the assignment to, and assumption by, Parent of one hundred percent (100%) of the Equity Interests of Remedy Opco; 

(d) evidence of the resignation or removal from office, effective as of the Closing, of each director of Remedy Opco and its Subsidiaries
identified by Parent no less than two (2) Business Days prior to the Closing; and 
 (e) (i) a counterpart signature page to such
A&R Parent LLCA duly executed by New Remedy Corp, and (ii) executed copies (executed by New Remedy Corp and each of its Affiliates that are identified as parties thereto) of the Joint Investment Agreement and the Registration Rights
Agreement. 

  
 - 36 - 

 ARTICLE 7 

CONDITIONS PRECEDENT 

Section 7.1 Conditions to Obligations of Parent . The obligation of Parent to effect the Combination is subject to the
satisfaction of the following conditions at or prior to the Closing unless waived in writing by Parent: 
 (a) Representations and
Warranties. The representations and warranties of Remedy Opco set forth in this Agreement (other than the Fundamental Representations of Remedy Opco) shall be true and correct as of the date of this Agreement and as of the Closing Date as though
made on and as of the Closing Date (except to the extent such representations and warranties speak as of another date, in which case such representations and warranties shall be true and correct as of such other date), subject to such exceptions or
failures to be so true and correct as do not have, and would not reasonably be expected to have, individually or in the aggregate, a Remedy Material Adverse Effect. The Fundamental Representations of Remedy Opco shall be true and correct in all
material respects as of the date of this Agreement and as of the Closing Date as though made on and as of the Closing Date (except to the extent such representations and warranties speak as of another date, in which case such representations and
warranties shall be true and correct as of such other date). 
 (b) Performance of Covenants of Remedy Opco. Remedy Opco shall have
performed in all material respects all covenants and agreements required to be performed by it under this Agreement at or prior to the Closing. 

(c) No Injunctions or Restraints: Illegality. No temporary restraining order, preliminary or permanent injunction or other order issued
by any court of competent jurisdiction or other legal restraint or prohibition (an “Injunction”) preventing the consummation of the transaction contemplated hereby shall be in effect. There shall not be any Action taken, or any Law
enacted, entered, enforced or deemed applicable to the transaction contemplated hereby, by any Governmental Entity of competent jurisdiction that makes the consummation of the transaction contemplated hereby illegal. 

(d) No Remedy Material Adverse Effect. No Effect shall have occurred or arisen since the date hereof that has had, or would be
reasonably likely to have, individually or in the aggregate, a Remedy Material Adverse Effect. 
 (e) CMS Approval. Either:
(i) Remedy Opco shall have received a waiver of the contractual notice periods required with respect to the transactions contemplated by this Agreement (and consent to close) (collectively, the “CMS Approval”) from the Centers
for Medicare & Medicaid Services (“CMS”) and the Center for Medicare and Medicaid Innovation (“CMMI”), or (ii) the corresponding notice and review periods shall have expired without written objection
to such transactions from such entities (the “CMS Expiration”). 
 (f) Closing Certificate. Parent shall have
received a certificate, dated the Closing Date, duly executed by an authorized officer of the Remedy Opco in his or her capacity as such (and not in his or her individual capacity) to the effect that the conditions set forth in
Section 7.1(a), Section 7.1(b) and Section 7.1(d) have been satisfied. 

  
 - 37 - 

 (g) New Remedy Corp Charter. The New Remedy Corp Charter shall have been duly
approved and filed, and shall be the effective certificate of incorporation of New Remedy Corp. 
 (h) Shareholder Approval. This
Agreement (including the Exhibits hereto) and the transactions contemplated hereby (including the Remedy Opco Merger and the filing of the New Remedy Corp Charter) shall have been approved by the holders of a majority of Equity Interests in Remedy
Opco. 
 Section 7.2 Conditions to Obligations of Remedy Opco . The obligation of Remedy Opco to effect the Combination
is subject to the satisfaction of the following conditions at or prior to the Closing unless waived in writing by Remedy Opco: 
 (a)
Representations and Warranties. The representations and warranties of Parent set forth in this Agreement (other than the Fundamental Representations of Parent) shall be true and correct as of the date of this Agreement and as of the Closing
Date as though made on and as of the Closing Date (except to the extent such representations and warranties speak as of another date, in which case such representations and warranties shall be true and correct as of such other date), subject to such
exceptions or failures to be so true and correct as do not have, and would not reasonably be expected to have, individually or in the aggregate, a Signify Material Adverse Effect. The Fundamental Representations of Parent shall be true and correct
in all material respects as of the date of this Agreement and as of the Closing Date as though made on and as of the Closing Date (except to the extent such representations and warranties speak as of another date, in which case such representations
and warranties shall be true and correct as of such other date). 
 (b) Performance of Covenants of Parent. Parent shall have
performed in all material respects all covenants and agreements required to be performed by it under this Agreement at or prior to the Closing. 

(c) No Injunctions or Restraints: Illegality. No Injunction preventing the consummation of the transaction contemplated hereby shall be
in effect. There shall not be any Action taken, or any Law enacted, entered, enforced or deemed applicable to the transaction contemplated hereby, by any Governmental Entity of competent jurisdiction that makes the consummation of the transaction
contemplated hereby illegal. 
 (d) No Signify Material Adverse Effect. No Effect shall have occurred or arisen since the date hereof
that has had, or would be reasonably likely to have, individually or in the aggregate, a Signify Material Adverse Effect. 
 (e) CMS
Approval. Either: (i) Remedy Opco shall have received the CMS Approval, or (ii) the CMS Expiration shall have occurred. 

  
 - 38 - 

 (f) Closing Certificate. Remedy Opco shall have received a certificate, dated the
Closing Date, duly executed by an authorized officer of the Parent in his or her capacity as such (and not in his or her individual capacity) to the effect that the conditions set forth in Section 7.2(a),
Section 7.2(b) and Section 7.2(d) have been satisfied. 
 (g) New Remedy Corp
Charter. The New Remedy Corp Charter shall have been duly approved and filed, and shall be the effective certificate of incorporation of New Remedy Corp. 

(h) Shareholder Approval. This Agreement (including the Exhibits hereto) and the transactions contemplated hereby (including the Remedy
Opco Merger and the filing of the New Remedy Corp Charter) shall have been approved by the holders of a majority of Equity Interests in Remedy Opco. 

Section 7.3 Frustration of Conditions Precedent; Waiver of Conditions. Neither Remedy Opco nor Parent may rely on or assert
the failure of any condition set forth in this Article 7 if such failure results from or was the proximate cause of such party’s failure to comply with or perform any of its obligations under any provision of this Agreement. All
conditions set forth in this Article 7 will be deemed to have been satisfied or waived if the Closing occurs. 
 ARTICLE 8 

TERMINATION 
 Section 8.1
Termination. Prior to the Closing, this Agreement may be terminated: 
 (a) by mutual consent of Remedy Opco and Parent in a written
instrument; 
 (b) by either Remedy Opco or Parent, upon written notice to the other Party, if any Governmental Entity of competent
jurisdiction shall have issued or taken any Action permanently restraining, enjoining or otherwise prohibiting the transactions contemplated hereby, and such Action has become final and nonappealable; provided, however, that the right
to terminate this Agreement under this Section 8.1(b) shall not be available to any party whose failure to comply with any provision of this Agreement has been the cause of, or resulted in, such Action; 

(c) by either Remedy Opco or Parent upon written notice to the other Party, if the Closing shall not have been consummated on or before the
date that is 120 days following the date of this Agreement (the “Outside Date”), which Outside Date may be extended by written agreement of the Parties; provided, however, that (i) the right to terminate this
Agreement pursuant to this Section 8.1(c) shall not be available to a party if the failure to of the Closing to have been consummated on or before the Outside Date was primarily due to or the result of the failure of such
party to perform any of its obligations under this Agreement, and (ii) if the only reason that the Closing has not occurred by the Outside Date is that the CMS Approval has not been obtained and the CMS Expiration has not occurred, then the
Outside Date shall be automatically extended until the date that is 3 Business Days after the date that the CMS Expiration would occur (assuming no objection to the transactions are raised by CMS or CMMI); or 

  
 - 39 - 

 (d) by Parent, if Remedy Opco shall have materially breached or materially failed to perform
any of its representations, warranties, covenants or agreements contained in this Agreement, or any such representation or warranty becomes untrue or inaccurate, which material breach or, failure to perform or untruth or inaccuracy (i) would
give rise to the failure of a condition set forth in Section 7.1(a) or Section 7.1(b) and (ii) cannot be or has not been cured within the earlier of (x) thirty (30) calendar days
following receipt by Remedy Opco of written notice of such material breach or, failure to perform or untruth or inaccuracy and (y) the Outside Date (as may be extended pursuant to Section 8.1(c)); or 

(e) by Remedy Opco, if Parent shall have materially breached or materially failed to perform any of its representations, warranties, covenants
or agreements contained in this Agreement, or any such representation or warranty becomes untrue or inaccurate, which material breach or, failure to perform or untruth or inaccuracy (i) would give rise to the failure of a condition set forth in
Section 7.2(a) or Section 7.2(b) and (ii) cannot be or has not been cured within the earlier of (x) thirty (30) calendar days following receipt by Parent of written notice of such
material breach or, failure to perform or untruth or inaccuracy and (y) the Outside Date (as may be extended pursuant to Section 8.1(c)). 

Section 8.2 Effect of Termination. In the event of termination of this Agreement by either Remedy Opco or Parent as provided in
Section 8.1, this Agreement shall forthwith become void and there shall be no liability or obligation on the part of any party to this Agreement or their respective officers or directors (or equivalent), except with respect to this
Section 8.2 which shall survive such termination, and except that no party shall be relieved or released from any liabilities or damages arising out of its willful, knowing and material breach of this Agreement. 

ARTICLE 9 
 MISCELLANEOUS 

Section 9.1 Survival; Liability. Except in the case of Fraud, none of the representations, warranties, covenants and
agreements contained in this Agreement or in any other Transaction Document, nor any rights that could arise out of any breach of such representations, warranties, covenants, and agreements, shall survive the Closing, except for (a) those covenants
and agreements contained herein and therein that by their terms apply or are to be performed in whole or in part following the Closing and (b) those rights arising out of any breach of those covenants and agreements contained herein and therein that
by their terms apply or are to be performed in whole or in part following the Closing. 
 Section 9.2 Expenses. All costs and
expenses incurred by the Parties in connection with this Agreement and the transactions contemplated hereby shall be borne by the party incurring such expense. 

  
 - 40 - 

 Section 9.3 Amendment; Benefit; Assignability. Except as otherwise required by
Law, the Parties may modify or amend this Agreement only by written agreement executed and delivered by or on behalf of Remedy Opco and Parent. This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective
successors and permitted assigns and no other Person shall have any right (whether third party beneficiary or otherwise) hereunder. This Agreement may not be assigned by any Party without the prior written consent of the other Party. As further
provided in Section 9.14 below, after Closing any modification or amendment to this Agreement shall require written agreement of New Remedy Corp instead of Remedy Opco. 

Section 9.4 Notices. Any notice, request, demand, waiver, consent, approval or other communication which is required or permitted
hereunder shall be in writing and shall be deemed given: (a) on the date established by the sender as having been delivered personally, (b) on the date delivered by a private overnight courier for next-day business delivery as established
by the sender by evidence obtained from the courier, or (c) on the date sent by attachment to e-mail in portable document format, with non-automatic confirmation of receipt, if sent prior to 6:00 p.m.
Eastern Time, or if sent later, then on the next Business Day, in each case, with a copy to be sent per clause (b) within one Business Day. Such communications, to be valid, must be addressed as follows: 

If to Remedy Opco or New Remedy Corp, to: 

Remedy Partners, Inc. 
 800
Connecticut Avenue 
 Norwalk CT 06854 

Attention: Steve Senneff; Adam McAnaney 

Email: 
 with required copies
(which shall not constitute notice) to: 
 New Mountain Capital, L.L.C. 

787 Seventh Avenue, 49th Floor 

New York, NY 10019 
 Attention:
Matthew Holt; Kyle Peterson 
 Email: 

and 
 Ropes & Gray LLP

 1211 Avenue of the Americas 

New York, NY 10036-8704 

Attention: John Sorkin, Esq.; Garrett Charon, Esq. 

Email: 
 and 

Barnes & Thornburg LLP 

One North Wacker Drive, Suite 4400 

Chicago, IL 60606 
 Attention:
Bruce Zivian; Dennis Peterson 
 Email: 

  
 - 41 - 

 If to Parent, to: 

Cure TopCo, LLC 
 c/o Cure
Borrower, LLC 
 4055 Valley View Lane, Suite 400 

Dallas, TX 75244 
 Attention:
Bradford Kyle Armbrester 
 Email: 

with required copies (which shall not constitute notice) to: 

New Mountain Capital, L.L.C. 
 787
Seventh Avenue, 49th Floor 
 New York, NY 10019 

Attention: Matthew Holt; Vig Aier 

Email: 
 and 

Ropes & Gray LLP 
 1211
Avenue of the Americas 
 New York, NY 10036-8704 

Attention: John Sorkin, Esq.; Garrett Charon, Esq. 

Email: 
 or to such other address or to the
attention of such Person or Persons as the recipient party has specified by prior written notice to the sending party (or in the case of counsel, to such other readily ascertainable business address as such counsel may hereafter maintain). 

Section 9.5 Waiver. Unless otherwise specifically agreed in writing to the contrary: (a) the failure of any Party at any time
to require performance by the other of any provision of this Agreement shall not affect such Party’s right thereafter to enforce the same, (b) no waiver by any Party of any rights under this Agreement, or waiver by any Party of a breach of any
provision of this Agreement by any other Party, shall be valid unless made in writing by such waiving Party, and no such waiver shall be taken or held to be a waiver by such Party of any other preceding or subsequent right or breach and (c) no
extension of time granted by any Party for the performance of any obligation or act by any other Party shall be deemed to be an extension of time for the performance of any other obligation or act hereunder. As further provided in
Section 9.14 below, after Closing any waiver under this Agreement shall require the written waiver of New Remedy Corp instead of Remedy Opco. 

  
 - 42 - 

 Section 9.6 Entire Agreement. This Agreement (including the Exhibits hereto,
which are incorporated by reference herein) constitute the entire agreement between the Parties with respect to the subject matter hereof and referenced herein, and supersede and terminate any prior agreements between the Parties (written or oral)
with respect to the subject matter hereof. 
 Section 9.7 Counterparts. This Agreement may be signed in any number of
counterparts with the same effect as if the signature on each such counterpart were on the same instrument. Facsimiles or other electronic forms of signatures (including e-mail, portable document format (.pdf) or similar generally accepted
electronic means) shall be deemed to be originals. 
 Section 9.8 Headings. The headings of the Sections of this Agreement are
for convenience only and in no way modify, interpret or construe the meaning of specific provisions of the Agreement. 
 Section 9.9
Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable Law, but if any provision of this Agreement is held to be prohibited by or invalid under
applicable Law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement and the Parties agree to negotiate in good
faith to adopt a replacement provision that is enforceable and as nearly as possible gives effect to the Parties’ original intent. 

Section 9.10 Governing Law; Jurisdiction.  

(a) This Agreement (including the interpretation and enforcement hereof) and all disputes or controversies arising out of, in connection with,
or relating to this Agreement or the transactions contemplated hereby shall be governed by, and construed in accordance with, the internal Laws of the State of Delaware, without regard to conflicts of Laws principles that could otherwise cause the
application of any other jurisdiction’s Laws. Each of the Parties irrevocably agrees that any legal Action arising out of, in connection with, or relating to this Agreement or for recognition and enforcement of any judgment in respect hereof
brought by any other Party or its successors or assigns shall be brought and determined exclusively by the Court of Chancery of the State of Delaware (or if such court will not accept jurisdiction, any federal court, or if such courts will not
accept jurisdiction, any state court, in each case in the State of Delaware), and each of the Parties (on behalf of itself and any Person claiming by, through or on behalf of such Party) hereby irrevocably submits to the exclusive jurisdiction of
the aforesaid court for itself and with respect to its property, generally and unconditionally, with regard to any such Action arising out of or relating to this Agreement and the transactions contemplated hereby (and agrees not to commence any
Action relating thereto except in such courts). Each of the Parties further agrees to accept service of process in any manner permitted by such court. Each of the Parties hereby irrevocably and unconditionally waives, and agrees not to assert, by
way of motion or as a defense, counterclaim or otherwise, in any action or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby, (a) any claim that it is not personally subject to the jurisdiction of
the above-named courts for any reason other than the failure lawfully to serve process, (b) that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such court (whether through
service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (c) to the fullest extent permitted by Law, that (i) the Action in any such court is brought in an
inconvenient forum, (ii) the venue of such Action is improper or (iii) this Agreement, or the subject matter hereof, may not be enforced in or by such courts. 

  
 - 43 - 

 Section 9.11 Counsel. Each Party is sophisticated and experienced in
transactions like those contemplated by this Agreement and has been represented by its own counsel in connection with the negotiation and preparation of this Agreement and, consequently, each Party hereby waives the application of any rule of Law
that would otherwise be applicable in connection with the interpretation of this Agreement based on one Party (or its counsel) having drafted this Agreement. 

Section 9.12 Waiver of Trial by Jury. EACH OF THE PARTIES HERETO HEREBY KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVES THE RIGHT
IT MAY HAVE TO A TRIAL BY JURY IN RESPECT TO ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH THIS AGREEMENT AND ANY AGREEMENT CONTEMPLATED TO BE EXECUTED IN CONNECTION HEREWITH (INCLUDING THE OTHER TRANSACTION
DOCUMENTS), OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER VERBAL OR WRITTEN), ACTIONS OR OMISSIONS OF ANY PARTY IN CONNECTION WITH ANY OF SUCH AGREEMENTS. 

Section 9.13 Specific Performance and Remedies. The Parties agree that irreparable damage for which monetary damages, even
if available, would not be an adequate remedy, would occur in the event that the Parties hereto do not perform the provisions of this Agreement (including failing to take such actions as are required of it hereunder in order to consummate the
transactions contemplated by this Agreement) in accordance with its specified terms or otherwise breach such provisions (including the obligation of the Parties to consummate such transactions in accordance with the terms and subject to the
conditions of this Agreement). The Parties agree that they will not oppose the granting of an injunction, specific performance and other equitable relief on the basis that (i) the other Party or Parties have an adequate remedy at law or
(ii) an award of specific performance is not an appropriate remedy for any reason at law or equity. No Party shall be required to provide any bond or other security in connection with any order or injunction enforcing, or to prevent breaches
of, this Agreement. 
 Section 9.14 New Remedy Corp; Certain Effects of Joint Investment Agreement. Parent hereby agrees that
New Remedy Corp is an intended third party beneficiary of this Agreement and that, after Closing, all rights of Remedy Opco under this Agreement may be waived, amended, modified, extended or enforced solely by New Remedy Corp instead of Remedy Opco
(as Remedy Opco will at such time be a Subsidiary of Parent). Further, Parent acknowledges and agrees that effective as of Closing, it will be party to and bound by the Joint Investment Agreement, including (i) the restrictions therein on (or
conditions upon) the ability of New Remedy Corp or Remedy Opco to waive, amend, modify or extend rights or obligations under this Agreement without the prior written consent of a Majority of the Minority Holders (as defined therein), and
(ii) the right of such Majority of the Minority Holders to enforce the rights of Remedy Opco or New Remedy Parent (or cause Remedy Opco or New Remedy Parent to enforce such rights) to the extent provided therein. 

  
 - 44 - 

 Section 9.15 Non-Recourse. Except as
set forth in Section 9.14, this Agreement may only be enforced against, and any claim or cause of action based upon, arising out of, or related to this Agreement or the transactions contemplated hereby may only be
brought against, the Persons that are expressly named as Parties and then only with respect to the specific obligations set forth herein with respect to such Party. Except to the extent a named party to this Agreement (and then only to the extent of
the specific obligations undertaken by such named party in this Agreement), no past, present or future incorporator, member, partner, stockholder or Representative or Affiliate of any of the foregoing shall have any Liability (whether in contract,
tort, equity or otherwise) for any one or more of the representations, warranties, covenants, agreements or other Liabilities of any one or more of the Parties (whether for indemnification or otherwise) or of or for any claim based on, arising out
of, or related to this Agreement or the transactions contemplated hereby. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.] 

  
 - 45 - 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first
written above. 
  

			
	REMEDY OPCO:
	
	REMEDY PARTNERS, INC.
		
	By:	 	 /s/ Steve Senneff

	Name: Steve Senneff
	Title: President & Chief Financial Officer

 Signature Page to Combination Agreement 

 
			
	PARENT:
	
	CHLOE OX HOLDINGS, LLC
		
	By:	 	 /s/ Bradford Kyle Armbrester

	Name: Bradford Kyle Armbrester
	Title: Chief Executive Officer

 Signature Page to Combination AgreementEX-10.35

 Exhibit 10.35 

 
  

 
 AMENDED AND RESTATED
STOCKHOLDERS’ AGREEMENT 
 by and among 

NEW REMEDY CORP. 
 REMEDY
ACQUISITION, L.P. 
 and 
 THE
OTHER STOCKHOLDERS (AS DEFINED HEREIN) 
 Dated as of November 26, 2019 

 
  

 

 TABLE OF CONTENTS 
  

					
	 	  	Page	 
		
	 1. DEFINITIONS
	  	 	2	 
		
	 1.1. Definitions
	  	 	2	 
		
	 2. VOTING AGREEMENT
	  	 	2	 
		
	 2.1. Size of the Board of Directors
	  	 	2	 
		
	 2.2. Election of Directors
	  	 	2	 
		
	 2.3. Director Expenses
	  	 	3	 
		
	 2.4. Significant Transactions
	  	 	4	 
		
	 2.5. Consent to Amendment
	  	 	4	 
		
	 2.6. The Company
	  	 	4	 
		
	 2.7. Period
	  	 	4	 
		
	 3. TRANSFER RESTRICTIONS
	  	 	4	 
		
	 3.1. Permitted Transferees
	  	 	4	 
		
	 3.2. Tag-Along, Drag-Along, Major Investor Group Transfers
	  	 	6	 
		
	 3.3. Restrictions on Certain Other Investors that are Entities.
	  	 	6	 
		
	 3.4. Impermissible Transfer
	  	 	7	 
		
	 3.5. Other Restrictions on Transfer
	  	 	7	 
		
	 3.6. Period
	  	 	7	 
		
	 4. INVESTOR TRANSFER RIGHTS; “TAG ALONG” AND “DRAG ALONG” RIGHTS
	  	 	8	 
		
	 4.1. Tag Along
	  	 	8	 
		
	 4.2. Lead Investor Drag Along
	  	 	10	 
		
	 4.3. Other Investor Drag Along
	  	 	11	 
		
	 4.4. Miscellaneous
	  	 	13	 
		
	 4.5. Cure TopCo Drag Along
	  	 	16	 
		
	 4.6. Period
	  	 	16	 
		
	 5. RIGHT OF PARTICIPATION
	  	 	16	 
		
	 5.1. Right of Participation
	  	 	16	 
		
	 5.2. Post-Issuance Notice
	  	 	19	 

					
		
	 5.3. Excluded Transactions
	  	 	20	 
		
	 5.4. Certain Provisions Applicable to Options, Warrants and Convertible Securities
	  	 	20	 
		
	 5.5. Acquired Shares
	  	 	20	 
		
	 5.6. Period
	  	 	20	 
		
	 6. REORGANIZATIONS
	  	 	21	 
		
	 6.1. Reorganization; Recap Drag
	  	 	21	 
		
	 6.2. Period
	  	 	22	 
		
	 7. NEGATIVE COVENANTS
	  	 	22	 
		
	 7.1. Majority Lead Investor Consent Rights
	  	 	22	 
		
	 7.2. Majority Other Investor Consent Rights
	  	 	23	 
		
	 7.3. Certain Expenses
	  	 	26	 
		
	 7.4. Information Rights
	  	 	26	 
		
	 7.5. Covenant Expiration
	  	 	27	 
		
	 8. COVENANTS
	  	 	28	 
		
	 8.1. Directors’ and Officers’ Insurance
	  	 	28	 
		
	 8.2. Confidentiality
	  	 	28	 
		
	 8.3. Other Business Opportunities
	  	 	29	 
		
	 8.4. Stockholder Covenants
	  	 	29	 
		
	 9. REMEDIES
	  	 	31	 
		
	 9.1. Generally
	  	 	31	 
		
	 9.2. Deposit
	  	 	32	 
		
	 10. LEGENDS
	  	 	32	 
		
	 10.1. Restrictive Legend
	  	 	32	 
		
	 10.2. 1933 Act Legends
	  	 	33	 
		
	 10.3. Stop Transfer Instruction
	  	 	33	 
		
	 10.4. Termination of 1933 Act Legend
	  	 	33	 
		
	 11. AMENDMENT, TERMINATION, ETC
	  	 	34	 
		
	 11.1. Oral Modifications
	  	 	34	 
		
	 11.2. Written Modifications
	  	 	34	 
		
	 11.3. Effect of Termination
	  	 	34	 

  
 - ii - 

					
		
	 12. DEFINITIONS
	  	 	35	 
		
	 12.1. Certain Matters of Construction
	  	 	35	 
		
	 12.2. Definitions
	  	 	35	 
		
	 13. MISCELLANEOUS
	  	 	44	 
		
	 13.1. Authority; Effect
	  	 	44	 
		
	 13.2. Notices
	  	 	45	 
		
	 13.3. Binding Effect, Etc
	  	 	46	 
		
	 13.4. Descriptive Headings
	  	 	46	 
		
	 13.5. Counterparts
	  	 	46	 
		
	 13.6. Severability
	  	 	46	 
		
	 13.7. No Recourse
	  	 	46	 
		
	 14. GOVERNING LAW
	  	 	47	 
		
	 14.1. Governing Law
	  	 	47	 
		
	 14.2. Consent to Jurisdiction; Venue; Service
	  	 	47	 
		
	 14.3. WAIVER OF JURY TRIAL
	  	 	48	 
		
	 14.4. Exercise of Rights and Remedies
	  	 	48	 

 Exhibits, Schedules and Appendices: 
  

					
	Schedule I	  	-	  	Capitalization of the Company
	Schedule II-A	  	-  	  	Capitalization of Remedy Founders
	Schedule II-B	  	-  	  	Capitalization of LHP Holding
	Schedule III	  	-  	  	List of Restricted Employees
	Schedule IV	  	-  	  	List of Non-Compete Stockholders
			
	Exhibit A	  	-	  	Form of Counterpart Signature Page
	Exhibit B	  	-	  	Form of Spousal Consent

  
 - iii - 

 AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT 

This Amended and Restated Stockholders’ Agreement (the “Agreement”) is made as of November 26, 2019 (the
“Effective Date”), by and among: 
  

	 	(i)	 New Remedy Corp., a Delaware corporation and the successor-in-interest to Remedy Opco (as defined below) (the
“Company”); 

  

	 	(ii)	 Remedy Acquisition, L.P., a Delaware limited partnership (together with its Permitted Transferees who become
party hereto after the Effective Date, the “Lead Investors”); 

  

	 	(iii)	 each of the investors designated as an “Other Investor” on Schedule I hereto and such other
Persons who from time to time after the Effective Date become party hereto by executing a Counterpart Signature page hereof in the form set forth in Exhibit A hereto or such other form as may be designated by the Board (a “Counterpart
Signature Page”) and who are designated by the Board as “Other Investors” (each, and together with its or their Permitted Transferees who become party hereto after the Effective Date, each an “Other Investor” and,
collectively the “Other Investors”); and 

  

	 	(iv)	 each of the investors designated as a “Manager” on Schedule I and such other Persons who from
time to time after the Effective Date become party hereto by executing a Counterpart Signature Page and who are designated by the Board as “Managers” (each, and together with its or their Permitted Transferees who become party hereto after
the Effective Date, “Managers” and together with the Lead Investors and the Other Investors, the “Stockholders”). For the avoidance of doubt, a Stockholder shall be treated as an Other Investor with respect to
certain shares of Common Stock (or any class or series thereof) (as defined below) held by such Stockholder as of the Effective Date or subsequently in such capacity, and a Manager with respect to other shares of Common Stock (or any class or series
thereof) held by such Stockholder as of the Effective Date or subsequently in such capacity. 

 Recitals 

1. On January 15, 2019, Remedy Partners, Inc., a Delaware corporation to be converted in connection herewith into a limited liability company named
“Remedy Partners, LLC” (“Remedy Opco”), and the Persons who were then stockholders of Remedy Opco entered into the Stockholders’ Agreement of Remedy Opco (the “Predecessor Stockholders’
Agreement”). 
 2. On the Effective Date, as part of the transactions contemplated by that certain Combination Agreement, dated as of
November 14, 2019, by and between Remedy Opco and Cure TopCo, LLC, a Delaware corporation formerly known as Chloe Ox Holdings, LLC (“Cure TopCo”) (the “Combination Agreement”), Remedy Opco assigned the
Predecessor Stockholders’ Agreement to the Company and the Company assumed the Predecessor Stockholders’ Agreement from Remedy Opco. 

 3. In connection with the consummation of the transactions contemplated by the Combination Agreement, the
Majority Lead Investors (as defined below) and the Majority Other Investors (as defined below), each acting pursuant to, and in accordance with, Section 11.2 of the Predecessor Stockholders’ Agreement, desire to amend and restate the
Predecessor Stockholders’ Agreement to set forth herein their agreements on certain matters relating to, among other things, the governance of the Company and the rights and obligations of the Stockholders. 

NOW, THEREFORE, in consideration of the foregoing and the representations, warranties, covenants and agreements
contained herein, and for other good and valuable consideration the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree that the Predecessor Stockholders’ Agreement is hereby amended and restated in its
entirety as follows: 
 AGREEMENT 
 1.
DEFINITIONS. 
 1.1. Definitions. Certain terms are used in this Agreement as specifically defined herein. These definitions are set
forth or referred to in Section 12 hereof. 
 2. VOTING AGREEMENT. 

2.1. Size of the Board of Directors. Each Stockholder hereby agrees to cast all votes to which such Stockholder is entitled in respect
of the Shares, whether at any annual or special meeting, by written consent or otherwise, to fix the initial number of members of the board of directors of the Company (the “Board”) at seven (7) members as set forth in
Section 2.2. below, and subsequently as the members of the Board may be increased or decreased (subject to Sections 7.1.10 and 7.2.1). The number of authorized members of the Board may not be increased or decreased after
the Effective Date unless approved by the Majority Lead Investors and a Majority of the Minority Holders. 
 2.2. Election of
Directors. Each Stockholder hereby agrees to cast all votes to which such Stockholder is entitled in respect of the Shares, whether at any annual or special meeting, by written consent or otherwise, to elect to the Board: 

2.2.1. A number of persons designated by the Majority Lead Investors to serve as Directors (the “Lead Investor
Directors”) such that the Lead Investor Directors constitute a majority of the directors on the Board (there shall initially be four (4) Lead Investor Directors, which persons shall be Brett Carlson, Matthew Holt, Kyle Peterson and
Kyle Armbrester); and 

  
 2 

 2.2.2. A number of persons designated to serve as Directors (the
“Other Investor Directors”) by (A) prior to the date upon which any of the Remedy Founders Group or the LHP Holding Group ceases to beneficially own in the aggregate at least thirty three and one-third percent (33 1/3%) of the
Equivalent Shares owned by them on the Effective Date, by a vote of the Remedy Founders (on behalf of the Remedy Founders Group) and LHP Holding (on behalf of the LHP Holding Group), with 50% of such vote held by each of the Remedy Founders Group
and the LHP Holding Group, and (B) following the date on which either of the Remedy Founders Group or the LHP Holding Group ceases to beneficially own in the aggregate at least thirty three and one-third percent (33 1/3%) of the Equivalent
Shares owned by them on the Effective Date, the holders of at least sixty percent (60%) of the shares of capital stock of the Company (calculated on an as-converted to Common Stock basis) not held by the Lead Investors, such that the number of
Other Investor Directors represents a minority of the directors on the Board, but is otherwise proportionate to the ownership of the Other Investors as compared to the Lead Investors (there shall initially be three (3) Other Investor Directors,
which persons shall initially be Steve Wiggins, Mark Caputo and Mike Krupka); provided, that in the event that the size of the Board is decreased and as a result there are less than three (3) Other Investor Directors, the Majority Other
Investors shall be entitled to appoint a number of non-voting observers to the Board (each, an “Other Investor Board Observer”) such that the total number of Other Investor Directors when combined with the total number of Other
Investor Board Observers is no less than three (3). Each Other Investor Board Observer shall be entitled to receive timely invitations to, and attend, all meetings of the Board and, in this respect, the Company shall give each such Other Investor
Board Observer copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to
hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude any Other Investor Board Observer
from any meeting or portion thereof if access to such information or attendance at such meeting would reasonably be expected to adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade
secrets or a material conflict of interest. 
 No Director elected pursuant to this Section 2.2 may be removed from office unless such removal
is directed or approved by the affirmative vote of the Persons entitled to designate such Director pursuant to this Section 2.2. If any Director shall cease for any reason to serve as a Director, the vacancy resulting thereby shall be
filled by another person selected by the affirmative vote of the Persons entitled to designate such Director pursuant to this Section 2.2. 

2.3. Director Expenses. The Company shall pay the reasonable out-of-pocket costs and expenses incurred by the Directors (including, for
the avoidance of doubt, the Lead Investor Directors) and the Other Investor Board Observers in connection with (a) attending the meetings of the Board and all committees thereof, as the case may be, (b) in the case of Directors, attending
the meetings of any board of directors, board of managers or similar governing body, as the case may be, of any subsidiary of the Company and all committees thereof, and (c) in the case of Directors, conducting any other Company business. 

  
 3 

 2.4. Significant Transactions. Each Stockholder agrees to cast all votes to which
such Stockholder is entitled in respect of the Shares, whether at any annual or special meeting, by written consent or otherwise, in the same proportion as Lead Investor Shares are voted by the Lead Investors (in each case, calculated on an
as-converted to Common Stock basis) to approve any sale, recapitalization, merger, consolidation, reorganization or any other transaction or series of transactions involving the Company or any of its subsidiaries (or all or any portion of their
respective assets) in connection with, or in furtherance of, the exercise by the Majority Lead Investors of their rights under Section 4.2. 

2.5. Consent to Amendment. Subject in all events to the terms of this Agreement, each Stockholder agrees to cast all votes to which such
Stockholder is entitled in respect of the Shares, whether at any annual or special meeting, by written consent or otherwise, in the same proportion as Lead Investor Shares are voted by the Majority Lead Investors to increase the number of authorized
shares of Senior Convertible Preferred Stock and/or Common Stock (or any class or series thereof), as the case may be, to the extent necessary to permit the Company to comply with the provisions of its Certificate of Incorporation; provided,
that no such obligation shall apply unless the underlying transaction or amendment is also approved by a Majority of the Minority Holders. 

2.6. The Company. The Company agrees not to give effect to any action by any Stockholder or any other Person that is in contravention of
this Section 2. 
 2.7. Period. The foregoing provisions of this Section 2 will expire (a) with respect
to Section 2.2.1, on the NMC Release Date, (b) with respect to Section 2.2.2, on the Other Investor Release Date, and (c) with respect to Section 2 in its entirety, on the earlier of (i) the Release
Date, (ii) the last date permitted by applicable law and (iii) immediately prior to the effectiveness of the Company’s registration statement in connection with an Initial Public Offering (but subject to the consummation of such
Initial Public Offering). 
 3. TRANSFER RESTRICTIONS. No Stockholder will Transfer any of such Stockholder’s Shares to any other Person except as
provided in this Section 3. 
 3.1. Permitted Transferees. 

3.1.1. Estate Planning. Following the delivery to the Company of written notice, any Stockholder who is a natural person
may Transfer any or all of such Stockholder’s Shares (a) by gift to, or for the benefit of, any Members of the Immediate Family of such Stockholder, (b) to a trust (or limited liability company, partnership or other estate planning
vehicle) for the sole benefit of such Stockholder and/or any Members of the Immediate Family of such Stockholder, or (c) to any other trust (or limited liability company, partnership or other estate planning vehicle) in respect of which such
Stockholder serves as trustee (or as managing member, manager, general partner or otherwise, as applicable); provided, that for purposes of subsections (b) or (c) above, the trust instrument governing such trust (or
limited liability company agreement or partnership agreement, as applicable) must provide that such Stockholder, as trustee (or managing member, manager, general partner or otherwise, as applicable), must retain control over the voting and
disposition of such Shares until the termination of the provisions of Section 3 of this Agreement. 

  
 4 

 3.1.2. Upon Death. Upon the death of any Stockholder who is a natural
person, such Stockholder’s Shares may be distributed by the will or other instrument taking effect at death of such Stockholder or by applicable laws of descent and distribution to such Stockholder’s estate, executors, administrators and
personal representatives, and then to such Stockholder’s heirs, legatees or distributees, whether or not such recipients are Members of the Immediate Family of such Stockholder. 

3.1.3. Additional Permitted Transfers by the Lead Investors. Any Lead Investor may Transfer any or all of its Lead
Investor Shares (a) to such Lead Investor’s partners, members, managers or stockholders, as applicable, pursuant to a liquidation or winding up of such Lead Investor or otherwise pursuant to a pro rata distribution-in-kind by such Lead
Investor, in each case, in accordance with the organizational documents of such Lead Investor, (b) to one or more Affiliates of such Lead Investor, or (c) with the prior written consent of the Majority Other Investors. 

3.1.4. Additional Permitted Transfers by Other Investors. Any Other Investor that is an entity may Transfer any or all
Shares to such Other Investor’s partners, members, managers or stockholders, as applicable, pursuant to a liquidation or winding up of such Other Investor or otherwise pursuant to a distribution-in-kind by such Other Investor. 

Any Shares Transferred in accordance with this Section 3.1 will remain Lead Investor Shares, Other Investor Shares or Management Shares, as the
case may be, and will be subject to all of the provisions of this Agreement applicable to such Shares. No Transfer shall be permitted under the terms of this Section 3.1, and any Transfer permitted under the terms of this
Section 3.1 shall not be effective, unless the transferee of such Shares (each, a “Permitted Transferee”) has delivered to the Company a written acknowledgment and agreement in form and substance reasonably satisfactory
to the Company that such Permitted Transferee will be bound by, and be a party to, this Agreement and the Company Registration Rights Agreement as the holder of Lead Investor Shares, Other Investor Shares and/or Management Shares hereunder, as the
case may be and in accordance with the prior sentence; provided, that no Transfer by any Stockholder to a Permitted Transferee will relieve such Stockholder of any of his, her or its obligations under this Agreement. In connection with any
Transfer by a Stockholder (other than a Lead Investor) pursuant to Sections 3.1.1, 3.1.2 or 3.1.4, such Stockholder shall provide written notice to the Company of such Transfer not less than ten (10) business days prior to
effecting such Transfer, which notice shall state the name and address of each Permitted Transferee to whom such Transfer is proposed to be made, the relationship of such Permitted Transferee to the Transferring Stockholder, and the number of Shares
proposed to be Transferred to such Permitted Transferee. Notwithstanding anything contained herein to the contrary, except in connection with a Drag Along Transaction pursuant to Section 4.2, no Transfer of Shares may be made by any
Stockholder to any Person who directly or indirectly competes with the business of the Company, as determined in the reasonable discretion of the Board, without the prior approval of the Board; provided, that no Person shall be deemed to
compete with the business of the Company solely by reason of such Person’s ownership of five percent (5%) or less of the voting securities of a publically traded entity that competes with the business of the Company. 

  
 5 

 3.2. Tag-Along, Drag-Along, Major Investor Group Transfers. In addition to Transfers
permitted under Section 3.1, and otherwise subject to the terms and conditions of this Agreement: 
 (a) any
Lead Investor may Transfer all or any portion of the Lead Investor Shares if such Lead Investor has complied with the “tag along” provisions contained in Section 4.1; provided, that no Lead Investor may Transfer Lead
Investor Shares to any such Person hereunder unless such Lead Investor and its Affiliates who directly or indirectly hold Units of Cure TopCo also simultaneously Transfer to such Person the percentage of such Units that is equal to the percentage of
the Lead Investor Shares held by the transferring Lead Investor that are being Transferred (and all on substantially the same terms and conditions); 

(b) any Lead Investor may Transfer all or any portion of the Lead Investor Shares if the Majority Lead Investors have
exercised their “drag along” rights set forth in Section 4.2; 
 (c) any other Stockholder may
Transfer any or all of such Stockholder’s Shares in accordance with the provisions, terms and conditions of Section 4.1, Section 4.2 or Section 4.3; 

(d) Any Other Investor that is not a Major Investor may Transfer any or all Shares with the approval of the Board; and 

(e) any Lead Investor may Transfer Shares to the Company pursuant to Section 5.2.4. 

Unless otherwise specified in writing by the Board, (i) any Shares Transferred in accordance with Section 4.1 or 4.2 shall immediately
and automatically become (and the Prospective Buyer will receive) Other Investor Shares, (ii) any Shares Transferred to any Lead Investor pursuant to Section 4.3 shall thereafter become Lead Investor Shares hereunder and
(iii) any Shares Transferred to the Company pursuant to this Agreement will conclusively be deemed thereafter not to be Shares under this Agreement and not to be subject to any of the provisions hereof or entitled to the benefit of any of the
provisions hereof, other than any rights pursuant to Section 5 in connection with any reissuance thereof. 
 3.3. Restrictions
on Certain Other Investors that are Entities. 
 3.3.1. Current Ownership. Each of Remedy Founders, LHP Holding
and the Lead Investor, hereby severally, and not jointly, represents and warrants to the Company that Schedule II-A (with respect to Remedy Founders), Schedule II-B (with respect to LHP Holding) or Schedule II-B (with respect to
Lead Investor), as applicable, contains a list that is true and correct in all material respects of such Person’s shareholders, limited partners or members, as applicable, as of the Effective Date. 

  
 6 

 3.3.2. Beneficial Owners. Each of Remedy Founders and LHP Holding
severally, and not jointly, agrees that it will not, from and after the Effective Date, without the approval of the Board (not to be unreasonably withheld, conditioned or delayed) (a) issue any membership interests or other equity or beneficial
interests to any Person that is not a member or other equity or beneficial interest holder of such entity as of the Effective Date or (b) amend, waive, repeal or otherwise alter or modify any provision of its certificate of formation, operating
agreement or other organizational document, or other agreement entered into or binding with respect to any Transfer of any such membership interests or other equity or beneficial interests. 

3.3.3. No Change of Control. Each of Remedy Founders, LHP Holding and Lead Investor severally, and not jointly, agrees
that any rights specific to such Person in this Agreement shall automatically terminate and be of no further force and effect upon any direct or indirect change of control of such Person after the Effective Date (for the avoidance of doubt, all
obligations of such Person pursuant to this Agreement shall remain in effect). 
 3.4. Impermissible Transfer. Any attempted Transfer
of Shares not permitted under the terms of this Section 3 will be null and void, and the Company will not in any way give effect to any such impermissible Transfer. 

3.5. Other Restrictions on Transfer. The restrictions on Transfer contained in this Agreement are in addition to any other restrictions
on Transfer to which a Stockholder may be subject, including any restrictions on transfer contained in any equity incentive plan, restricted stock agreement, stock option agreement, stock subscription agreement or other agreement to which such
Stockholder is a party or instrument by which such Stockholder has agreed to be bound. Notwithstanding any other provision of this Agreement, prior to the consummation of an Initial Public Offering, each Stockholder agrees that it will not, directly
or indirectly, Transfer any of its Shares: (a) except as permitted under the Securities Act and other applicable federal or state securities or blue sky laws; (b) if such Transfer would cause the Company or any subsidiary of the Company to
be required to register as an investment company under the Investment Company Act of 1940, as amended; or (c) if such Transfer would cause the assets of the Company or any subsidiary of the Company to be deemed “plan assets” as
defined under the Employee Retirement Income Security Act of 1974 or its accompanying regulations or result in any “prohibited transaction” thereunder involving the Company or any subsidiary of the Company. 

3.6. Period. The foregoing provisions of this Section 3 will expire on the earlier of (a) the Release Date and
(b) immediately prior to the effectiveness of the Company’s registration statement in connection with an Initial Public Offering (but subject to the consummation of such Initial Public Offering). 

  
 7 

 4. INVESTOR TRANSFER RIGHTS; “TAG ALONG” AND “DRAG ALONG” RIGHTS. 

4.1. Tag Along. If one or more holders of Lead Investor Shares (each such holder, a “Prospective Selling Investor”)
proposes to Sell any such Shares to any Prospective Buyer in a transaction (a) to which the terms of Sections 3.1, 3.2(b) or 3.2(e) do not apply, and (b) in connection with which the Majority Lead Investors have not
elected to exercise their “drag along” rights under Section 4.2: 
 4.1.1. Notice. The
Prospective Selling Investors will deliver a written notice (the “Tag Along Notice”) to each other Stockholder holding Senior Convertible Preferred Stock and/or Common Stock (or any class or series thereof) as of the date of the Tag
Along Notice (each, a “Tag Along Holder”) at least ten (10) business days prior to such proposed Transfer. The Tag Along Notice must include: 

(a) The principal terms of the proposed Sale insofar as it relates to such Shares, including (i) the number and class(es)
of the Shares to be purchased from the Prospective Selling Investors, (ii) the fraction, expressed as a percentage, determined by dividing the number of Shares (on an as-converted to Common Stock basis) to be purchased from the Prospective
Selling Investors by the total number of Lead Investor Shares (on an as-converted to Common Stock basis) held by the Lead Investors immediately prior to the consummation of such Sale (the “Tag Along Sale Percentage”), (iii) the
per share purchase price or the formula by which such price is to be determined and (iv) the name and address of the Prospective Buyer; and 

(b) An invitation to each Tag Along Holder to make an offer to include in the proposed Sale to the applicable Prospective
Buyer an additional number of Shares held by such Tag Along Holder (not in any event to exceed the Tag Along Sale Percentage of the total number of Shares held by such Tag Along Holder), on the same terms and conditions (subject to
Section 4.3), with respect to each Share sold, as the Prospective Selling Investors shall sell each of their Shares. 

4.1.2. Exercise. Within ten (10) business days after the effectiveness of the Tag Along Notice, each Tag Along
Holder desiring to make an offer to include issued, outstanding and vested Shares in the proposed Sale (each a “Tag Along Participating Seller” and, together with the Prospective Selling Investors, collectively, the “Tag
Along Sellers”) shall furnish a written notice (the “Tag Along Offer”) to the Prospective Selling Investors offering to include an additional number of Shares (not in any event to exceed the Tag Along Sale Percentage of the
total number of Shares held by such Tag Along Participating Seller) that such Tag Along Participating Seller desires to have included in the proposed Sale. Each Tag Along Holder who does not accept the Prospective Selling Investors’ invitation
to make an offer to include Shares in the proposed Sale will be deemed to have waived all rights with respect to such Sale, and the Tag Along Sellers will thereafter be free to sell to the Prospective Buyer, at a per share price no greater than 110%
of the per share price set forth in the Tag Along Notice, and on other principal terms that are not materially more favorable to the Tag Along Sellers than those set forth in the Tag Along Notice, without any further obligation to such non-accepting
Tag Along Holder. 

  
 8 

 4.1.3. Irrevocable Offer. The offer of each Tag Along Participating
Seller contained in his, her or its Tag Along Offer will be irrevocable, and, to the extent such offer is accepted, such Tag Along Participating Seller will be bound and obligated to sell in the proposed Sale on the same terms and conditions, with
respect to each Share sold (subject to Section 4.3.3), as the Prospective Selling Investors, up to such number of Shares as such Tag Along Participating Seller shall have specified in his, her or its Tag Along Offer; provided,
that if the principal terms of the proposed Sale change with the result that the per share price becomes less than 90% of the per share price set forth in the Tag Along Notice or the other principal terms are materially less favorable to the Tag
Along Sellers than those set forth in the Tag Along Notice, then each Tag Along Participating Seller will be permitted to withdraw the offer contained in such Tag Along Participating Seller’s Tag Along Offer and be released from his, her or its
obligations thereunder. 
 4.1.4. Reduction of Shares Sold. The Prospective Selling Investors shall obtain the
inclusion in the proposed Sale of the entire number of Shares that each of the Tag Along Sellers requests to have included in the Sale (as evidenced in the case of the Prospective Selling Investors by the Tag Along Notice and in the case of each Tag
Along Participating Seller by such Tag Along Participating Seller’s Tag Along Offer). In the event the Prospective Selling Investors are unable to obtain the inclusion of such entire number of Shares in the proposed Sale, the number of Shares
to be sold in the proposed Sale will be allocated among the Tag Along Sellers in proportion, as nearly as practicable, to the respective number of Shares which each Tag Along Seller properly requested to be included in the proposed Sale. 

4.1.5. Treatment of Options, Warrants and Convertible Securities. A Tag Along Holder may not include Options, Warrants
or Convertible Securities in a Sale of Shares pursuant to this Section 4.1. 
 4.1.6. Additional
Compliance. If prior to consummation, the terms of the proposed Sale change with the result that the per share price to be paid in such proposed Sale becomes greater than 110% of the per share price set forth in the Tag Along Notice or the other
principal terms of such proposed Sale are materially more favorable to the Tag Along Sellers than those set forth in the Tag Along Notice, then the Tag Along Notice will be null and void, and a separate Tag Along Notice must be furnished, and the
terms and provisions of this Section 4.1 separately complied with, in order to consummate such proposed Sale pursuant to this Section 4.1; provided, that in the case of such a separate Tag Along Notice, the applicable
period to which reference is made in Sections 4.1.1 and 4.1.2 will be the greater of (a) five (5) business days and (b) the remaining period under the initial Tag Along Notice for such Sale. 

  
 9 

 4.1.7. Notwithstanding anything to the contrary in this
Section 4.1, no Lead Investor may Transfer Lead Investor Shares to any Person under this Section 4.1 unless such Lead Investor and its Affiliates who directly or indirectly hold Units also simultaneously Transfer to such
Person the percentage of such Units that is equal to the percentage of the Lead Investor Shares held by the transferring Lead Investor that are being Transferred (and all on substantially the same terms and conditions). 

4.2. Lead Investor Drag Along. Each Stockholder hereby agrees, if requested by the Majority Lead Investors, to Transfer (whether through
a direct Sale or Transfer of Shares or indirectly by means of conversion of Shares through a merger or similar transaction) the same percentage of such Stockholder’s Shares, calculated on an as-converted to Common Stock basis (the “Drag
Along Sale Percentage”), directly or indirectly, that is proposed to be Transferred by holders of Lead Investor Shares (each such holder, a “Prospective Selling Stockholder”) in a transaction or series of related
transactions that (a) would (after giving effect to this Section 4.2) constitute a Change of Control or (b) are otherwise approved by the Majority Other Investors (a “Drag Along Transaction”), in each case, in
the manner and on the terms set forth in this Section 4.2. 
 4.2.1. Exercise. If the Majority Lead
Investors elect to exercise their rights under this Section 4.2, the Prospective Selling Stockholder must furnish a written notice (the “Drag Along Notice”) to each other Stockholder. The Drag Along Notice must set forth
the principal terms of the proposed Drag Along Transaction insofar as it relates to such Shares including (a) the number and class of Shares to be acquired from the Prospective Selling Stockholders, (b) the Drag Along Sale Percentage,
(c) the consideration to be received in the proposed Drag Along Transaction to the extent known at the time of the issuance of the Drag Along Notice and (d) the written commitment of the Majority Lead Investors that it or they will not
receive any consideration for such Transfer unless such consideration is offered to the other Stockholders on the same terms and conditions. If the Prospective Selling Stockholders consummate the proposed Drag Along Transaction to which reference is
made in the Drag Along Notice, each other Stockholder (each a “Drag Along Participating Seller”, and, together with the Prospective Selling Stockholders, collectively, the “Drag Along Sellers”) shall be bound and
obligated to Transfer the Drag Along Sale Percentage of his, her or its Shares in the proposed Drag Along Transaction on the same terms and conditions, with respect to each Share sold, as the Prospective Selling Stockholders shall Transfer their
Lead Investor Shares in the Drag Along Transaction (subject to Section 4.4). 
 4.2.2. Waiver of Appraisal
Rights. Each Drag Along Seller agrees not to seek, demand or exercise appraisal, dissenters’ or similar rights under any applicable business corporation statute or other law (including Section 262 of the Delaware General Corporation
Law) with respect to a transaction subject to this Section 4.2, whether or not such rights are otherwise available. 

  
 10 

 4.2.3. Treatment of Options, Warrants and Convertible Securities. Any
Options, Warrants or Convertible Securities that are exercisable or become exercisable in connection with a Drag Along Transaction pursuant this Section 4.2 shall be subject to the provisions of the agreements and plan documents pursuant
to which such Options, Warrants or Convertible Securities were issued, and to the extent that any Options, Warrants or Convertible Securities (i) are not exercisable or do not become exercisable in connection with a Drag Along Transaction
pursuant this Section 4.2 and (ii) do not terminate in connection with any such Sale pursuant to such agreements and plan documents, then, notwithstanding the provisions of such agreements and plan documents, such Options, Warrants
or Convertible Securities shall terminate upon such Drag Along Transaction. Subject to the preceding sentence, each Drag Along Participating Seller agrees that to the extent any Options, Warrants or Convertible Securities are included in any
Transfer of Shares pursuant to this Section 4.2, such Drag Along Participating Seller will be deemed to have exercised, converted or exchanged such Options, Warrants or Convertible Securities immediately prior to the closing of such Drag
Along Transaction to the extent necessary to Transfer Common Stock to the Prospective Buyer, except to the extent permitted under the terms of any such Option, Warrant or Convertible Security and agreed to by the Prospective Buyer. If any Drag Along
Participating Seller Transfers any Option, Warrant or Convertible Security in any Drag Along Transaction pursuant to this Section 4.2, such Drag Along Participating Seller will receive in exchange for each such Option, Warrant or
Convertible Security consideration equal to the amount (if greater than zero) determined by multiplying (a) (x) the purchase price per share implied by such Drag Along Transaction of the underlying class or series of Shares into which such
Option, Warrant or Convertible Security is exercisable into less (y) the exercise price, if any, per share of such Option, Warrant or Convertible Security by (b) the number of such class or series of Shares issuable upon exercise,
conversion or exchange of such Option, Warrant or Convertible Security (to the extent exercisable, convertible or exchangeable at the time of such Drag Along Transaction), subject to reduction for any tax or other amounts required to be withheld
under applicable law. 
 4.2.4. Notwithstanding anything to the contrary in this Section 4.2, the Majority Lead
Investors shall not exercise rights under this Section 4.2, and a transaction shall not be treated as a Drag Along Transaction, unless the Majority Lead Investors and their Affiliates who directly or indirectly hold Units of Cure TopCo
also simultaneously exercise an Approved Company Sale under Section 12.2 of the Cure TopCo LLCA with respect to such transaction and sell to the same Person the percentage of such Units that is equal to the Drag Along Sale Percentage (and all
on substantially the same terms and conditions). 
 4.3. Other Investor Drag Along. In the event that the Majority Other Investors
desire to Sell all, but not less than all, of the Shares held by such Majority Other Investors (each, a “Prospective Selling Minority Holder”) to the Lead Investors or one or more of their Affiliates, each Stockholder (other than
the Lead Investors) shall Transfer (whether through a direct Sale or Transfer of Shares or indirectly by means of conversion of Shares through a merger or similar transaction) all of such Stockholder’s Shares in the manner and on the terms set
forth in this Section 4.3 (an “Other Investor Drag Along Transaction”). 

  
 11 

 4.3.1. Exercise. In the event of an Other Investor Drag Along
Transaction, the Company shall furnish a written notice (the “Other Investor Drag Along Notice”) to each other Stockholder (other than the Lead Investors). The Other Investor Drag Along Notice shall set forth the principal terms of
the proposed Other Investor Drag Along Transaction insofar as it relates to such Shares including (a) the number and class of Shares to be acquired from the Majority Other Investors, and (b) the consideration to be received in the proposed
Other Investor Drag Along Transaction to the extent known at the time of the issuance of the Other Investor Drag Along Notice. If the Lead Investors and the Majority Other Investors consummate the proposed Other Investor Drag Along Transaction to
which reference is made in the Other Investor Drag Along Notice, each other Stockholder (other than the Lead Investors) (each a “Other Investor Drag Along Participating Seller”, and, together with the Prospective Selling Minority
Holders, collectively, the “Other Investor Drag Along Sellers”) shall be bound and obligated to Transfer all, but not less than all, of his, her or its Shares in the proposed Other Investor Drag Along Transaction on the same terms
and conditions, with respect to each Share sold, as the Majority Other Investors shall Transfer their Other Investor Shares in the Other Investor Drag Along Transaction (subject to Section 4.4.3). 

4.3.2. Waiver of Appraisal Rights. Each Other Investor Drag Along Seller agrees not to seek, demand or exercise
appraisal, dissenters’ or similar rights under any applicable business corporation statute or other law (including Section 262 of the Delaware General Corporation Law) with respect to a transaction subject to this Section 4.3,
whether or not such rights are otherwise available. 
 4.3.3. Treatment of Options, Warrants and Convertible
Securities. Any Options, Warrants or Convertible Securities that are exercisable or become exercisable in connection with an Other Investor Drag Along Transaction pursuant this Section 4.3 shall be subject to the provisions of the
agreements and plan documents pursuant to which such Options, Warrants or Convertible Securities were issued, and to the extent that any Options, Warrants or Convertible Securities (i) are not exercisable or do not become exercisable in
connection with an Other Investor Drag Along Transaction pursuant this Section 4.3 and (ii) do not terminate in connection with any such Sale pursuant to such agreements and plan documents, then, notwithstanding the provisions of
such agreements and plan documents, such Options, Warrants or Convertible Securities shall terminate upon such Other Investor Drag Along Transaction. Subject to the preceding sentence, each Other Investor Drag Along Participating Seller agrees that
to the extent any Options, Warrants or Convertible Securities are included in any Transfer of Shares pursuant to this Section 4.3, such Other Investor Drag Along Participating Seller will be deemed to have exercised, converted or
exchanged such Options, Warrants or Convertible Securities immediately prior to the closing of such Other Investor Drag Along Transaction to the extent necessary to Transfer Common Stock to the Lead Investors, except to the extent permitted under
the terms of any such Option, Warrant or Convertible Security and agreed to by the Lead Investors. If any Other Investor Drag Along Participating Seller Transfers any Option, Warrant or Convertible Security in any Other Investor Drag Along
Transaction pursuant to this Section 4.3, such Other Investor Drag Along Participating Seller will receive in exchange for each such Option, Warrant or Convertible Security consideration equal to the amount (if greater than zero)
determined by multiplying (a) (x)

  
 12 

 
the purchase price per share of the underlying class or series of Shares into which such Option, Warrant or Convertible Security is exercisable into to be received by the Majority Other Investors
in respect of such underlying class or series of Shares in such Other Investor Drag Along Transaction less (y) the exercise price, if any, per share of such Option, Warrant or Convertible Security by (b) the number of shares of such
underlying class or series of Shares issuable upon exercise, conversion or exchange of such Option, Warrant or Convertible Security (to the extent exercisable, convertible or exchangeable at the time of such Other Investor Drag Along Transaction),
subject to reduction for any tax or other amounts required to be withheld under applicable law. 
 4.4. Miscellaneous. The following
provisions apply to any proposed Sale to which Section 4.1, 4.2 or 4.3 applies: 
 4.4.1.
Certain Legal Requirements. In the event the consideration to be paid in exchange for Shares in a proposed Sale pursuant to Section 4.1, Section 4.2 or Section 4.3 includes any securities, and the receipt
thereof by a Participating Seller would require under applicable law (a) the registration or qualification of such securities or of any Person as a broker or dealer or agent or registrant with respect to such securities where such registration
or qualification is not otherwise required for the Sale by the Prospective Selling Investor(s), Prospective Selling Stockholder(s) or Prospective Selling Minority Holder(s), as applicable, or (b) the provision to any Tag Along Seller, Drag
Along Seller or Other Investor Drag Along Seller of any additional information regarding the Company or any of its subsidiaries, such securities or the issuer thereof, including by reason of the failure of one or more Stockholders to be an
“accredited investor” as such term is defined in Rule 501 of Regulation D of the Securities Act, such Participating Seller will not have the right to Sell Shares in such proposed Sale. In such event, the Prospective Selling Investors, the
Prospective Selling Stockholders or Prospective Selling Minority Holders, as applicable, as applicable, shall cause to be paid to such Participating Seller in lieu thereof, against surrender of the Shares (in accordance with
Section 4.4.5 hereof) which would have otherwise been Sold by such Participating Seller to the Prospective Buyer in the proposed Sale, an amount in cash equal to the fair market value of such Shares as of the date such securities would
have been issued in exchange for such Shares. 
 4.4.2. Further Assurances. The Company and each Participating Seller,
whether in his, her or its capacity as a Participating Seller, stockholder, officer or director of the Company, or otherwise, will take or cause to be taken all such actions as may be necessary or reasonably desirable in order expeditiously to
consummate each Transfer or Sale pursuant to Section 4.1, Section 4.2 or Section 4.3 and any related transactions, including executing, acknowledging and delivering consents, assignments, waivers and other
documents or instruments; furnishing information and copies of documents; filing applications, reports, returns, filings and other documents or instruments with governmental authorities; complying and agreeing to comply with non-disclosure,
exclusive dealing or other preliminary agreements entered into in connection with a proposed Transfer or Sale transaction to which Section 4.1, Section 4.2 or Section 4.3 would apply to the extent the Prospective
Selling Investors, the Prospective Selling 

  
 13 

 
Stockholders or the Prospective Selling Minority Holders, as applicable, agree to comply with such arrangements; and otherwise cooperating with the Prospective Selling Investors, the Prospective
Selling Stockholders or the Prospective Selling Minority Holders, as applicable, and the Prospective Buyer; provided, however, that Participating Sellers will be obligated to become liable in respect of any representations, warranties,
covenants, indemnities or otherwise to the Prospective Buyer solely to the extent provided in the immediately following sentence; provided, further, that (x) no Participating Seller will be subject to any obligation, arrangement,
condition or term of a Drag Along Transaction to which any Lead Investor is not also so subject; and (y) no Stockholder shall be required to enter into any non-competition, employee, customer or other non-solicit or similar restrictive covenant
or other business limitation in connection with a Drag Along Transaction to the extent such restrictive covenant or other business limitation is different than the restrictive covenants and other business limitations as set forth in this Agreement
and binding on such Stockholder. Each Participating Seller agrees to execute and deliver such agreements as may be reasonably specified by the Prospective Selling Investors, the Prospective Selling Stockholders or the Prospective Selling Minority
Holders, as applicable, to which such Prospective Selling Investors, the Prospective Selling Stockholders or Prospective Selling Minority Holders, as applicable, will also be party, including agreements to (a) (i) make individual and
several representations, warranties, covenants and other agreements as to the unencumbered title to its Shares and the power, authority and legal right to Transfer such Shares and the absence of any Adverse Claim with respect to such Shares, and
(ii) be severally liable without limitation as to such individual representations, warranties, covenants and other agreements and (b) be liable (whether by purchase price adjustment, indemnity payments or otherwise) in respect of
representations, warranties, covenants and agreements in respect of the Company and its subsidiaries; provided, however, that the aggregate amount of liability described in this clause (b) in connection with any Transfer or Sale
of Shares will not exceed the lesser of (i) such Participating Seller’s pro rata portion of any such liability, to be determined in accordance with such Participating Seller’s portion of the total number of Shares (calculated on an
as-converted to Common Stock basis) included in such Transfer or Sale and (ii) the proceeds to such Participating Seller in connection with such Transfer or Sale. Each Participating Seller that is not a Major Other Investor hereby constitutes
and appoints each of the Prospective Selling Investors, the Prospective Selling Stockholders or the Prospective Selling Minority Holders, as applicable, or any of them, with full power of substitution, as such Participating Seller’s true and
lawful representative and attorney-in-fact, in such Participating Seller’s name, place and stead, to execute and deliver any and all agreements that such Prospective Selling Investor, the Prospective Selling Stockholder or Prospective Selling
Minority Holder, as applicable, reasonably believes are consistent with this Section 4.4.2 and such Prospective Selling Investor, the Prospective Selling Stockholder or the Prospective Selling Minority Holder, as applicable, will provide
a copy of such agreements to such Participating Seller within five (5) business days of execution; provided, however, that failure to deliver such documents within such time period will not impair or affect the validity of such
agreements. The foregoing power of attorney is coupled with an interest and, to the maximum extent permitted by applicable law, will continue in full force and effect notwithstanding the subsequent death, incapacity, bankruptcy or dissolution of any
Participating Seller. 

  
 14 

 4.4.3. Sale Process. The Lead Investors will, in their sole
discretion, decide whether or not to pursue, consummate, postpone or abandon any proposed Transfer or Sale and the terms and conditions thereof. Neither the Lead Investor nor any Participating Seller nor any of their respective Affiliates will have
any liability to the Company or to any other holder of Shares arising from, relating to or in connection with the pursuit, consummation, postponement, abandonment or terms and conditions of any proposed Transfer or Sale except to the extent such
Lead Investor shall have failed to comply with the provisions of this Section 4. 
 4.4.4. Expenses. All
reasonable costs and expenses incurred by the Prospective Selling Investors or the Prospective Selling Stockholders, as applicable, or the Company in connection with any proposed Transfer or Sale pursuant to this Section 4 (whether or
not consummated), including all attorney’s fees and expenses, all accounting fees and charges and all finders, brokerage or investment banking fees, charges or commissions, will be paid by the Company. Any other costs and expenses incurred by
or on behalf of any or all of the other Tag Along Sellers, Drag Along Sellers or Other Investor Drag Along Sellers in connection with any proposed Sale pursuant to this Section 4 (whether or not consummated) will be borne by such Tag
Along Seller(s), Drag Along Seller(s) or Other Investor Drag Along Sellers, provided that in connection with any proposed Transfer or Sale pursuant to this Section 4, the Company shall reimburse the Drag Along Sellers (other than the
Prospective Selling Investors or the Prospective Selling Stockholders), for the fees and expenses of a single counsel designated by holders of the majority of Shares sold by the Drag Along Sellers in an amount for each such transaction not to exceed
$250,000. 
 4.4.5. Closing. The closing of a Transfer or Sale to which Section 4.1,
Section 4.2 or Section 4.3 applies will take place at such time and place as the Prospective Selling Investors, the Prospective Selling Stockholders or the Prospective Selling Minority Holders, as applicable, specify by
notice to each Participating Seller. At the closing of such Sale, each Participating Seller will (a) with respect to certificated Shares, deliver the certificates evidencing the Shares to be Sold by such Participating Seller, duly endorsed, or
with stock (or equivalent) powers duly endorsed, for transfer with signature guaranteed free and clear of any lien or encumbrance or (b) with respect to uncertificated shares, deliver such transfer documentation as is reasonably requested by
the Company and in form and substance reasonably acceptable to the Company, in each case, reflecting that the Shares to be Sold are free and clear of any liens or encumbrances and, in each case, with any applicable stock (or equivalent) transfer tax
stamps affixed, in exchange for delivery of the applicable consideration. 

  
 15 

 4.4.6. Auction. Any Transfer or Sale of Shares pursuant to
Section 4.2 may be structured by the Prospective Selling Investor or the Prospective Selling Stockholder, as applicable, as an auction and may be initiated by the delivery to the Company and the other Stockholders of a written notice
that the Prospective Selling Investor or the Prospective Selling Stockholder, as applicable, has elected to initiate an auction sale procedure. The Prospective Selling Investor or the Prospective Selling Stockholder, as applicable, shall be entitled
to take all steps reasonably necessary to carry out an auction of the Company and its subsidiaries, including selecting an investment bank to represent the Company and selling Stockholders in the auction, providing confidential information (pursuant
to confidentiality agreements), selecting the winning bidder and negotiating the requisite documentation. 
 4.5. Cure TopCo Drag
Along. Notwithstanding anything to the contrary contained herein, each Stockholder acknowledges and agrees that, subject to Section 12.7 of the Cure TopCo LLCA, the Company is obligated to Transfer its equity securities of Cure TopCo
pursuant to Section 12.2 of the Cure TopCo LLCA in connection with an Approved Cure TopCo Sale (or to have Other Investors Transfer Shares instead as contemplated by Sections 12.2 and 12.7 of the Cure TopCo LLCA), and hereby agrees to consent
to the Company taking all such action as is required by the Cure TopCo LLCA in connection with an Approved Cure TopCo Sale; provided that such Approved Cure TopCo Sale complies with all applicable requirements of the Cure TopCo LLCA. 

4.6. Period. The foregoing provisions of this Section 4 will expire upon the earlier of (a) the Release Date and
(b) immediately prior to the effectiveness of the Company’s registration statement in connection with an Initial Public Offering (but subject to the consummation of such Initial Public Offering); provided that the terms of
Section 4.2.2 and 4.3.2 shall survive such expiration and continue indefinitely. 
 5. RIGHT OF PARTICIPATION. The Company will not issue
or sell any additional shares of any of its capital stock or any securities (including any debt securities) convertible into or exchangeable for any shares of its capital stock, issue or grant any options or warrants for the purchase of, or enter
into any agreements providing for the issuance (contingent or otherwise) of, any of its capital stock or any stock or securities (including any debt securities) convertible into or exchangeable for any shares of its capital stock, in each case, to
any Stockholder or other Person (each an “Issuance” of “Subject Securities”), except in compliance with the provisions of Section 5.1 or 5.2. 

5.1. Right of Participation. 

5.1.1. Offer. Not fewer than fifteen (15) calendar days prior to the consummation of an Issuance, the Company will
furnish a notice (the “Participation Notice”) to each Stockholder that holds (either individually or together with his, her or its Affiliates) more than one percent (1%) of all Shares then outstanding (the
“Participation Offerees”). The Participation Notice will include: 
 (a) (i) the amount and kind of
Subject Securities to be included in the Issuance, (ii) the number of Equivalent Shares represented by such Subject Securities (if applicable), (iii) the percentage of the total number of Equivalent Shares outstanding held by such
Participation Offeree as of immediately prior to giving effect to such Issuance (the “Participation  

  
 16 

 
Portion”), (iv) the price (including, if applicable, the maximum and minimum Price Per Equivalent Share) per Share (or other applicable unit of the Subject Securities), and (v) the
name and address of the Stockholder or other Person to whom the Subject Securities are proposed to be issued (the “Prospective Subscriber”); and 

(b) An offer by the Company to issue, at the option of each Participation Offeree, to such Participation Offeree such portion
of the Subject Securities to be included in the Issuance as may be requested by such Participation Offeree (not to exceed the Participation Portion of the total amount of Subject Securities to be included in the Issuance), on the same economic terms
and conditions, with respect to each unit of Subject Securities issued to the Participation Offerees, as each of the Prospective Subscribers shall be issued units of Subject Securities. 

5.1.2. Exercise. 

5.1.2.1. General. Each Participation Offeree desiring to accept the offer contained in the Participation Notice must
send a written commitment to the Company within twenty (20) calendar days after the effectiveness of the Participation Notice specifying the amount of Subject Securities (not in any event to exceed the Participation Portion of the total amount
of Subject Securities to be included in the Issuance) that such Participation Offeree desires to be issued (each a “Participating Buyer”). Each Participation Offeree who has not so accepted such offer will be deemed to have waived
all of such Participation Offeree’s rights with respect to the Issuance, and the Company will thereafter be free to issue Subject Securities in the Issuance to the Prospective Subscriber and any Participating Buyers, at a price no less than the
minimum price set forth in the Participation Notice and on other principal terms not substantially more favorable to the Prospective Subscriber than those set forth in the Participation Notice, without any further obligation to such non-accepting
Participation Offerees. If, prior to consummation, the terms of such proposed Issuance change with the result that the price becomes less than the minimum price set forth in the Participation Notice or the other principal terms are substantially
more favorable to the Prospective Subscriber than those set forth in the Participation Notice, a separate Participation Notice must be furnished, and the terms and provisions of this Section 5.1 separately complied with, in order to
consummate such Issuance pursuant to this Section 5.1; provided, however, that in the case of such a separate Participation Notice, the applicable period to which reference is made in the first sentence of this
Section 5.1.2.1 will be the greater of five (5) business days and the remaining period under the initial Participation Notice for such Sale. 

5.1.2.2. Irrevocable Acceptance. The written acceptance of each Participating Buyer will be irrevocable except as
provided herein, and each such Participating Buyer will be bound and obligated to acquire in the Issuance on the same terms and conditions, with respect to each unit of Subject Securities issued, as the Prospective Subscriber, such amount of Subject
Securities as such Participating Buyer shall have specified in such Participating Buyer’s written commitment. 

  
 17 

 5.1.3. Certain Legal Requirements. In the event that the
participation in the Issuance by a Stockholder as a Participating Buyer would require under applicable law (i) the registration or qualification of any Subject Securities or any other securities contemplated to be issued in such Issuance or of
any Person as a broker or dealer or agent or issuer with respect to such securities or (ii) the provision to any participant in the Sale of any additional information regarding the Company or the securities (including by reason of the failure
of such Participating Buyer to be an “accredited investor” as such term is defined in Rule 501 of Regulation D of the Securities Act), such Stockholder will not have the right to participate in the Issuance. Without limiting the generality
of the foregoing, it is understood and agreed that the Company will not be under any obligation to effect a registration of such securities under the Securities Act or similar state law. 

5.1.4. Further Assurances. Each Participation Offeree and each Stockholder to whom the Shares held by such Participation
Offeree were originally issued, will, whether in his, her or its capacity as a Participating Buyer, Stockholder, officer or director of the Company, or otherwise, take or cause to be taken all such reasonable actions as may be necessary in order
expeditiously to consummate each Issuance pursuant to this Section 5.1 and any related transactions, including executing, acknowledging and delivering consents, assignments, waivers and other documents or instruments; filing
applications, reports, returns, filings and other documents or instruments with governmental authorities; and otherwise cooperating with the Company and the Prospective Subscriber. Without limiting the generality of the foregoing, each such
Participating Buyer and Stockholder agrees to execute and deliver such subscription and other agreements specified by the Company to which the Prospective Subscriber will be party. 

5.1.5. Expenses. All reasonable costs and expenses incurred by the holders of Lead Investor Shares or the Company in
connection with any proposed Issuance of Subject Securities (whether or not consummated), including all attorney’s fees and charges, all accounting fees and charges and all finders, brokerage or investment banking fees, charges or commissions,
will be paid by the Company. Any other costs and expenses incurred by or on behalf of any other Stockholder in connection with such proposed Issuance of Subject Securities (whether or not consummated) will be borne by such Stockholder,
provided that in connection with any proposed Issuance of Subject Securities pursuant to this Section 5, the Company shall reimburse the Participating Buyers (other than the holders of Lead Investor Shares) for the fees and
expenses of a single counsel designated by holders of the majority of the Subject Securities anticipated to be purchased in such Issuance by the Participating Buyers in an amount for each such transaction not to exceed $250,000. 

  
 18 

 5.1.6. Issuance Process. The Company may, in its sole discretion,
decide whether or not to pursue, consummate, postpone or abandon any proposed Issuance of Subject Securities. No Participating Buyer or any Affiliate of any Participating Buyer will have any liability to any other holder of Shares arising from,
relating to or in connection with the pursuit, consummation, postponement, abandonment or terms and conditions of any proposed Issuance of Subject Securities except to the extent the Company shall have failed to comply with the provisions of this
Section 5. 
 5.1.7. Closing. The closing of an Issuance pursuant to Section 5.1 will take
place at such time and place as the Company specifies by notice to each Participating Buyer. At the closing of any Issuance under this Section 5.1.7, the Company will deliver or cause to be delivered to each Participating Buyer, if
applicable, the notes, certificates or other instruments evidencing the Subject Securities (and, if applicable, other securities) to be issued to such Participating Buyer, registered in the name of such Participating Buyer or his, her or its
designated nominee, free and clear of any liens or encumbrances, against delivery by such Participating Buyer of the applicable consideration. 

5.2. Post-Issuance Notice. Notwithstanding the notice requirements of Sections 5.1.1 and 5.1.2, the Company may proceed
with any Issuance prior to having complied with the provisions of Section 5.1; provided, that the Company will: 

5.2.1. provide to each Stockholder who would have been a Participation Offeree in connection with such Issuance (i) prompt
notice of such Issuance and (ii) the Participation Notice described in Section 5.1.1 in which the actual price per Share (or other applicable unit) of Subject Securities (and, if applicable, actual Price Per Equivalent Share) is set
forth; 
 5.2.2. offer to issue to such Stockholder such number of securities of the type issued in the Issuance as may be
requested by such holder (not to exceed an amount equal to (i) the Participation Portion that such holder would have been entitled to pursuant to Section 5.1.1 multiplied by the number of Subject Securities included in the Issuance
plus (ii) a number of additional securities sufficient to permit such holder to acquire, in total, the same percentage of the aggregate number of all securities included in the relevant Issuances effected pursuant to this
Section 5.2 as such holder would have been entitled to acquire had the Company proceeded with the relevant Issuances under Section 5.1.1 rather than pursuant to this Section 5.2) on the same economic terms and
conditions with respect to such securities as the subscribers in the Issuance received; and 
 5.2.3. keep such offer open
for a period of twenty (20) calendar days, during which period each such holder may accept such offer by sending a written acceptance to the Company committing to purchase an amount of such securities (not in any event to exceed the
Participation Portion that such holder would have been entitled to pursuant to Section 5.1.1 multiplied by the number of Subject Securities included in such issuance). 

  
 19 

 5.2.4. In the event the Company issues Subject Securities pursuant to this
Section 5.2, the Company may repurchase the same number (and type) of Subject Securities from the Lead Investors and/or Affiliated Funds (as determined by such Lead Investors and Affiliated Funds) without any other Stockholder having a
rights to participate in such Sale pursuant to Section 4.1. 
 5.3. Excluded Transactions. Notwithstanding the preceding
provisions of this Section 5, the preceding provisions of this Section 5 will not restrict: 
 5.3.1. any
Issuance of Common Stock upon the exercise or conversion of any Senior Convertible Preferred Stock, Common Stock, Warrants, Options or Convertible Securities outstanding on the Effective Date or issued after the Effective Date in compliance with the
provisions of this Section 5 (including this Section 5.3.1); 
 5.3.2. the Issuance of Shares to the
Stockholders as part of the transactions contemplated by the Combination Agreement; 
 5.3.3. any Issuance pursuant to any
stock split, stock combination, stock dividend or similar distribution or recapitalization of outstanding Shares; 
 5.3.4.
any Issuance of an “equity kicker” in connection with the incurrence by the Company or any of its subsidiaries of indebtedness provided by an unaffiliated third party in a bona fide debt financing transaction; and 

5.3.5. any Issuance of Shares which the Board, including for this purpose a majority of the Other Investor Directors, has
elected not be subject to this Section 5. 
 5.4. Certain Provisions Applicable to Options, Warrants and Convertible
Securities. If the Issuance of Subject Securities would result in any increase in the number of shares of any class or series of capital stock of the Company issuable upon exercise, conversion or exchange of any Options, Warrants or Convertible
Securities, the number of shares (or Equivalent Shares, if applicable) of Subject Securities (and other securities, if applicable) which the holders of such Options, Warrants or Convertible Securities, as the case may be, are entitled to purchase
pursuant to Section 5.1 or 5.2, if any, will be reduced, share for share, by the amount of any such increase. 
 5.5.
Acquired Shares. Any Subject Securities constituting shares of capital stock of the Company acquired by any holder of Shares pursuant to this Section 5 will be deemed for all purposes hereof to be Lead Investor Shares, Other
Investor Shares or Management Shares hereunder of like kind with the Shares then held by the acquiring holder (and in the case of any Manager that holds Other Investor Shares, will be deemed for all purposes hereof to be Other Investor Shares). 

5.6. Period. The foregoing provisions of this Section 5 will expire on the earlier of (a) the Release Date and
(b) immediately prior to the effectiveness of the Company’s registration statement in connection with an Initial Public Offering (but subject to the consummation of such Initial Public Offering). 

  
 20 

 6. REORGANIZATIONS 

6.1. Reorganization; Recap Drag. Notwithstanding anything to the contrary contained in this Agreement, the Stockholders acknowledge and
agree that in connection only with a Change of Control or the Company’s Initial Public Offering, the Lead Investors shall have the right to cause the Company to effect a recapitalization, reorganization, change of form, an exchange of the
capital of the Company into other equity securities, or any similar transaction (a “Reorganization”) that (i) does not involve a Transfer to any Person (other than any Stockholder or a Permitted Transferee of any Stockholder),
(ii) that does not result in Disproportionate Adverse Tax Consequences to any of the Stockholders, and (iii) otherwise results in any of the Stockholders holding equity interests with substantially similar economic, governance, priority
and other covenants, conditions, rights and privileges as in effect immediately prior to such conversion. “Disproportionate Adverse Tax Consequences” means (1) material and adverse tax consequences to the Stockholders (other
than the Lead Investors) or their direct or indirect owners with respect to their Shares as a result of the Reorganization that are disproportionate to the tax consequences to the Lead Investors or their Permitted Transferees or (2) the
realization of, or a material risk of the realization of, solely as a result of the Reorganization (including, but not limited to, as a result of (x) direct or indirect ownership of any equity or other assets received or retained by any
Stockholder in such Reorganization or (y) a Stockholder becoming responsible for any liability in connection with such Reorganization, but in each case not taking into account any actions by a Stockholder other than participation in such
Reorganization pursuant to the terms thereof), any “effectively connected income” within the meaning of Section 864 or 897 of the Code, “unrelated business taxable income” within the meaning of Sections 512 or 514 of the
Code, or income derived from the conduct of any commercial activity within the meaning of Section 892 of the Code to any of the Stockholders (other than the Lead Investors) or their indirect or indirect owners; provided, however that it is
understood that Disproportionate Adverse Tax Consequences shall be deemed not to arise solely from any right to receive proceeds or amounts (or solely from the actual receipt of proceeds or amounts) pursuant to (A) a “tax receivable
agreement” or similar agreement entered into in connection with an initial public offering or (B) a sale or other exit transaction, in each case where all or a portion of such proceeds or other amounts may be directly or indirectly
calculated on a substantially equivalent basis for both equity holders in the Company and other direct and indirect equity holders in one or more entities engaged in a trade or business, which calculation may include adjustments for assets and
liabilities of such other entities, including tax attributes. The Lead Investors shall not have the right to cause the Company to, and the Company shall not, effect a Reorganization that would result in Disproportionate Adverse Tax Consequences to
any of the Stockholders (other than the Lead Investors) without the prior written consent of each of BCV (on behalf of the Bain Group), the Remedy Founders (on behalf of the Remedy Founders Group), and LHP Holding (on behalf of the LHP Holding
Group). At least fifteen (15) business days prior to effecting any Reorganization, the Company shall provide written notice to each Stockholder (other than the Lead Investors) describing the proposed Reorganization in a reasonably detailed
manner sufficient for such Stockholders to assess the intended tax consequences of such Reorganization on such Stockholders. In connection with any Reorganization permitted pursuant to this Section 6.1, the Lead Investors shall have the
right to compel all the other Stockholders, and such other Stockholders hereby agree (subject to the terms and conditions of this Section 6.1), to transfer 

  
 21 

 
the same percentage of their Shares as, and on the same terms and conditions as applicable to, the Lead Investors (the “Recap Drag”). Each of the Stockholders hereby further
agrees that it will take such actions and execute such documents as may reasonably be requested to effect such Recap Drag provided that such Recap Drag otherwise complies with the terms and conditions of this Section 6.1. 

6.2. Period. The foregoing provisions of this Section 6 will expire upon the earlier of (a) the NMC Release Date and
(b) immediately prior to the effectiveness of the Company’s registration statement in connection with an Initial Public Offering (but subject to the consummation of such Initial Public Offering). 

7. NEGATIVE COVENANTS 
 7.1. Majority Lead
Investor Consent Rights. On or before the NMC Release Date, the Company shall not, either directly or indirectly by amendment, merger, consolidation, or otherwise, do any of the following without the written consent or affirmative vote, given in
writing or by vote at a meeting, of the Majority Lead Investors: 
 7.1.1. (i) liquidate, dissolve or wind up,
(ii) consolidate or merge into or with any other entity, (iii) sell, lease or otherwise transfer all or substantially all of its assets to another entity, or (iv) enter into any other business combination transaction with another
entity, in each case of (ii), (iii) or (iv), where the Stockholders immediately preceding such transaction own, following such transaction, less than fifty percent (50%) of the voting securities of the Company; 

7.1.2. enter into any new line of business or otherwise change significantly the scope or nature of the Company and its
subsidiaries’ business or operations, taken as a whole; 
 7.1.3. adopt any annual budget or annual business plan or
materially amend such budget or business plan if adopted; 
 7.1.4. incur any indebtedness, including entry into any
guarantee in respect of indebtedness, in each case in excess of $10,000,000, other than working capital loans and other similar transactions in the ordinary course of business; 

7.1.5. sell, transfer or otherwise dispose of (which for purposes of clarification excludes inventory and other sales in the
ordinary course of business) in any transaction or series of related transactions of more than twenty five percent (25%) of the fair market value of the Company’s consolidated assets; 

7.1.6. declare or make payment of any dividends on or the make redemptions of any class of stock (except as otherwise expressly
provided in this Agreement); 

  
 22 

 7.1.7. create, issue or sell (by reclassification, merger, consolidation,
reorganization or otherwise) equity securities or Convertible Securities; provided, that the consent of the Majority Lead Investors shall not be required in connection with (x) the issuance of restricted stock or options to employees,
officers, directors, consultants or other persons performing services for the Company (or for the issuance of Common Stock upon exercise of options) pursuant to the Company’s equity incentive plans as in existence on the Effective Date (or any
other or subsequent equity incentive plan of the Company that has hereafter been approved in accordance with this Agreement), and (y) the issuance of Common Stock upon the conversion of shares of Senior Convertible Preferred Stock or Class B
Common Stock or Class C Common Stock; 
 7.1.8. adopt any equity incentive or option plans or amend any such plans to
increase the number of Shares to be issued thereunder; 
 7.1.9. alter, amend or waive any term or condition of the
Company’s Certificate of Incorporation or Bylaws; 
 7.1.10. increase of decrease the size of the Board; 

7.1.11. select or change the Company’s independent auditors; 

7.1.12. grant any severance or terminate pay to any officer of the Company or its subsidiaries except (i) payments made
pursuant to any written agreements outstanding on the Effective Date and furnished to the Lead Investors on or prior to the Effective Date or (ii) as determined by counsel to the Company to be required by applicable law; 

7.1.13. hire, terminate, remove or replace, or change the compensation for, any senior executive officers; 

7.1.14. enter into, amend, terminate or modify of, any contract that would purport to apply to the Lead Investors or any of
their Affiliates (other than the Company and its subsidiaries); 
 7.1.15. enter into, amend, terminate or modify any
“material contract” (as defined in Item 601 of Regulation S-K promulgated under the Securities Act); or 

7.1.16. enter into any agreement to do any of the foregoing. 

7.2. Majority Other Investor Consent Rights. On or before the Other Investor Release Date, the Company shall not, either directly or
indirectly by amendment, merger, consolidation, or otherwise, do any of the following without the written consent of the Majority Other Investors: 

7.2.1. increase or decrease the size of the Board or the manner in which Directors are elected, provided that no such consent
will be required if the number of directors as so increased or decreased are designated by the Lead Investor and the Other Investors in a proportionate manner; 

  
 23 

 7.2.2. alter, amend or waive any term or condition of the Company’s
Certificate of Incorporation or Bylaws (including an amendment effected by merger, consolidation or other reorganization) in a manner that would have a materially adverse and disproportionate effect on the rights of Stockholders (other than the Lead
Investors) relative to the Lead Investors; provided, that no such approval shall be required with respect to an amendment to increase the number of authorized shares of Senior Convertible Preferred Stock or Common Stock to the extent
necessary to permit the Company to comply with provisions of its Certificate of Incorporation, and provided, further that (a) any alteration, amendment or change of any terms of the Company’s Senior Convertible Preferred
Stock with respect to the liquidation preference, voting rights, dividend rights (either as to payment or amount) or any similar changes proposed by the Lead Investors, and (b) any alteration, amendment or change of Section 9 of Article
NINTH, ARTICLE TENTH and Article TWELTH of the Company’s Certificate of Incorporation, shall, in either instance and for purposes of this Section 7.2.2, be deemed to be materially adverse and disproportionate); 

7.2.3. enter into any transactions with the Lead Investors or any of their controlled Portfolio Companies or Affiliates
(including any commercial transactions or any purchases or Sales of assets or business); provided, that no such approval shall be required with respect to (i) any arms-length transaction with the Lead Investors or any of their controlled
Portfolio Companies or Affiliates in the ordinary course of business of the Company or its subsidiaries; (ii) any arms-length indemnification or insurance arrangements with any Directors or any other customary arrangements and agreements with
any Directors who are not employees, directors, managers or officers of the Lead Investors or their Affiliates or (iii) any transaction, agreement or other arrangement specifically contemplated by this Agreement, including any Sale or Transfer
of Shares by the Lead Investors or their Affiliates that complies with the terms and conditions set forth in Section 3 or any issuance of Subject Securities by the Company that complies with the terms and conditions set forth in
Section 5; 
 7.2.4. enter into any new line of business or otherwise change significantly the scope or nature of
the Company and its subsidiaries’ business or operations, taken as a whole; 
 7.2.5. make, or commit to make, any
redemptions of any class of stock (except for redemptions of Common Stock from Managers as approved by the Board and as provided for under such agreements and plans with respect to the original issuance of Common Stock to any such Manager as has
previously been approved by the Board); or 
 7.2.6. declare, commit to declare, or pay any distribution or dividend in cash
or other property of the Company or any Affiliate of the Company (other than dividends payable in the form of Common Stock to all Stockholders on an as-converted to Common Stock basis), provided that no such approval shall be required with respect
to any such distribution or dividend if such distribution or dividend is paid to all holders of Senior Convertible Preferred Stock and Common Stock (treating all such Senior Convertible Preferred Stock on an as-converted to Common Stock basis for
purposes of such distribution or dividend). 

  
 24 

 7.2.7. enter into any new line of business or otherwise change significantly
the scope or nature of the Company and its subsidiaries’ business or operations, taken as a whole; 
 7.2.8. incur any
indebtedness, including entry into any guarantee in respect of indebtedness, in each case in excess of $10,000,000, other than working capital loans and other similar transactions in the ordinary course of business; 

7.2.9. adopt any equity incentive or option plans or amend any such plans to increase the number of Shares to be issued
thereunder (other than amendments or modifications to grants or awards made prior to the Effective Date, including with respect to waiving or modifying any vesting terms thereof); 

7.2.10. grant any severance or terminate pay to any officer of the Company or its subsidiaries, in each case, solely to the
extent such grants or payments are to be made by the Company, except (i) payments made pursuant to any written agreements outstanding on the Effective Date or (ii) as determined by counsel to the Company to be required by applicable law;

 7.2.11. hire, terminate, remove or replace, or change the compensation for, any senior executive officers of the Company
that are paid a salary or other compensation by the Company; 
 7.2.12. consummate a Reorganization or an Initial Public
Offering of the Company by itself, or take any action to commit the Company to do so (for the avoidance of doubt, this Section 7.2.12 shall not prohibit or limit the structuring of an initial public offering of Cure TopCo or the businesses of
Cure TopCo and its subsidiaries, including if the Company is merged or collapsed into the legal entity that consummates its initial public offering); 

7.2.13. issue or sell any additional shares of any of its capital stock or any securities (including any debt securities)
convertible into or exchangeable for any shares of its capital stock, issue or grant any options or warrants for the purchase of, or enter into any agreements providing for the issuance (contingent or otherwise) of, any of its capital stock or any
stock or securities (including any debt securities) convertible into or exchangeable for any shares of its capital stock, in each case, to any Stockholder or other Person; 

7.2.14. (i) liquidate, dissolve or wind up, (ii) consolidate or merge into or with any other entity, or
(iii) enter into any other business combination transaction with another entity (for the avoidance of doubt, this Section 7.2.14 shall not prohibit or limit the structuring of an Approved Company Sale or an initial public offering of Cure
TopCo or the businesses of Cure TopCo and its subsidiaries, including if the Company is merged or collapsed into the legal entity that consummates its initial public offering); 

  
 25 

 7.2.15. make redemptions of any class of stock (except as otherwise
expressly provided in this Agreement); 
 7.2.16. alter, amend or waive any term or condition of the Company’s
Certificate of Incorporation or Bylaws; 
 7.2.17. enter into, amend, terminate or modify any “material contract”
(as defined in Item 601 of Regulation S-K promulgated under the Securities Act); provided, that the foregoing shall not prohibit or limit amendments or modifications of the Cure TopCo LLCA, the Combination Agreement, the Cure TopCo Registration
Rights Agreement or this Agreement that are made in full compliance with the requirements of such documents; 
 7.2.18.
authorize, declare or permit to occur any stock dividend, stock split, combination or other similar recapitalization with respect to any class or series of the capital stock of the Company; 

7.2.19. authorize, declare or pay any dividends or distributions unless the Company has provided written notice thereof to all
holders of options or warrants to acquire capital stock of the Company (including reasonable information with respect thereto, including the projected amounts) at least 30 days prior to the record date for such dividend or distribution, so as to
give such holders adequate time to elect to exercise such options or warrants if they so choose and thus participate in such dividend or distribution; or 

7.2.20. enter into any agreement to do any of the foregoing. 

7.3. Certain Expenses. Except with the prior written consent of the Majority Other Investors, the Company shall not pay, or enter into
any agreement to pay, any management fee, transaction fee, financing fee, banking or advisory fee or any similar charge or fee to the Lead Investors or their Affiliates. For the avoidance of doubt, nothing in this Section 7.3 will
prohibit the Company from paying for, or reimbursing, (i) expenses of Directors in accordance with Section 2.3 or (ii) expenses of the Lead Investors or their Affiliates pursuant to the term and conditions of the Purchase
Agreement, this Agreement or the Company Registration Rights Agreement solely to the extent such agreements expressly provide for payment or reimbursement of costs or expenses of the Lead Investors or their Affiliates. 

7.4. Information Rights. The Company shall deliver to each Major Other Investor: 

7.4.1. as soon as practicable, but in any event within ninety (90) days after the end of each fiscal year of the Company
(i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and (iii) a statement of stockholders’ equity as of the end of such year, all such financial statements audited and
certified by independent public accountants of nationally or regionally recognized standing selected by the Company; 

  
 26 

 7.4.2. as soon as practicable, but in any event within forty five
(45) days after the end of each of the first three (3) quarters of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of stockholders’
equity as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required
in accordance with GAAP); and 
 7.4.3. upon reasonable request by any Major Other Investor, a statement showing the number
of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period, the Common Stock issuable upon conversion or exercise of any outstanding securities
convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as
to permit the Major Other Investors to calculate their respective percentage equity ownership in the Company; 
 7.4.4. such
other information relating to the financial condition, tax status or corporate affairs of the Company as any Major Other Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated
under this subsection to provide information the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

For purposes of this Section 7.4, if, for any reporting period, the Company has any subsidiary whose accounts are consolidated with those of the
Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. Notwithstanding
anything to the contrary in this Section 7.4, unless otherwise requested by a Majority of the Minority Holders, the Company may satisfy all of its obligations under this Section 7.4 by promptly making available to each Major
Other Investor the information received by the Company under Section 12.6 of the Cure TopCo LLCA. 
 7.5. Covenant Expiration.
The covenants set forth in Section 7.1 shall expire upon the earlier of (a) the NMC Release Date and (b) immediately prior to the effectiveness of the Company’s registration statement in connection with an Initial Public
Offering (but subject to the consummation of such Initial Public Offering). The covenants set forth in Sections 7.2 through and including 7.4 shall expire upon the earlier of (i) the Other Investor Release Date and
(ii) immediately prior to the effectiveness of the Company’s registration statement in connection with an Initial Public Offering (but subject to the consummation of such Initial Public Offering). 

  
 27 

 8. COVENANTS 

8.1. Directors’ and Officers’ Insurance. As of the Effective Date, the Company has, and following the Effective Date shall
continue to maintain for such periods as the Board in good faith determines, at its expense, insurance in an amount determined in good faith by the Board to be appropriate, on behalf of any person who after the Effective Date is or was a director or
officer of the Company, or was a director or officer of Remedy Opco prior to the Effective Date, or is or was serving at the request of the Company, or, prior to the Effective Date, Remedy Opco, as a director, officer, employee or agent of another
corporation, partnership, joint venture, trust or other enterprise, including any direct or indirect subsidiary of the Company, against any expense, liability or loss asserted against such Person and incurred by such Person in any such capacity, or
arising out of such Person’s status as such, subject to customary exclusions. The Company hereby acknowledges that any director, officer or other indemnified person covered by any such indemnity insurance policy (any such Person, a
“Covered Indemnitee”) may have certain rights to indemnification, advancement of expenses and/or insurance provided by any of the Lead Investors and certain of their respective Affiliates (collectively, the “Fund
Indemnitors”). The Company hereby agrees (a) that the Company shall be the indemnitor of first resort (i.e., its obligations to a Covered Indemnitee shall be primary and any obligation of any Fund Indemnitor to advance expenses
or to provide indemnification for the same expenses or liabilities incurred by Covered Indemnitee shall be secondary) and (b) the Company irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the
Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of a Covered Indemnitee with respect to any claim for
which such Covered Indemnitee has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights
of recovery of such Covered Indemnitee against the Company. The provisions of this Section 8.1 will survive any termination of this Agreement. Any Fund Indemnitor not a party to this Agreement is an express third party beneficiary of
this Section 8.1, and is entitled to enforce this Section 8.1 according to its terms to the same extent as if such Fund Indemnitor were a party hereto. 

8.2. Confidentiality. Each Stockholder (other than the Lead Investors) agrees that it will keep confidential and will not disclose,
divulge or use for any purpose, other than to monitor its investment in the Company and its subsidiaries, any confidential information obtained from the Company, unless such confidential information (a) is known or becomes known to the public
in general (other than as a result of a breach of this Section 8.2 by such Stockholder or its Affiliates), (b) is or has been independently developed or conceived by such Stockholder without use of the Company’s confidential
information or (c) is or has been made known or disclosed to such Stockholder by a third party (other than an Affiliate of such Stockholder) without a breach of any obligation of confidentiality such third party may have; provided,
however, that a Stockholder may disclose confidential information (u) in the course of such Stockholder’s duties as an employee, director or officer of the Company or its subsidiaries, (v) to its attorneys, accountants,
consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company, (w) to any prospective purchaser of any Shares from such Stockholder in any Transfer permitted
under this Agreement as long as such prospective purchaser agrees prior to such disclosure to be bound by a confidentiality 

  
 28 

 
agreement no less favorable to the Company than the provisions of this Section 8.2, (x) to any Affiliate, partner, member or related investment fund of such Stockholder and their
respective directors, employees and consultants, in each case in the ordinary course of business, (y) as may be reasonably determined by such Stockholder to be necessary in connection with such Stockholder’s enforcement of its rights in
connection with this Agreement or its investment in the Company and its subsidiaries or (z) as may otherwise be required by law or legal, judicial or regulatory process or requested by any regulatory or self-regulatory authority or examiner;
provided, that such Stockholder notifies the Company of any required disclosure described in this clause (z); provided, further, however, that the acts and omissions of any Person to whom such Stockholder may disclose
confidential information pursuant to clauses (v) through (x) of the preceding proviso will be attributable to such Stockholder for purposes of determining such Stockholder’s compliance with this Section 8.2. Each party
hereto acknowledges that the Stockholders or any of their Affiliates and, as applicable, related investment funds may review the business plans and related proprietary information of many enterprises, including enterprises which may have products or
services which compete directly or indirectly with those of the Company and its subsidiaries, and may trade in the securities of such enterprises. Subject to Section 8.4, nothing in this Section 8.2 will preclude or in any
way restrict the Stockholders or their Affiliates or related investment funds from investing or participating in any particular enterprise, or trading in the securities thereof, whether or not such enterprise has products or services that compete
with those of the Company and its subsidiaries. 
 8.3. Other Business Opportunities. Each Stockholder hereby acknowledges and agrees
to the terms set forth in Article Twelfth of the Certificate of Incorporation. 
 8.4. Stockholder Covenants. 

8.4.1. Each Stockholder that at any time holds more than 20,000 shares of Common Stock (including Common Stock issued or
issuable on the conversion of the Senior Convertible Preferred Stock) hereby severally and not jointly agrees that it will not, and it will not permit, cause or encourage any of its Affiliates to, directly or indirectly (i) solicit or hire for
employment, or induce or attempt to persuade to terminate or significantly reduce his or her employment relationship with the Company, any of the Restricted Employees (as defined below) or (ii) introduce or assist or otherwise facilitate the
introduction of any Restricted Employees to or by any Portfolio Company for purposes of soliciting such person for employment or hire or inducing or attempting to persuade such person to terminate or significantly reduce his or her employment or
consulting relationship with the Company, unless such Stockholder receives the approval of the Board to such solicitation or hiring; provided, that any solicitation, engagement or hiring of a Restricted Employee by a Portfolio Company shall
not be deemed a violation of this Section 8.4.1 so long as subsection (ii) of this Section 8.4.1 shall not have been violated with respect to such Restricted Employee. Notwithstanding the foregoing, nothing in this
Section 8.4.1 shall prohibit (x) any general advertisement or general solicitation that does not specifically target the Restricted Employees, so long as such advertisement or solicitation does not result in a Stockholder or
Affiliate of any Stockholder hiring a Restricted Employee or (y) the solicitation and/or hiring of any individual who is no longer and who has not been employed by the Company for nine (9)

  
 29 

 
months prior to the time of such solicitation or hiring. For purposes of this Section 8.4.1, the term “Restricted Employees” means and includes (a) the executive
officers and senior employees of Remedy Opco and its subsidiaries listed on Schedule III attached hereto and (b) thereafter from time to time, such other persons as may be hired, appointed or designated as an executive officer or senior
employee of Remedy Opco and its subsidiaries; provided, that no such Person shall be deemed a Restricted Employee hereunder until such time as the Company (as approved by the Board) shall have amended Schedule III to include such
Person and shall have delivered such updated Schedule III to the Stockholders pursuant to Section 15.2 below. 

8.4.2. Each Stockholder specifically listed on Schedule IV attached hereto severally, and not jointly, agrees that he,
she or it will not, and it will not authorize, cause or encourage any other Person to, engage, directly or indirectly, whether as owner, operator, shareholder, manager, consultant, strategic partner or employee or otherwise, in any business that
provides or manages bundled payment programs for managed care, the government and non-governmental payers, patients and healthcare providers competitive with Remedy Opco and/or its subsidiaries (a “Competing Business”), unless such
Stockholder receives the prior approval of the Board to such activity; provided, that nothing in this Section 8.4.2 shall preclude such Stockholder or Affiliate from owning up to five percent (5%) of any Person engaged in a
Competing Business if (i) such Competing Business is publicly traded and (ii) such Stockholder does not control or have the power to direct the operation or management of such Competing Business. It is the desire and intent of the parties
hereto that the provisions of this Section 8.4.2 shall be enforced to the fullest extent permitted under the laws and public policies of each jurisdiction in which enforcement is sought. If any court determines that any provision of this
Section 8.4.2 is unenforceable, such court will have the power to reduce the duration or scope of such provision, as the case may be, or terminate such provision and, in reduced form, such provision shall be enforceable. It is the
intention of the parties hereto that the foregoing restrictions shall not be terminated, unless so terminated by a court, but shall be deemed amended to the extent required to render them valid and enforceable, such amendment to apply only with
respect to the operation of this Section 8.4.2 in the jurisdiction of the court that has made the adjudication. The restrictions set forth in this Section 8.4.2 shall survive with respect to each Stockholder who is not a Lead
Investor for so long as such Stockholder holds any Equivalent Shares. 
 8.4.3. If the final judgment of a court of competent
jurisdiction declares that any term or provision of this Section 8.4 is invalid, unenforceable or overbroad, each of the parties hereto agree that the court making such determination shall have the power to reduce the scope, duration, or
area of the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid, enforceable and reasonable and that comes closest to expressing the intention of
the invalid or unenforceable term or provision. Each Stockholder recognizes and agrees that immediate irreparable damages for which there is not adequate remedy at law would occur in the event that the provisions of this Section 8.4 are
not performed in accordance with the specific terms hereof or are otherwise breached. It is 

  
 30 

 
accordingly agreed that in the event of a failure by the Stockholder or their Affiliates to perform their respective obligations under this Section 8.4, the Company shall be entitled
to seek specific performance through injunctive relief, without the necessity of posting a bond, to prevent breaches of and to enforce specifically the provisions of this Section 8.4 in addition to any other remedy to which Company may
be entitled, at law or in equity. Nothing in this Section 8.4 shall be deemed to limit the obligations of any Person under any other agreement to which such Person is party. 

8.5. Other Limitations. Notwithstanding anything to the contrary in this Agreement, the Company shall not (and the Lead Investor shall
not permit the Company to), without the prior written consent of each of BCV (on behalf of the Bain Group), the Remedy Founders (on behalf of the Remedy Founders Group), and LHP Holding (on behalf of the LHP Holding Group), take any action that
would result, solely as a result of such action (including, but not limited to, by reason of such action resulting in (x) direct or indirect ownership by any Stockholder of any equity or other assets or (y) a Stockholder becoming
responsible for any liability in connection with such action, but in each case not taking into account any actions by a Stockholder other than actions connected with actions of the Company (such as, for example, accepting a dividend paid by the
Company)), in the realization of (or the material risk of realization of) any (1) “effectively connected income” within the meaning of Sections 864 or 897 of the Code, (2) “unrelated business taxable income” within the
meaning of Sections 512 or 514 of the Code, or income derived from the conduct of any commercial activity within the meaning of Section 892 of the Code to any of the Other Investors or any of their direct or indirect owners; provided, however
that this Section 8.5 does not limit actions that result in the realization of (or the material risk of the realization of) the items listed in clauses (1) or (2) solely to the extent such result (or risk) derives from any right to
receive proceeds or amounts (or the actual receipt of proceeds or amounts) pursuant to (A) a “tax receivable agreement” or similar agreement entered into in connection with an initial public offering or (B) a sale or other exit
transaction, in each case where all or a portion of such proceeds or other amounts may be directly or indirectly calculated on a substantially equivalent basis for both equity holders in the Company and other direct and indirect equity holders in
one or more entities engaged in a trade or business, which calculation may include adjustments for assets and liabilities of such other entities, including tax attributes. 

9. REMEDIES. 
 9.1. Generally. The rights
and remedies under this Agreement are cumulative and the Company and each Stockholder will have all remedies available at law, in equity or otherwise in the event of any breach or violation of this Agreement or any default hereunder by the Company
or any Stockholder. The parties acknowledge that breach or threatened breach by a party of any of its obligations under this Agreement would give rise to irreparable harm to the other parties, for which monetary damages would not be an adequate
remedy, and hereby agree that, in addition to any other remedies that may be available, each of the parties hereto will be entitled to specific performance of the obligations of the other parties hereto and, in addition, to such other equitable
remedies (including preliminary or temporary relief) as may be appropriate in the circumstances, without posting a bond or other undertaking. 

  
 31 

 9.2. Deposit. Without limiting the generality of Section 9.1, if any
Stockholder, as applicable, fails to deliver to the purchaser thereof the certificate or certificates evidencing Shares to be Sold (or an affidavit of loss and indemnity agreement in form reasonably satisfactory to the Company in the case of a lost
certificate), if any, or transfer documentation required to be provided pursuant to Section 4 hereof, as applicable, such purchaser may, at its option, in addition to all other remedies it may have, deposit the purchase price (including
any promissory note constituting all or any portion thereof) for such Shares with any national bank or trust company having combined capital, surplus and undivided profits in excess of One Hundred Million Dollars ($100,000,000) (the “Escrow
Agent”) and the Company will cancel on its books the certificate or certificates representing such Shares, if any, and thereupon all of such holder’s rights in and to such Shares will terminate. Thereafter, upon delivery to such
purchaser by such holder of the certificate or certificates (or an affidavit of loss and indemnity agreement in form reasonably satisfactory to the Company in the case of a lost certificate) evidencing such Shares or other required transfer
documentation for such Shares (in each case, duly endorsed, or with stock powers duly endorsed, for transfer, with signature guaranteed, free and clear of any liens or encumbrances, and with any transfer tax stamps affixed), such purchaser will
instruct the Escrow Agent to deliver the purchase price (without any interest) to such holder. Each Stockholder hereby constitutes and appoints each Lead Investor, or any of them, with full power of substitution, as such Stockholder’s true and
lawful representative and attorney-in-fact, in such Stockholder’s name, place and stead, to execute and deliver any escrow agreement in reasonable and customary form entered into with respect to such Stockholder in accordance with this
Section 9.2, and such Lead Investor will provide a copy of such agreement to such Stockholder within five (5) business days of execution; provided, however, that failure to deliver such documents within such time
period will not impair or affect the validity of such agreements. The foregoing power of attorney is coupled with an interest and will, to the maximum extent permitted by applicable law, continue in full force and effect notwithstanding the
subsequent death, incapacity, bankruptcy or dissolution of any Stockholder. 
 10. LEGENDS. 

10.1. Restrictive Legend. Each certificate representing Shares will have the following legend endorsed conspicuously thereupon: 

THE VOTING OF THE SHARES OF STOCK REPRESENTED BY THIS CERTIFICATE, AND THE SALE, ENCUMBRANCE OR OTHER DISPOSITION THEREOF, ARE SUBJECT TO
THE PROVISIONS OF A STOCKHOLDERS’ AGREEMENT TO WHICH THE ISSUER AND CERTAIN OF ITS STOCKHOLDERS ARE PARTY, A COPY OF WHICH MAY BE INSPECTED AT THE PRINCIPAL OFFICE OF THE ISSUER OR OBTAINED FROM THE ISSUER WITHOUT CHARGE. 

  
 32 

 Each certificate representing Lead Investor Shares will also have the following legend
endorsed conspicuously thereupon: 
 The shares of stock represented by this certificate were originally issued to, or issued with respect
to shares originally issued to, the following Lead Investor:             . 

Each certificate representing Other Investor Shares will also have the following legend endorsed conspicuously thereupon: 

The shares of stock represented by this certificate were originally issued to, or issued with respect to shares originally issued to, the
following Other Investor:             . 
 Each certificate
representing Management Shares will also have the following legend endorsed conspicuously thereupon: 
 The shares of stock represented by
this certificate were originally issued to, or issued with respect to shares originally issued to, the following Manager:             . 

Any Person who acquires Shares that are not subject to all or part of the terms of this Agreement has the right to have such legend (or the
applicable portion thereof) removed from certificates representing such Shares. 
 10.2. 1933 Act Legends. Each certificate
representing Shares will have the following legend endorsed conspicuously thereupon: 
 THE SECURITIES REPRESENTED BY THIS CERTIFICATE
WERE ISSUED IN A PRIVATE PLACEMENT, WITHOUT REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), AND MAY NOT BE SOLD, ASSIGNED, PLEDGED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION UNDER THE
ACT COVERING THE TRANSFER OR AN OPINION OF COUNSEL, SATISFACTORY TO THE ISSUER, THAT REGISTRATION UNDER THE ACT IS NOT REQUIRED. 
 10.3.
Stop Transfer Instruction. The Company will instruct any transfer agent not to register the Transfer of any Shares until the conditions specified in the foregoing legends are satisfied. 

10.4. Termination of 1933 Act Legend. The requirement imposed by Section 10.2 hereof will cease and terminate as to any
particular Shares (a) when, in the reasonable opinion of Ropes & Gray LLP, or other counsel reasonably acceptable to the Company, such legend is no longer required in order to assure compliance by the Company with the Securities Act or
(b) when such Shares have been effectively registered under the Securities Act or transferred pursuant to Rule 144. Wherever (x) such requirement ceases and terminates as to any Shares or (y) such Shares are transferable under
paragraph (b)(1) of Rule 144, the holder of such Shares will be entitled to receive from the Company, without expense, new certificates not bearing the legend set forth in Section 10.2 of this Agreement. 

  
 33 

 11. AMENDMENT, TERMINATION, ETC. 

11.1. Oral Modifications. This Agreement may not be orally amended, modified, extended or terminated, nor will any oral waiver of any of
its terms be effective. 
 11.2. Written Modifications. Subject to Section 7.2, this Agreement may be amended, modified,
extended or terminated, and the provisions hereof may be waived, only by an agreement in writing signed by the Majority Lead Investors; provided, however, that (a) the consent of the Majority Other Investors will be required for
any amendment, modification, extension, termination or waiver which has a materially adverse and disproportionate effect on the rights of the holders of Other Investor Shares relative to the Lead Investors under this Agreement, (b) the consent
of the Majority Other Investors will be required for any amendment, modification, extension, termination or waiver which has an adverse effect on the specific rights of the holders of Other Investor Shares under this Agreement or provides any Lead
Investor (or any Affiliate of any Lead Investor) with any additional or different rights specific to such Lead Investor or Affiliate thereof which are not otherwise granted to the Other Investors (whether as a result of the identification of such
Lead Investor or Affiliate or the creation of any test, standard or other qualifying fact or circumstance that applies uniquely to such Lead Investor or Affiliate), (c) the consent of the Majority Managers will be required for any amendment,
modification, extension, termination or waiver which has a materially adverse and disproportionate effect on the rights of the holders of Management Shares relative to other Stockholders under this Agreement, and (d) the consent of the Majority
Other Investors will be required for any amendment, modification, waiver, extension or termination of Section 3 that is adverse in any respect to the Other Investors. Each such amendment, modification, extension, termination and waiver
will be binding upon each party hereto and each holder of Shares subject hereto. In addition, each party hereto and each holder of Shares subject hereto may waive any right hereunder by an instrument in writing signed by such party or holder.
Notwithstanding the foregoing, the amendment, modification, extension, termination or waiver of Section 6.1 or Section 8.5 of this Agreement shall not be permitted without the consent of each of BCV (on behalf of the Bain
Group), the Remedy Founders (on behalf of the Remedy Founders Group), and LHP Holding (on behalf of the LHP Holding Group). Subject to the foregoing sentence (and all additional approvals required thereunder, where applicable), but notwithstanding
anything else to the contrary in this Section 11.2, after the Effective Date, this Agreement may be amended, modified, extended or terminated, and the provisions hereof may be waived, only by an agreement in writing signed by the
Majority Lead Investors and a Majority of the Minority Holders. 
 11.3. Effect of Termination. No expiration or termination of this
Agreement or any part hereof will relieve any Person of liability for a breach at or prior to such expiration or termination. 

  
 34 

 12. DEFINITIONS. For purposes of this Agreement: 

12.1. Certain Matters of Construction. In addition to the definitions referred to or set forth below in this Section 12:

 (a) The words “hereof”, “herein”, “hereunder” and words of similar import refer to this
Agreement as a whole and not to any particular Section or provision of this Agreement, and references to a particular Section of this Agreement include all subsections thereof; 

(b) The word “including” means including, without limitation; 

(c) Definitions are equally applicable to both nouns and verbs and the singular and plural forms of the terms defined; 

(d) References to a particular statute or regulation include all rules and regulations thereunder and any successor statute,
regulations or rules, in each case as from time to time in effect; 
 (e) References to “Dollars” and
“$” mean United States Dollars; 
 (f) Terms defined in the singular will have comparable meanings when used in
the plural and vice versa; and 
 (g) The masculine, feminine and neuter genders shall each be deemed to include the other.

 (h) The parties have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or
question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the
provisions of this Agreement. 
 12.2. Definitions. The following terms shall have the following meanings: 

“Act” has the meaning set forth in Section 10.2. 

“Adverse Claim” has the meaning set forth in Section 8-102 of the applicable
Uniform Commercial Code. 
 “Affiliate” means, with respect to any specified Person, (a) any other Person which
directly or indirectly through one or more intermediaries controls, or is controlled by, or is under common control with, such specified Person (for the purposes of this definition, “control” (including, with correlative meanings, the
terms “controlling,” “controlled by” and “under common control with”), as used with respect to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of the management or
policies of such Person, whether through the ownership of voting securities, by agreement or otherwise) and (b) with respect to any natural person, any Member of the Immediate Family of such natural person. 

  
 35 

 “Affiliated Fund” means each corporation, trust, limited liability company,
general or limited partnership or other entity under common control with any Lead Investor. 
 “Agreement” has the meaning
set forth in the Preamble. 
 “Approved Cure TopCo Sale” means any transaction that constitutes an “Approved Company
Sale” under the Cure TopCo LLCA. 
 “Award Agreement” means a written agreement, contract, certificate or other
instrument or document evidencing the terms and conditions of any individual grant of Options under the Stock Option Plan. 
 “Bain
Group” means BCV and each of its Affiliates who holds Common Stock (or any class or series thereof) as of the Effective Date, together with its and their respective Permitted Transferees who become party hereto after the Effective Date.

 “BCV” means Bain Capital Venture Fund 2014, L.P. 

“Board” has the meaning set forth in Section 2.1. 

“business day” means any day that is not a Saturday, a Sunday or other day on which banks are required or authorized by law
to be closed in the City of New York. 
 “Bylaws” means the bylaws of the Company as adopted by the Board. 

“Certificate of Incorporation” means the Amended and Restated Certificate of Incorporation of the Company, filed on
November 26, 2019 with the Secretary of State of the State of Delaware, as amended, modified, supplemented or restated from time to time. 

“Change of Control” means the first to occur of any (i) any Transfer to any third party of the Company’s equity
interests by the holders thereof as a result of which any Person or group other than the Lead Investors or their Affiliates obtains possession, directly or indirectly, of a majority of the Equivalent Shares outstanding immediately prior to the
subject Transfer, (ii) any sale or Transfer by the Company or its subsidiaries of all or substantially all (as defined under the Delaware General Corporation Law) of their assets on a consolidated basis to a Person or group other than the Lead
Investors or their Affiliates, or (iii) any consolidation, merger or reorganization of the Company with or into any other entity or entities as a result of which any Person or group other than the Lead Investors or their Affiliates obtains
possession, directly or indirectly, of a majority of the Equivalent Shares outstanding immediately prior to the subject Transfer. 

  
 36 

 “Class A Common Stock” means the Class A Common Stock, par value
$0.001 per share, of the Company having the rights, preferences, and other terms set forth in the Certificate of Incorporation (and any shares of capital stock of the Company issued or issuable with respect to such Class A Common Stock by way
of a stock dividend or distribution payable thereon or stock split, reverse stock split, recapitalization, reclassification, reorganization, exchange, subdivision or combination thereof). 

“Class B Common Stock” means the Class B Common Stock, par value $0.001 per share, of the Company having the rights,
preferences, and other terms set forth in the Certificate of Incorporation (and any shares of capital stock of the Company issued or issuable with respect to such Class B Common Stock by way of a stock dividend or distribution payable thereon or
stock split, reverse stock split, recapitalization, reclassification, reorganization, exchange, subdivision or combination thereof). 

“Class C Common Stock” means the Class C Common Stock, par value $0.001 per share, of the Company having the rights,
preferences, and other terms set forth in the Certificate of Incorporation (and any shares of capital stock of the Company issued or issuable with respect to such Class C Common Stock by way of a stock dividend or distribution payable thereon or
stock split, reverse stock split, recapitalization, reclassification, reorganization, exchange, subdivision or combination thereof). 

“Class D Common Stock” means the Class D Common Stock, par value $0.001 per share, of the Company having the rights,
preferences, and other terms set forth in the Certificate of Incorporation (and any shares of capital stock of the Company issued or issuable with respect to such Class D Common Stock by way of a stock dividend or distribution payable thereon or
stock split, reverse stock split, recapitalization, reclassification, reorganization, exchange, subdivision or combination thereof). 

“Code” means the United States Internal Revenue Code of 1986. 

“Combination Agreement” has the meaning set forth in the Recitals. 

“Commission” means the Securities and Exchange Commission. 

“Common Stock” means the Class A Common Stock, the Class B Common Stock, the Class C Common Stock and/or the Class D
Common Stock, as applicable. 
 “Company” has the meaning set forth in the Preamble. 

“Company Registration Rights Agreement” means the Registration Rights Agreement of the Company, dated as of the
January 15, 2019, among the Company and the Lead Investors and the other parties thereto. 
 “Convertible Securities”
means any evidence of indebtedness, shares of stock (other than Common Stock) or other securities (other than Options and Warrants) which are directly or indirectly convertible into or exchangeable or exercisable for shares of Common Stock. 

  
 37 

 “Cost” means, for any security, the price paid to the issuer for such
security; provided, that (a) the “Cost” for any Other Investor Shares (or other securities that were received in exchange for or in respect of other securities) shall be $3.01 and (b) the “Cost” for any Shares
issued upon exercise of an Option shall be the exercise price for such Shares. 
 “Counterpart Signature Page” has the
meaning set forth in the Recitals. 
 “Covered Action” has the meaning set forth in Section 14.1. 

“Covered Indemnitee” has the meaning set forth in Section 9.1. 

“Cure TopCo” has the meaning set forth in the Recitals. 

“Cure TopCo LLCA” means the certain Second Amended and Restated Limited Liability Company Agreement of Cure TopCo, dated as
of the Effective Date, as amended, modified or supplemented from time to time. 
 “Cure TopCo Registration Rights
Agreement” means the Registration Rights Agreement of the Cure TopCo, to be dated on or about the date hereof, among the Cure TopCo and the other parties thereto. 

“Director” means a member of the Board. 

“Disproportionate Adverse Tax Consequence” has the meaning set forth in Section 6.1. 

“Drag Along Notice” has the meaning set forth in Section 4.2.1. 

“Drag Along Participating Seller” has the meaning set forth in Section 4.2.1. 

“Drag Along Sale Percentage” has the meaning set forth in Section 4.2. 

“Drag Along Sellers” has the meaning set forth in Section 4.2.1. 

“Drag Along Transaction” has the meaning set forth in Section 4.2. 

“Equivalent Shares” means, at any date of determination, (a) as to any outstanding shares of Senior Convertible
Preferred Stock, the maximum number of shares of Common Stock into which such shares of Senior Convertible Preferred Stock may at the date of determination be converted in accordance with the Certificate of Incorporation, (b) as to any
outstanding shares of Common Stock, such number of shares of Common Stock and (c) as to any outstanding Options, Warrants or Convertible Securities which constitute Shares, the maximum number of shares of Common Stock for which or into which
such Options, Warrants or Convertible Securities may at the date of determination be exercised, converted or exchanged (or which will become exercisable, convertible or exchangeable on or prior to, or by reason of, the transaction or circumstance in
connection with which the number of Equivalent Shares is to be determined) but excluding any shares of restricted stock that are not then vested or will not become vested on or prior to, or by reason of, the transaction or circumstance in connection
with which the number of Equivalent Shares is to be determined. 

  
 38 

 “Escrow Agent” has the meaning set forth in Section 9.2. 

“Exchange Act” means the Securities Exchange Act of 1934, as in effect from time to time. 

“Fund Indemnitor” has the meaning set forth in Section 8.1. 

“Initial Public Offering” means the initial public offering and sale of Common Stock of the Company for cash pursuant to an
effective registration statement under the Securities Act on Form S-1 (or any successor form under the Securities Act). 

“JIA” means that certain letter agreement, entitled “Joint Investment Agreement” and dated as of the Effective
Date, by and among the Company, the Lead Investor, Remedy Founders, LHP Holding, BCV and certain other parties. 

“Issuance” has the meaning set forth in Section 5. 

“Lead Investor Director” has the meaning set forth in Section 2.2. 

“Lead Investors” has the meaning set forth in the Preamble. 

“Lead Investor Shares” means (a) all shares of Senior Convertible Preferred Stock originally issued to, or issued with
respect to shares originally issued to, or held by, a Lead Investor, whenever issued, (b) all shares of Common Stock originally issued to, or issued with respect to shares originally issued to, or held by, a Lead Investor, whenever issued,
including all shares of Common Stock issued upon the exercise, conversion or exchange of any Options, Warrants or Convertible Securities and (c) all Options, Warrants and Convertible Securities originally granted or issued to a Lead Investor
(treating such Options, Warrants and Convertible Securities as a number of Shares equal to the number of Equivalent Shares represented by such Options, Warrants and Convertible Securities for all purposes of this Agreement except as otherwise
specifically set forth herein). 
 “LHP Holding” means LHP Holding LLC, a Delaware limited liability company. 

“LHP Holding Group” means LHP Holding, together with its Permitted Transferees who become party hereto after the Effective
Date. 
 “Major Investor” means each Lead Investor and each Major Other Investor. 

“Major Other Investor” means (a) each of the Remedy Founders Group, the LHP Holding Group, the Bain Group and the Spring
Lake Group for so long as such Person holds the lesser of (i) at least thirty three and one-third percent (33 1/3%) of the
Equivalent Shares held by them as of the Effective Date and (ii) two percent (2%) of the issued and outstanding shares of Common Stock of the Company calculated on a fully-diluted basis and treating for such purpose all shares of issued
and outstanding Senior Convertible Preferred Stock on an as-converted to Common Stock basis as of the applicable date of determination, and (b) each Other Investor Group, for so long as such Person holds the lesser of (x) at least
thirty three and one-third percent (33 1/3%) of 

  
 39 

 
the Equivalent Shares held by such Other Investor as of the Effective Date or, if such Other Investor Group does not own any Equivalent Shares as of the Effective Date, such subsequent date on
which such Other Investor Group first directly holds Equivalent Shares, and (y) two percent (2%) of the issued and outstanding shares of Common Stock of the Company calculated on a fully-diluted basis and treating for such purpose all
shares of issued and outstanding Senior Convertible Preferred Stock on an as-converted to Common Stock basis as of the applicable date of determination. 

“Majority Lead Investors” means, as of any date, the holders of a majority of the Lead Investor Shares outstanding on such
date. 
 “Majority Managers” means, as of any date, the holders of a majority of the Management Shares outstanding on such
date. 
 “Majority of the Minority Holders” means, (A) at any time that the Minority Key Holders and their Affiliates
own a majority of the Shares then owned by all MRH Persons: (x) for so long as Remedy Founders, LHP Holding and BCV are each Minority Key Holders, at least two (2) of such Persons and (y) following the time when any of Remedy
Founders, LHP Holding or BCV ceases to be a Minority Key Holder, the Minority Key Holders holding a majority of the Shares held by all Minority Key Holders as of time applicable time, and (B) at any other time, the MRH Persons holding a
majority of the Shares then owned by all MRH Persons. 
 “Majority Other Investors” means (a) prior to the date upon
which any of the Remedy Founders Group, the LHP Holding Group or the Bain Group cease to beneficially own in the aggregate at least thirty three and one-third percent (33 1/3%) of the Equivalent Shares owned by them on the Effective Date, (i) Remedy Founders (on behalf of the Remedy Founder Group) and (ii) either (x) LHP Holding (on behalf of the
LHP Holding Group) or (y) BCV (on behalf of the Bain Group); and (b) following the date on which any of the Remedy Founders Group, the LHP Holding Group or the Bain Group cease to beneficially own in the aggregate at least thirty
three and one-third percent (33 1/3%) of the Equivalent Shares owned by them on the Effective Date, the holders of at least sixty percent
(60%) of the shares of Common Stock outstanding as of the applicable date of determination (excluding for this purpose any shares of Common Stock that have been issued (or are issuable) upon the conversion of Senior Convertible Preferred Stock
and further excluding any Common Stock acquired by the Lead Investors from any Other Investor). 
 “Management Shares”
means (a) all shares of Senior Convertible Preferred Stock originally issued to, or issued with respect to shares originally issued to, or held by, a Manager, whenever issued, (b) all shares of Common Stock (excluding any Other Investor
Shares) originally issued to, or issued with respect to shares originally issued to, or held by, a Manager, whenever issued, including all shares of Common Stock issued upon the exercise, conversion or exchange of any Options, Warrants or
Convertible Securities, (c) all vested Options, Warrants and Convertible Securities originally granted or issued to a Manager (treating such Options, Warrants and Convertible Securities as a number of Shares equal to the number of Equivalent
Shares represented by such Options, Warrants and Convertible Securities for all purposes of this Agreement except that such Options and Convertible Securities shall not constitute Shares (i) for purposes of Section 5 and
(ii) as otherwise specifically set forth herein) and (d) all unvested Options originally granted or issued to a Manager (treating such unvested Options as a number of Shares equal to the number of Equivalent Shares represented by such
unvested Options for all purposes of this Agreement except that such unvested Options shall not constitute Shares (I) for purposes of Sections 4.1 and 5, and (II) as otherwise specifically set forth herein). 

  
 40 

 “Managers” has the meaning set forth in the Preamble. 

“Members of the Immediate Family” means, with respect to any individual, each parent, sibling, spouse or child or other
descendants or ancestors of such individual (including by adoption), each trust created solely for the benefit of one or more of the aforementioned Persons and their spouses and each custodian or guardian of any property of one or more of the
aforementioned Persons in his or her capacity as such custodian or guardian. 
 “Minority Holders” means, at any given
time, all stockholders of New Remedy Corp as of such time other than (a) stockholders that are not a Lead Investor or an Affiliate of a Lead Investor and (b) any Person that was not a stockholder of New Remedy Corp on the Effective Date
that at the given time holds shares of capital stock of New Remedy Corp that were previously held by any NM Person. 
 “Minority Key
Holders” means each of Remedy Founders, LHP and BCV (or its designee), in each case as long as it or any of its Affiliates holds any Shares. 

“MRH Persons” means, at any given time, (a) all Minority Holders and (b) all Affiliates of any then current or
former Minority Holder who have acquired equity securities of Cure TopCo after the Effective Date directly or indirectly; and “MRH Person” means any of the foregoing. 

“NMC Release Date” means the date upon which the Lead Investors cease to beneficially own in the aggregate at least thirty
three and one-third percent (33 1/3%) of the Equivalent Shares owned by the Lead Investors on the Effective Date. 

“Options” means any options to subscribe for, purchase or otherwise directly acquire Common Stock. 

“Other Investor Director” has the meaning set forth in Section 2.2. 

“Other Investor Drag Along Transaction” has the meaning set forth in Section 4.3. 

“Other Investor Drag Along Notice” has the meaning set forth in Section 4.3.1. 

“Other Investor Drag Along Participating Seller” has the meaning set forth in Section 4.3.1. 

“Other Investor Drag Along Sellers” has the meaning set forth in Section 4.3.1. 

  
 41 

 “Other Investor Group” means, with respect to each Other Investor, such
Other Investor and each of its Affiliates who holds Common Stock (or any class or series thereof) as of the Effective Date or, if such Other Investor Group does not own any Equivalent Shares as of the Effective Date, such subsequent date on which
the subject Other Investor first directly holds Equivalent Shares, together with its and their respective Permitted Transferees who become party hereto after the Effective Date. 

“Other Investor Release Date” means the date upon which the Remedy Founders Group, the LHP Holding Group and the Bain Group
cease to beneficially own in the aggregate at least thirty three and one-third percent (33 1/3%) of the Equivalent Shares owned by them (in
the aggregate) on the Effective Date. 
 “Other Investor Shares” means (a) all shares of Senior Convertible Preferred
Stock originally issued to, or issued with respect to shares originally issued to, or held by, an Other Investor, whenever issued, (b) all shares of Common Stock (excluding any Management Shares) originally issued to, or issued with respect to
shares originally issued to, or held by, an Other Investor, whenever issued, including all shares of Common Stock issued upon the exercise, conversion or exchange of any Options or Convertible Securities and (c) all Options and Convertible
Securities originally granted or issued to an Other Investor (treating such Options and Convertible Securities as a number of Shares equal to the number of Equivalent Shares represented by such Options and Convertible Securities for all purposes of
this Agreement except as otherwise specifically set forth herein). 
 “Other Investors” has the meaning set forth in the
Preamble. 
 “Participating Buyer” has the meaning set forth in Section 5.1.2.1. 

“Participating Seller” means a Tag Along Participating Seller, a Drag Along Participating Seller or an Other Investor Drag
Along Participating Seller, as applicable. 
 “Participation Notice” has the meaning set forth in
Section 5.1.1. 
 “Participation Offerees” has the meaning set forth in Section 5.1.1. 

“Participation Portion” has the meaning set forth in Section 5.1.1. 

“Permitted Transferee” has the meaning set forth in Section 3.1. 

“Person” means any individual, partnership, corporation, company, association, trust, joint venture, limited liability
company, unincorporated organization, entity or division, or any government, governmental department or agency or political subdivision thereof. 

“Portfolio Company” means any operating entity in which a Stockholder or any of its Affiliates has any direct or indirect
convertible debt or equity investment and any such operating entity’s direct or indirect subsidiaries. 
 “Predecessor
Stockholders’ Agreement” has the meaning set forth in the Recitals. 

  
 42 

 “Price Per Equivalent Share” means the Board’s good faith
determination of the price per Equivalent Share of any Convertible Securities, Warrants or Options which are the subject of an Issuance pursuant to Section 5 hereof. 

“Prospective Buyer” means (a) any Person (other than an Affiliate of a Prospective Selling Investor or Prospective
Selling Stockholder, as applicable) proposing to purchase shares from such Prospective Selling Investor or Prospective Selling Stockholder, as applicable, and (b) any Lead Investor proposing to purchase shares from one or more Prospective
Selling Minority Holders in an Other Investor Drag Along Transaction. 
 “Prospective Selling Investor” has the meaning set
forth in Section 4.1 and 4.2. 
 “Prospective Selling Minority Holder” has the meaning set forth in
Section 4.3. 
 “Prospective Selling Stockholder” has the meaning set forth in Section 4.2 and
4.3. 
 “Prospective Subscriber” has the meaning set forth in Section 5.1.1. 

“Recap Drag” has the meaning set forth in Section 6.1. 

“Regulation D” means Regulation D under the Securities Act (or any successor provision). 

“Release Date” means the date upon which both the NMC Release Date and the Other Investor Release Date have occurred. 

“Remedy Founders” means Remedy Founders LLC, a Delaware limited liability company. 

“Remedy Founders Group” means Remedy Founders, together with its Permitted Transferees who become party hereto after the
Effective Date. 
 “Remedy Opco” has the meaning set forth in the Recitals. 

“Reorganization” has the meaning set forth in Section 6.1. 

“Rule 144” means Rule 144 under the Securities Act (or any successor provision). 

“Sale” means a Transfer for value; and “Sell” and “Sold” shall each have a correlative
meaning. 
 “Securities Act” means the Securities Act of 1933, as in effect from time to time. 

“Senior Convertible Preferred Stock” means the Senior Convertible Preferred Stock, par value $0.001 per share, of the Company
having the rights, preferences and other terms set forth in the Certificate of Incorporation. 

  
 43 

 “Shares” means all Lead Investor Shares, Other Investor Shares, and
Management Shares. 
 “Spousal Consent” has the meaning set forth in Section 15.8. 

“Spring Lake Group” means Spring Lake Equity Partners, LLC and each of its Affiliates who holds Common Stock as of the
Effective Date, together with its and their respective Permitted Transferees who become party hereto after the Effective Date. 

“Stock Option Plan” means the Remedy Partners, Inc. 2012 Equity Incentive Plan of the Company, as amended, restated or
modified from time to time. 
 “Stockholders” has the meaning set forth in the Preamble. 

“Subject Securities” has the meaning set forth in Section 5. 

“Tag Along Holder” has the meaning set forth in Section 4.1.1. 

“Tag Along Notice” has the meaning set forth in Section 4.1.1. 

“Tag Along Participating Seller” has the meaning set forth in Section 4.1.2. 

“Tag Along Sale Percentage” has the meaning set forth in Section 4.1.1. 

“Tag Along Sellers” has the meaning set forth in Section 4.1.2.”Transaction” has the meaning set
forth in the Recitals. 
 “Transfer” means any sale, pledge, assignment, encumbrance or other transfer or disposition to
any other Person, whether directly, indirectly, voluntarily, involuntarily, by operation of law, pursuant to judicial process or otherwise, and “Transferred”, “Transferee”, “Transferability”, and
“Transferor” shall each have a correlative meaning; provided, in no event shall any Transfer of the equity interests in a Lead Investor be deemed a Transfer for purposes hereof so long as such Lead Investor remains an
Affiliate of New Mountain Partners V, L.P. 
 “Units” means the limited liability company interests of Cure TopCo. 

“Warrants” means any warrants to subscribe for, purchase or otherwise directly acquire Common Stock. 

 

	13.	 MISCELLANEOUS. 

13.1. Authority; Effect. Each party hereto represents and warrants to and agrees with each other party hereto that (a) the
execution and delivery of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized on behalf of such party and do not violate any agreement or other instrument applicable to such party or by which such
party’s assets are bound and (b) this Agreement constitutes a legal, valid and binding obligation of such party, enforceable against such party in accordance with its terms, except to 

  
 44 

 
the extent that the enforcement of the rights and remedies created hereby is subject to (i) bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting
the rights and remedies of creditors generally and (ii) general principles of equity. This Agreement does not, and shall not be construed to, give rise to the creation of a partnership among any of the parties hereto, or to constitute any of
such parties members of a joint venture or other association. 
 13.2. Notices. Any notices and other communications required or
permitted in this Agreement shall be effective if in writing and (a) delivered personally or (b) sent (i) by nationally-known, reputable overnight carrier, (ii) by registered or certified mail, postage prepaid, (iii) by
facsimile; provided, that no notice may be sent by facsimile to the Company or any Lead Investor, or (iv) by attachment to electronic mail in portable document (i.e., .pdf) format, in each case, addressed as follows: 

If to the Company or any Lead Investor: 

c/o New Mountain Capital, L.L.C. 

787 Seventh Avenue, 49th Floor 

New York, NY 10019 
 Attention:
Matthew Holt and Kyle Peterson 
 E-mail:   

with a copy to: 
 Ropes &
Gray LLP 
 1211 Avenue of the Americas 

New York, NY 10036 
 Attention:
John E. Sorkin and Garrett T. Charon 
 Email:      

If to an Other Investor or a Manager, to him at the address set forth in the stock record book of the Company. 

Notice to the holder of record of any shares of capital stock will be deemed to be notice to the holder of such shares for all purposes
hereof. 
 Unless otherwise specified herein, such notices or other communications will be deemed effective (a) on the date received,
if personally delivered, (b) one (1) business day after being sent by nationally-known, reputable overnight carrier, (c) three (3) business days after deposit with the U.S. Postal Service, if sent by registered or certified mail,
and (d) when receipt is acknowledged, in the case of facsimile or electronic mail; provided, that if sent by facsimile or electronic mail such notice must be followed by a hard copy sent by nationally-known, reputable overnight courier
service. Each party hereto is entitled to specify a different address by giving notice as aforesaid to the Company and the Lead Investors. 

  
 45 

 13.3. Binding Effect, Etc. Except for restrictions on Transfer of Shares set forth in
other agreements, plans or other documents, this Agreement, together with the Certificate of Incorporation, the JIA, the Bylaws, the Stock Option Plan, the Award Agreements, the Company Registration Rights Agreement and, to the extent applicable,
the Cure TopCo LLCA, constitutes the entire agreement of the parties with respect to its subject matter, supersedes all prior or contemporaneous oral or written agreements or discussions with respect to such subject matter (including the Predecessor
Stockholders’ Agreement), and is binding upon and will inure to the benefit of the parties hereto and their respective heirs, representatives, successors and assigns. In the event of any inconsistency or conflict between the provisions of this
Agreement and any provisions of any of the foregoing agreements with respect to the subject matter herein, the terms of this Agreement shall control. Except as otherwise expressly provided herein, no Stockholder party hereto may assign any of its
respective rights or delegate any of its respective obligations under this Agreement without the prior written consent of the other parties hereto, and any attempted assignment or delegation in violation of the foregoing will be null and void. This
Agreement is for the sole benefit of the parties hereto (and their respective heirs, executors, administrators, successors and assigns) and nothing herein, express or implied, is intended to or shall confer upon any other person, including any
creditor of the Company, any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. 

13.4. Descriptive Headings. The descriptive headings of this Agreement are for convenience of reference only, are not to be considered a
part hereof and will not be construed to define or limit any of the terms or provisions hereof. 
 13.5. Counterparts. This Agreement
may be executed in multiple counterparts, each of which will be deemed an original, but all of which taken together constitute one instrument. A facsimile or electronic signature (i.e., .pdf or any electronic signature complying with the U.S.
federal ESIGN Act of 2000, e.g., www.docusign.com) will be considered due execution and will be binding upon the signatory thereof with the same force and effect as if the signature were an original. 

13.6. Severability. In the event that any provision hereof would, under applicable law, be invalid or unenforceable in any respect, such
provision will be construed by modifying or limiting it so as to be valid and enforceable to the maximum extent compatible with, and possible under, applicable law and the parties will negotiate in good faith to modify this Agreement so as to effect
the original intent of the parties as closely as possible in an acceptable manner to the fullest extent possible. The provisions hereof are severable, and in the event any provision hereof is held invalid or unenforceable in any respect, that will
not invalidate, render unenforceable or otherwise affect any other provision hereof. 
 13.7. No Recourse. Notwithstanding anything
that may be expressed or implied in this Agreement, each party to this Agreement covenants, agrees and acknowledges that no recourse under this Agreement or any documents or instruments delivered in connection with this Agreement will be had against
any former, current or future, direct or indirect director, officer, employee, agent or affiliate of a Stockholder, any former, current or future, direct or indirect holder of any equity interests or securities of a Stockholder (whether such holder
is a limited or 

  
 46 

 
general partner, member, stockholder or otherwise), any former, current or future assignee of a Stockholder or any former, current or future director, officer, employee, agent, general or limited
partner, manager, member, stockholder, affiliate, controlling person, representative or assignee of any of the foregoing (collectively, the “No Recourse Persons”), as such, whether by the enforcement of any assessment or by any
legal or equitable proceeding, or by virtue of any statute, regulation or other applicable law, it being expressly agreed and acknowledged that no personal liability whatsoever will attach to, be imposed on or otherwise be incurred by any No
Recourse Person for any obligation of any Stockholder under this Agreement or any documents or instruments delivered in connection with this Agreement for any claim based on, in respect of or by reason of such obligations or their creation except as
otherwise expressly and specifically set forth herein. 
 13.8. Spousal Consent. Each Stockholder who is married on the Effective Date
and the resident of a community property (or equivalent) state or jurisdiction shall cause such Stockholder’s spouse to execute and deliver to the Company a consent of spouse in the form of Exhibit B hereto (a “Spousal
Consent”), dated as of the Effective Date. If any Stockholder should marry following the Effective Date, such Stockholder shall cause his or her spouse to execute and deliver to the Company a Spousal Consent within thirty (30) days
thereof. 
  

	14.	 GOVERNING LAW. 

14.1. Governing Law. This Agreement and all Covered Actions will be governed by and construed in accordance with the domestic
substantive laws of the State of Delaware without giving effect to any choice or conflict of laws provision or rule that would cause the application of the domestic substantive laws of any other jurisdiction. As used herein, the term
“Covered Action” means any action claim, cause of action or suit (whether based in contract, tort or otherwise), inquiry, proceeding or investigation arising out of, based upon or relating to (a) this Agreement or relating to
the subject matter hereof, (b) the corporate affairs, corporate governance or internal affairs of the Company and its subsidiaries, whether or not specifically addressed in this Agreement, (c) any derivative action or proceeding brought by
any stockholder on behalf of the Company, (d) relating to any breach or alleged breach of fiduciary duty owed by any director or officer of the Company to the Company or its stockholders or (e) relating to any breach or alleged breach of
fiduciary duty by any director or officer of any subsidiary of the Company to such subsidiary or to the Company. 
 14.2. Consent to
Jurisdiction; Venue; Service. Each party to this Agreement, by its execution hereof, (a) hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of Wilmington in the State of Delaware for
the purpose of any Covered Action, (b) hereby waives to the extent not prohibited by applicable law, and agrees not to assert, and agrees not to allow any of its subsidiaries to assert, by way of motion, as a defense or otherwise, in any
Covered Action, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that any such proceeding brought in one of the above-named courts is
improper, or that this Agreement or any Covered Action or the subject matter hereof or thereof may not be enforced in or by such court and (c) hereby agrees not to commence or maintain any Covered Action other than before one of the above-named
courts nor to make any motion or take any other action 

  
 47 

 
seeking or intending to cause the transfer or removal of any such Covered Action to any court other than one of the above-named courts whether on the grounds of inconvenient forum or otherwise.
Each party consents to service of process in any Covered Action in any manner permitted by Delaware law, and agrees that service of process by registered or certified mail, return receipt requested, at its address specified pursuant to
Section 13.2 hereof is reasonably calculated to give actual notice. Notwithstanding the foregoing in this Section 14.2, a party may commence any action in a court other than the above-named courts solely for the purpose of
enforcing an order or judgment issued by one of the above-named courts. 
 14.3. WAIVER OF JURY TRIAL. TO THE EXTENT NOT PROHIBITED BY
APPLICABLE LAW WHICH CANNOT BE WAIVED, EACH PARTY HERETO HEREBY WAIVES AND COVENANTS THAT IT WILL NOT ASSERT (WHETHER AS PLAINTIFF, DEFENDANT OR OTHERWISE) ANY RIGHT TO TRIAL BY JURY IN ANY FORUM IN RESPECT OF ANY ISSUE OR ACTION, CLAIM, CAUSE OF
ACTION OR SUIT (IN CONTRACT, TORT OR OTHERWISE), INQUIRY, PROCEEDING OR INVESTIGATION ARISING OUT OF OR BASED UPON THIS AGREEMENT OR THE SUBJECT MATTER HEREOF OR IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE TRANSACTIONS CONTEMPLATED
HEREBY, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING. EACH PARTY HERETO ACKNOWLEDGES THAT IT HAS BEEN INFORMED BY THE OTHER PARTIES HERETO THAT THIS SECTION 14.3 CONSTITUTES A MATERIAL INDUCEMENT UPON WHICH THEY ARE RELYING AND WILL
RELY IN ENTERING INTO THIS AGREEMENT. ANY PARTY HERETO MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION 14.3 WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF EACH SUCH PARTY TO THE WAIVER OF ITS RIGHT TO TRIAL BY JURY. 

14.4. Exercise of Rights and Remedies. No delay of or omission in the exercise of any right, power or remedy accruing to any party as a
result of any breach or default by any other party under this Agreement will impair any such right, power or remedy, nor shall it be construed as a waiver of or acquiescence in any such breach or default, or of any similar breach or default
occurring later; nor will any such delay, omission or waiver of any single breach or default be deemed a waiver of any other breach or default occurring before or after that waiver. 

[Signature Pages Follow.] 

  
 48 

 IN WITNESS WHEREOF, each of the undersigned has duly executed this Agreement (or caused this
Agreement to be executed on its behalf by its officer or representative thereunto duly authorized) under seal as of the date first above written. 
  

											
	THE COMPANY:	 		 	NEW REMEDY CORP.
				
		 		 	By:	  	 /s/ Adam McAnaney

		 		 		  	Name: Adam McAnaney
		 		 		  	Title: General Counsel and Secretary
				
	THE MAJORITY LEAD INVESTOR:	 	        	 		  	REMEDY ACQUISITION, L.P.
					
		 		 		  	By:	  	Remedy Investment GP, L.L.C.,
		 		 		  		  	its general partner
						
		 		 		  		  	By:	  	 /s/ Matthew Holt

		 		 		  		  		  	Name: Matthew Holt
		 		 		  		  		  	Title: President

 THE MAJORITY OTHER INVESTORS: 

 

			
	REMEDY FOUNDERS LLC
		
	By:	 	 /s/ Steve Wiggins

		 	Name: Steve Wiggins
		 	Title: President

 THE MAJORITY OTHER INVESTORS: 

 

			
	LHP HOLDING LLC
	By: LIBERTY XII LLC
	Its: Managing Member
		
	By:	 	 /s/ Mark Caputo

		 	Name: Mark Caputo
		 	Title: Member

 THE MAJORITY OTHER INVESTORS: 

 

			
	BAIN CAPITAL VENTURE FUND 2014, L.P.
	
	By: Bain Capital Venture Partners 2014, L.P., its general partner
	
	By: Bain Capital Venture Investors, LLC, its general partner
		
	By:	 	 /s/ Michael A. Krupka

		 	Name: Michael A. Krupka
		 	Title: Managing Director
	
	BCIP VENTURE ASSOCIATES
	By: Boylston Coinvestors, LLC, as Managing Partner
	By:	 	 /s/ Michael A. Krupka

		 	Name: Michael A. Krupka
		 	Title: Managing Director
	
	BCIP VENTURE ASSOCIATES-B
	By: Boylston Coinvestors, LLC, as Managing Partner
	By:	 	 /s/ Michael A. Krupka

		 	Name: Michael A. Krupka
		 	Title: Managing Director

  
 - 52 - 

 EXHIBIT A 

Counterpart Signature Page 

The undersigned hereby agrees to join, become a party to and be bound, as a “Stockholder”, and a [Lead Investor / Manager / Other
Investor], by the Amended and Restated Stockholders’ Agreement of New Remedy Corp., a Delaware corporation (the “Company”), entered into as of [•], 2019, by and among: (i) the Company; (ii) Remedy
Acquisition, L.P., a Delaware limited partnership, and (iii) certain other holders of the Company’s outstanding securities, as the same may be in effect from time to time. 

 

			
	  

	Name of Stockholder
		
	By:	 	  

		 	(if applicable)
		
	By:	 	  

		 	Name:
		 	Title:

 Dated:                  ,
20     
  

	
	Address for notices:
	
	  

	
	  

	
	  

 EXHIBIT B 

Spousal Consent 
 The
undersigned spouse of Stockholder hereby acknowledges that I have read the foregoing Amended and Restated Stockholders’ Agreement of New Remedy Corp., a Delaware corporation (the “Company”), entered into as of [•], 2019,
by and among: (i) the Company (ii) Remedy Acquisition, L.P., and (iii) certain other holders of the Company’s outstanding securities, as the same may be in effect from time to time (the “Stockholders Agreement”)
and the agreements referenced therein and that I understand their contents. I am aware that the Stockholders Agreement provides for the sale or repurchase of my spouse’s Shares under certain circumstances and/or imposes other restrictions on
such securities (including restrictions on transfer). I agree that my spouse’s interest in these securities is subject to these restrictions and any interest that I may have in such securities shall be irrevocably bound by these agreements and
further, that my community property interest, if any, shall be similarly bound by this Agreement and by the Stockholders Agreement. 
  

	
	        Date:                          ,
        
	
	Signature:
                                         
                       
	
	Spouse’s Name:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]